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Abstract 
 
   This thesis employs Patient-reported Outcomes (PROs) to conduct empirical 
research on the treatment of cancer patients with prescription medications. One is a 
macro-level study which examines the association of factors related to cancer 
prescription medication use, Health-Related Quality of Life (HRQoL) and 
prescription medication expenditures in the United States. The other one is a 
meso-level study which examines patient satisfaction and subjective experiences of 
treatment with breast cancer hormonal medications. 
 
   Firstly, this thesis helps establish a framework for understanding HRQoL and the 
real spending on cancer-related medications among cancer patients by using survey 
data. It was pointed out that cancer medication use was associated with significant 
impairment of HRQoL. Differences in the impairment also exist across groups of 
different socioeconomic status (SES). Additionally, total and out-of-pocket 
prescription medication expenditures were significantly affected by patient 
characteristics such as age, region, insurance status, chronic conditions and HRQoL. 
Secondly, this thesis gives a better understanding of breast cancer patients‟ subjective 
experiences and satisfaction with hormonal medications by using patient self-reported 
data. It revealed that musculoskeletal symptoms or nervous system problems have a 
significantly negative impact on patient satisfaction, while long-term medication 
treatment or currently consistent use of medication has a significantly positive impact 
on patient satisfaction. 
 
   Overall, this thesis provides a new benchmark for these values which can be 
applied to the management of cancer medications, as well as a reference point for 
future research and baseline into clinical practice.  
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Zusammenfassung 
 
   Diese Arbeit befasst sich mit der empirischen Untersuchung von Krebstherapien 
mit verschreibungspflichtigen Medikamenten unter Verwendung Ergebnismessung 
aus der Sicht des Patienten (PROs). Die Arbeit ist untergliedert in eine Studie auf 
Makroebene, in der die Beziehung zwischen der Verwendung von Krebs 
verschreibungspflichtigen Medikamenten, Gesundheitsbedingte Lebensqualität 
(HRQoL) und Verschreibungspflichtigen Medikamentenausgaben in den Vereinigten 
Staaten von Amerika untersucht wird. Weiter wurde eine Studie auf Mesoebene 
durchgeführt, welche Patientenzufriedenheit und subjektive Erfahrung mit 
Brustkrebshormonbehandlungen untersucht. 
 
   In dieser Arbeit wird ein System aufgebaut um HRQoL und die tatsächlichen 
Ausgaben für Krebsbezogene Medikamente bei Krebspatienten von Umfragedaten zu 
verstehen. Es zeigte sich, dass die medikamentöse Krebsbehandlung mit einer 
signifikanten Einschränkung der HRQoL in Zusammenhang steht. Außerdem zeigte 
sich, dass diese Einschränkung der Lebensqualität je nach sozioökonomischem Status 
variiert. Zusätzlich werden die Gesamt- und Privatausgaben für die Behandlung mit 
verschreibungspflichtigen Medikamenten signifikant durch Charakteristika des 
Patienten wie Alter, Region, Versichertenstatus, chronischen Krankheiten sowie 
HRQoL beeinflusst. Im zweiten Teil dieser Arbeit wird ein besseres Verständnis für 
subjektive Erfahrungen und Zufriedenheit der Brustkrebspatienten vermittelt von die 
Daten aus der Sicht des patienten. Es wird deutlich gemacht, dass Symptome des 
Bewegungsapparats und Probleme des Nervensystems maßgeblich die 
Patientenzufriedenheit negativ beeinflussen, während Langzeitbehandlungen oder 
regelmäßige Medikamenteneinnahmen diese positiv beeinflussen. 
 
   Zusammenfassend bietet diese Arbeit eine neue Bezugsnorm für diese Werte, 
welche in der Planung von Krebstherapien angewendet werden, sowie als Referenz 
für weitere Forschung und Basis für die klinische Praxis dienen kann.  
 
Stichwörter:  
Krebs, Ergebnismessung aus der Sicht des Patienten, Verschreibungspflichtigen 
Medikamentenausgaben 
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Chapter 1: Introduction 
 
1.1 Study Background 
 
Cancer is a group of diseases in which abnormal cells divide out of control and are 
able to invade other tissues.
1
 All cancers begin in cells. The genetic material (DNA) 
of a cell can become damaged or changed, resulting in mutations that affect normal 
cells to grow and divide.
1
 When normal cells are damaged and cannot be repaired, 
they are eliminated by apoptosis. However, cancer cells continue to multiply in an 
unregulated manner. See Figure 1. 
 
Figure 1: Cell Division
 
 
 
                      Cited from: National Cancer Institute
1
 
 
The extra cells may form a mass of tissue called tumor. Tumors can be divided 
into benign (non-cancerous) and malignant (cancerous) tumors. Benign tumors can 
often be removed, and recurrence is rare in most cases. Usually, benign tumors are not 
life-threatening. Cells in malignant tumors may spread to surrounding tissues, nearby 
lymph nodes, or other parts of the body. The cancer that spreads from one part of the 
body into other parts of the body through the blood and lymph systems is called 
metastasis or a secondary tumor.
  
 2 
 
 
The year 2008 World Cancer Report released by the International Agency for 
Research on Cancer (IARC) estimates that cancer is the leading cause of death 
worldwide in 2008.
2
 Globally there were over 12 million new cases of cancer 
diagnosed, and 7 million deaths from cancer.
2
 In addition, the incidence of cancer 
continues to increase; by the year 2030 there will be 27 million incident cases of 
cancer and 17 million cancer deaths.
2
  
 
   In the worldwide, cancer cases are rising in prevalence as well as incidence 
resulting in a growing need to allocate financial resources to this sector of the health 
care system. The rising healthcare costs leave a growing economy a heavy burden of 
cancer.  
 
Figure 2: Total Health Expenditures on Health, Percentage of GDP  
 
 
 All the data are collected from OECD Health Data 2010: Statistics and Indicators.3 
 
   Figure 2 shows that healthcare costs in some developed countries have been 
increasing for decades. The proportion of Gross Domestic Product (GDP) devoted to 
health care has dramatically increased which reflects changes in volume, intensity and 
service costs provided to patients. In 2008, the expenditures on healthcare totalled 
percentage of GDP were 10.4% for Canada, 10.5% for Germany, 8.7% for the UK and 
16% for the United States. Compared with other countries, the U.S. poses the most 
dramatic increase.  
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   In the United States, cancer is the second leading cause of all deaths, which 
accounts for nearly one of every four deaths.
4
 According to the National Institutes of 
Health (NIH)‟s estimation, the costs of cancer treatment have increased substantially 
in the past two decades.
4
 See Table 1 for the cancer costs in the last decade in the U.S.  
 
Table 1: Cancer Cost Figures in the U.S. in Last 10 Years 
 
 
   The overall annual costs of treating cancer consist of direct and indirect medical 
costs. Compared with direct medical costs (e.g., inpatient, outpatient and emergency 
room care, drugs, and facilities), indirect medical costs, especially mortality costs (i.e., 
lost productivity because of premature death), take up more than half of overall cost. 
Taking year 2010 as an example: among the $263.8 billion overall costs, 39% was 
attributed to direct medical costs, 7.9% was attributed to indirect morbidity costs (i.e., 
lost productivity because of illness), and 53.1% was attributed to indirect mortality 
costs. However, from year 2001 to 2010, the increasing rate of direct medical costs 
( 47.0%) is much faster than that of overall annual costs ( 35.8%) and indirect 
medical costs ( 29.5%) (inflation adjusted to year 2001). It is also anticipated that 
cancer costs may grow faster than overall medical expenditures in the near future.
5
 
 
Year
Overall Annual 
Cost for Cancer 
($, Billion)
Direct 
Medical Cost                
($, Billion)
Indirect 
Morbidity Costs 
1 
($, Billion)
 Indirect 
Mortality Costs 
2 
($, Billion)
2001 156.7 56.4 15.6 84.7
2002 171.6 60.9 15.5 95.2
2003 189.5 64.2 16.3 109.0
2004 189.8 69.4 16.9 103.5
2005 209.9 74.0 17.5 118.4
2006 206.3 78.2 17.9 110.2
2007 219.2 89.0 18.2 112.0
2008 228.1 93.2 18.8 116.1
2009 243.4 99.0 19.6 124.8
2010 263.8 102.8 20.9 140.1
[1] Indirect morbidity costs are the costs of lost productivity due to illness.
[2] Indirect mortality costs are the costs of lost productivity due to premature death.
All the data are collected from American Cancer Society, Cancer Facts and Figures 2001 - 2010.
4
Notes: 
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   In order to manage cancer, medications dispensed to patients are considered as a 
primary method of therapy. As a result, medication costs represent the largest portion 
of direct medical expenditures to society. Dr. Florence Tangka of the Centers for 
Disease Control and Prevention (CDC) and her colleagues used five years data from 
the Medical Expenditure Panel Survey (MEPS) to estimate the cancer cost in the 
United States.
6
 They estimated that the total yearly medical cost of cancer in the U.S. 
nearly doubled from $24.7 billion in year 1987 to $48.1 billion which was the average 
cost from year 2001 to 2005. As a proportion of all cancer-related costs, 
cancer-related prescription drug spending also increase from 1.8% to 6.1%. For 
Medicare, the overall spending increase 47% ($210 billion vs. $309 billion) from year 
1997 to year 2004, while the spending on cancer-related drugs rose 267% ($3 billion 
vs. $11 billion) during the same period.
7
 USA Today examined “how the high prices 
of new cancer medications - up to $10,000 a month for a single drug - are causing 
alarm among patients and insurance companies”.8 It pointed that “according to the 
report released by pharmacy benefit manager Express Scripts, the cost of cancer 
medications increased by almost 16% in 2005, compared with a 3% increase for other 
treatments”.8 This report also found that in 2005 the average cost of a 30-day 
prescription for cancer medications was about $1,600.
8
 
 
   The strong upward rise in cancer drug prices and spending has given both patients 
and health economists great cause for concern. The high cost of cancer treatment 
leads to financial difficulty for patients and their families, even including those 
covered with health insurance. One recent survey finds that 25 percent of individuals 
with cancer report consumption of all or most of their savings to treat cancer.
9
 Even 
among insurance beneficiaries, 22 percent report consumption of all or most of their 
savings to treat cancer.
9 
In addition, in some cases, the prices of cancer drugs rise 
faster than the health benefits associated with them, which attracted health economists‟ 
attention.
7
 Therefore, cancer outcome research becomes more and more vitally 
important now than ever. The purpose of cancer outcome research is “describing, 
interpreting and predicting the impact of cancer interventions, as well as other effects 
with regard to the outcomes that are crucial to decision makers”.10 Such outcomes 
include not only traditional biomedical outcomes (e.g., survival, disease-free survival), 
but also patient-reported outcomes (PROs) (e.g., health-related quality of life 
(HRQoL), patient satisfaction and economic burden).
10
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1.1.1 Patient-reported Outcomes (PROs) 
   
   As the differences in efficacy benefit for the patients between cancer therapies 
become smaller, there is a growing recognition on “the patient‟s perspective” in 
cancer treatment decision making. If we know the value people attach to the health 
improvement they receive from different interventions, it could be helpful to 
determine how to efficiently provide more or less of the outcomes that people desire 
or not desire.
11
 Patient-reported outcomes (PROs) are collected directly from patients. 
This information can describe the clinical course of cancer, help select optimal 
treatment, or assess the effectiveness of interventions and the overall burden of cancer. 
Hence, PROs of cancer patients as an important therapeutic endpoint is increasingly 
being given a high priority in clinical trials. 
 
   Many U.S. research and policy-related developments value the importance of 
PROs in the cancer sphere. The National Cancer Institute (NCI) has designated it as a 
Strategic Objective – Using PROs to ensure the improvement of the quality of life for 
cancer patients, survivors and their families.
12
 One of the American Cancer Society 
(ACS)‟s 2015 goals for the nation is improving the quality of life of all those affected 
by the disease.
13
 Thus, it would be crucial to measure the cancer and its treatment‟s 
impact on quality of life (QoL) from cancer patients‟ standpoint.  
 
   The U.S. Food and Drug Administration (FDA) also grant that new drugs must be 
both safe and effective for approval. They encourage using PROs in clinical trials to 
indicate whether a new drug or treatment is working and how well it is working. The 
additional information from PROs can support the approval and also label claims for a 
new drug. In Feb. 2006, the FDA issued a draft guidance document on the use of PRO 
measures in industry-sponsored studies to support drug-labeling claims. The guidance 
published by FDA points out that “a PRO is a measurement of any aspect of a 
patient‟s health status that comes directly from the patient, including the symptom 
status, functional status (e.g., daily living, social functioning), health-related quality of 
life (HRQoL) and patient satisfaction”.14  
 
 6 
 
1.1.1.1 Health-related Quality of Life (HRQoL) 
 
   In practice, the patient‟s assessment of HRQoL is considered the most prominent 
end point or outcome measure to show changes from the patient‟s perspective.14 
Assessing HRQoL is more complex than some other PROs and may provide 
information about treatment outcomes in multiple domains. Therefore, the patient‟s 
assessment of HRQoL is an essential indicator of treatment effectiveness and may 
influence recovery goals.
15
 
 
   The important dimension of health is quality of life (QoL). The World Health 
Organization (WHO) in year 1995 defined QoL as “the individual‟s perceptions of 
their position in life in the context of the culture and value system in which they live, 
and in relationship to their goals, expectations, and standards”.16 QoL refers to every 
facet of a patient‟s life. The patients‟ view of their quality of life may also include the 
aspects of life that are not health related. Thus, QoL is not an appropriate outcome for 
evaluating a medical product. In contrast, HRQoL can complementally provide 
valuable information on the patient‟s self-health perception about treatment impact. 
For this reason, the FDA permits HRQoL claims on the label of certain drugs.  
  
   Assessing HRQoL is most commonly used to test the safety and efficacy of new 
therapies in randomized trials by special QoL instruments, which include physical, 
psychological (including emotional and cognitive), and social domains. These 
multidimensional HRQoL measures can assess the impact of the disease on each of 
these domains. In addition, these measures can be used to assess both the positive 
impact of the treatments and the negative impact from side effects associated with the 
treatments.
17
  
 
   Due to the importance of HRQoL in assessing both the burden of cancer and 
benefits of treatment, over the past ten years, lots of instruments developed to assess 
HRQoL have been made available to clinicians and researchers. To be accepted as a 
scientific measure, a HRQoL questionnaire must confirm validity, reliability, and 
sensitivity to clinically important changes, otherwise the assessments of symptom 
relief and quality of life will be hampered.
18
 In general, two types of HRQoL 
measures are classified: health status measures that describe the health state of an 
 7 
 
individual along various attributes of health for a specific period or at a particular 
time;
19
 utility measures that provide numerical assessments of health states. Table 2 
lists the most frequently used HRQoL instruments in cancer treatment. 
 
Table 2: Commonly Used Health-related Quality of Life (HRQoL) 
Instruments in Cancer Outcome Researches 
 
 
Health Status Measures 
 
 Generally, health status measures are typically subdivided into generic and 
specific measures. For assessing both the burden of cancer and benefits of treatment, 
these measures can be classified as generic measures, general cancer measures and 
cancer-specific measures.
17
  
HRQoL Instruments
Health Status Measures
Generic Measures SF-36 (Medical Outcomes Study 36-item Short Form Health Survey)
Karnodsky Performance Scale (KPS)
General Cancer Measures European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
Core 30 (EORTC QLQ C-30)
Functional Assessment of Cancer Therapy-General (FACT-G)
Functional Living Index-Cancer (FLIC)
Spitzer Quality of Life Index (SQLI)
Cancer Linear Analog Scale (CLAS)
Cancer-specific Measures
 1
Functional Assessment of Cancer Therapy-Lung (FACT-L)
Functional Assessment of Cancer Therapy-Prostate cancer (FACT-P)
Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B)
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
Breast Cancer (EORTC QLQ BR23)
Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM)
Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane)
Breast Chemotherapy Questionnaire (BCQ)
Functional Assessment of Cancer Therapy-Fatigue (FACT-F)
Functional Assessment of Cancer Therapy-Anemia (FACT-An)
Functional Assessment of Cancer Therapy-Endocrine Symptom (FACT-ES)
Brief Fatigue Inventory (BFI)
Mental Health Inventory (MHI)
Rotterdam Symptom Checklist (RSCL)
Symptom Distress Scale (SDS)
Brief Pain Inventory (BPI)
Menopause-specific quality of life Questionnaire (MENQOL)
Utility Measures Visual Analogue Scales (VAS)
Time Trade-Off (TTO)
EQ-5D (EuroQoL)
Quality of Well-Being Scale (QWB)
Health Utilities Index (HUI)
Notes:
[1] Here only list most commonly used cancer-specific instruments. For specific form of cancer, here only list lung cancer, prostate cancer and breast cancer, 
which rank the top 3 of the U.S. national expenditures for medical treatment for the cancers.
 8 
 
 
   The generic measures are performed for general use. It is suitable for a wide range 
of diseases and health conditions of patient groups. Patients‟ overall life is dissimilar 
under alternative medical interventions and the extent of the difference is reflected by 
measuring general health status. These measures help to quantify the relative impact 
of interventions on the patients with different diseases.
20
 Therefore, measuring 
general health stats is important. The Medical Outcomes Study 36-item Short Form 
Health Survey (SF-36) is most frequently applied to cancer treatment. It has 36 
questions covering eight health domains. 
 
   General cancer measures assess individuals‟ functioning and well-being as 
pertains to cancer, but without reference to a specific type of cancer.
17
 These measures 
address the general areas of HRQoL relevant to all forms of cancer. Thus, they cannot 
be used in patients with specific types of cancer. Examples of general cancer measures 
are the European Organization for the Research and Treatment of Cancer Quality of 
Life Questionnaire-Core 30 (EORTC QLQ C-30) and the Functional Assessment of 
Cancer Therapy-General (FACT-G). 
 
   The cancer-specific measures emphasize the specific form of cancer (e.g., breast 
cancer), such as the Functional Assessment of Cancer Therapy-Breast cancer 
(FACT-B). In addition, they also assess individual‟s functioning and well-being as 
pertains to a specific treatment for cancer (e.g. chemotherapy), or a particular impact 
of cancer on HRQoL (e.g. fatigue, depression). Examples are the Breast 
Chemotherapy Questionnaire (BCQ) and the Hospital Anxiety and Depression Scale 
(HADs). 
 
   In terms of the application of the three types of measures introduced above, 
generic measures are broadly applicable and allow for comparisons among disease 
groups and population. Thus, they can enable comparison of the burden of cancer 
versus the burden associated with other conditions.
17
 While when assessing QoL of 
specific patient groups, cancer-specific measures are more sensitive and responsive to 
the changes than generic measures.
18
 However, there is no single instrument 
incorporating all aspects of HRQoL, therefore it is typical that one of these generic 
measures is combined with one or more cancer-specific measures to measure baseline 
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health status, comparative health status, and effectiveness/outcomes of clinical 
intervention.  
 
Utility Measures 
 
   Utility measures assign numerical values for health states from 0 to 1, where 0 
indicates death and 1 indicates the best health state.
20
 Utility measures are able to 
integrate morbidity and mortality. They consist of two main components: a) the 
definition and description of health states; b) the measurement of the preference for 
each health state.
21
 These components can be applied in direct preference-based 
measures and indirect preference-based measures.  
 
   Direct preference-based measures assess the preference for a health state, 
including Visual Analogue Scales (VAS), Standard Gamble (SG) and Time Trade-Off 
(TTO). VAS is a method used to measure preference for health outcomes. Patients are 
asked to mark the position of their current health state on the 10 cm line, and the 
position that corresponds with their feelings as well.
20
 The results of VAS give an 
indication of the ordinal ranking of the health outcomes. SG estimates patients‟ 
preferences under uncertainty, which contains a risk of death or some other 
outcomes.
20 
TTO also attempts to measures patients‟ preferences under certainty. 
Patients are asked to indicate that they prefer to choose one year in perfect health or 
one year in impaired health. Both SG and TTO are practical on most populations, and 
TTO could be used to replace to the SG.
20
 While, VAS is more commonly used. By 
using these direct preference-based measures, patients could provide global 
assessments of the net effect of treatment on their HRQoL, including positive 
treatment effects and negative side effects. However, these measures have been found 
to be less responsive to health change than standardised health status measures.
22
 
 
   Indirect preference-based measures describe the health status of a subject by using 
a multi-attribute health status classification system and a scoring system to value 
health status, such as the EuroQoL (EQ-5D), the SF-6D, the Quality of Well-Being 
Scale (QWB) and the Health Utilities Index (HUI). Usually, these measures only have 
a few questions. For example, patients using the EQ-5D questionnaire have to answer 
six questions in two sections. One section consists of five questions to assess QoL in 
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the domains of mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. The other section gives an expression of their current health 
statuses via the VAS.
20 
In practice, due to the ease of use, the indirect utility measures 
are widely used.
22
 
 
   In health economics, the health state utilities are usually combined with survival 
estimates, then aggregated across patients to generate quality-adjusted life years 
(QALYs).
21
 QALYs can be used in cost-utility or cost-effectiveness analyses to assess 
the extent of the benefits gained from healthcare interventions.
23
 When combined 
with the costs of providing the interventions, the comparisons between interventions 
can be made. 
 
Differences between Health Status Measures and Utility Measures 
 
   Unlike health status instruments, utility measures are patient preference-based 
measures of health states. In health economics, utilities are principal values that 
reflect an individual‟s preferences for different health outcomes.21 From the patients‟ 
point of view, their preferences are the important criteria to assess whether the 
treatment can be considered efficient. In addition, economists also suggest extracting 
the patient preference affected by an intervention.
20
 Utility assessments use a single 
number to summarise HRQoL. This number not only reflects the health status of the 
patient, but also reflects the patients‟ preferences for treatment process and outcome.24 
Therefore, utility measures are the preferred outcome measure for modelling the 
cost-utility analysis to aid in making resource allocation decision.  
 
   Due to the difficulties encountered in interpreting the quality of life scores, it is 
often impossible to use HRQoL instruments directly. However, they can still be useful 
to be included in an economic evaluation to  
 
 gain more information about the changes of quality of life with different 
treatments in specific dimensions; 
 ensure that different treatments have identical outcomes in cost-minimization 
studies; 
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 classify patients into different health states. Such classifications can be used as 
a basis for measuring the quality weights to construct QALYs and/or the 
willingness to pay for health changes. 
 
1.1.1.2 Patient Satisfaction 
 
   Patient satisfaction has been of increasing interest over the past few decades. It is 
an important patient-reported outcome measure for estimating the extent to which 
health care service meets patients‟ needs and expectations.25 Patient satisfaction can 
be considered as a hierarchy.
26
 See Figure 3.  
 
Figure 3: Hierarchy of Levels of Patient Satisfaction
 
 
 
   The broadest level of the hierarchy is satisfaction with health care. It covers all 
aspects of the health care received. The middle level represents global treatment 
satisfaction. It involves not only patient satisfaction with medication, but also 
satisfaction with other issues, such as recommendations by the physician about other 
procedures and therapies (e.g., activity limitations, dietary restrictions, physical 
rehabilitation), and interaction between physician and patient.
26
 Lastly, at the 
Satisfaction with Medication
(e.g., impact on symptoms; side effects)
Precise
Treatment Satisfaction
(may include other procedures & therapies, 
e.g., activity limitations, dietary restrictions)
Satisfaction with Health Care
(e.g., issues of accessibility,  perceived 
quality of staff and facilities)
Broad
Cited from: Shikiar R, Rentz AM. Satisfaction with Medication: An Overview of Conceptual,Methodologic, and Regulatory Issues.
26 
Page 205.
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narrowest end of the hierarchy, it is the satisfaction with the medication received.
 
These levels interact and impact each other.  
 
   Patient satisfaction, this type of PRO, is different from other PROs such as 
health-related quality of life (HRQoL) and self-reported symptoms or functioning. 
The theoretical basis of patient satisfaction research is found in the planned behaviour 
theory, which is an extension of the Theory of Reasoned Action (TRA).
26
 The most 
important insight provided by TRA is its attempt to explain behaviour regarding 
medical care or medication in terms of beliefs about the outcomes of performing the 
behaviour and the evaluation of each of these outcomes.
26 
On one hand, patient 
satisfaction affects the patient‟s health-related decision making. On the other hand, it 
provides the professional health care providers, the researcher and the policy makers 
with important feedback from patients, and may help to support a claim for a new 
product.
15
 
 
 
   Patient satisfaction with medical care is considered an indicator of quality of care. 
It includes a number of factors, such as access to medical staff timely, perceived 
quality of medical staff and facilities, the patient‟s experience with regard to the 
duration or side effects of the treatment, and patient‟s expectations for receiving 
effective medical care on time.
26
 Currently, many countries or organizations develop 
corresponding patient-experience measures. For example, the United Kingdom 
conducts a yearly Survey of Patient and User Experience to report detailed patient 
experiences in some selected areas such as hospital care.
27
 The department of Agency 
for Healthcare Research and Quality (AHRQ) in the United States has supported and 
helped to develop the Consumer Assessment of Health Plans.  
 
   With regard to cancer, the Comprehensive Assessment of Satisfaction with Care 
(CASC) is developed to assess the perception of cancer patients with regard to the 
quality of care received in the hospital.
28, 29
 It focuses on patients‟ interactions with 
doctors or nurses and mainly evaluates psycho-social interventions that affect patients‟ 
quality of life.
29 
This questionnaire consists of 60 items regarding doctors‟ behaviour, 
nurses‟ behaviour and services (i.e., the technical, communication and interpersonal 
skills, availability and co-ordination, waiting time, access, comfort, kindness and 
helpfulness of other hospital personnel). Each item is aimed at an aspect of care which 
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is rated on a five-Likert scale ranging from 1 (poor) to 5 (excellent). A scale of overall 
satisfaction is also included. 
 
   Medication satisfaction is increasingly recognized to be essential in determining 
the efficacy of new therapies. It is a feedback from the patients with respect to the 
experience of taking the medication and the outcomes related to the medication.
26
 It is 
directly associated with drug adherence and treatment preference, indirectly 
associated with clinical and HRQoL outcomes. Currently, there are three instruments 
measuring medication satisfaction regarding cancer drugs. Two are generic 
instruments. The other is designed for cancer therapy, particularly for intravenous 
and/or oral anticancer treatments. 
 
   Treatment Satisfaction Questionnaire for Medication (TSQM) is a generic 
instrument, which is designed to assess patient satisfaction with medication for any 
disease.
30, 31
 It is a psychometrically robust and validated instrument and comprises 
four domains: global satisfaction, effectiveness, side effects, and convenience. In each 
domain, the scores range from 0 to 100, with higher scores representing greater 
satisfaction in that domain. 
 
   Treatment Satisfaction with Medications Questionnaire (SATMED-Q) is also a 
generic instrument. It aims at assessing patient satisfaction with chronic drug-based 
treatment for any disease including cancer.
32
 It consists of 17 items on a five-Likert 
scale from 0 to 4 points (0 = No, not at all, 1 = Somewhat, 2 = So-so, 3 = Quite, 4 = 
Yes, very much). Mean scores are converted into a scale ranging from 0 (the worst or 
no satisfaction) to 100 (total or maximum satisfaction). This questionnaire covers six 
domains (each with 2-3 items) of treatment satisfaction: undesirable effects, 
medication efficacy, medication ease and convenience, medication impact on daily 
activities, satisfaction with medical care and overall satisfaction. The SATMED-Q has 
been proved to be feasible, valid and reliable. 
 
   The Cancer Therapy Satisfaction Questionnaire (CTSQ) is designed to measure 
treatment satisfaction in cancer patients.
33,
 
34
 It could be used in every cancer types 
and stages, but it is specific to patients receiving oral and/or intravenous anticancer 
therapies.
34
 21 items are used across seven multi-item domains: expectations of 
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therapy, feelings about side effects, oral therapy compliance, convenience, satisfaction 
with therapy, stopping therapy, and reasons for noncompliance. All items are scored 
on a five-Likert scale. 15 of the items are scored from 1 (the worst response) to 5 (best 
response). Six of the items are reverse-coded. The CTSQ proves to be with good 
metric properties. 
 
   Overall, patient satisfaction is essential in the studies of cancer outcome. These 
valuable information, especially the factors affecting satisfaction, could be 
particularly useful to assess the patterns of care organization, monitor health care 
delivery, understand the cancer patients‟ experience on their current treatment, reflect 
patients‟ treatment-related behaviours (e.g., drug adherence, treatment preference), 
and differentiate among alternative treatments. Health care providers and policy 
makers could be assisted to improve the quality of health services, perform efficient 
patient and/or cancer treatment management, optimize health expenditure through 
patient-guided planning and evaluation,
35
 then determine the best strategy for cancer 
interventions.  
 
1.1.2 Economic Evaluation of Cancer Burden 
 
   PROs are only partial measures of evaluating cancer burden, because they do not 
measure the costs spent by individuals or nations in producing these outcomes.
27
 Thus, 
when comparing the costs and efficacy of alternative cancer interventions, economic 
evaluation is vitally important. There are four types of economic analysis in cancer 
studies: cost-minimization analysis, cost-benefit analysis, cost-effectiveness analysis, 
and cost-utility analysis. Each follows the same general methodology but differs in the 
methods used to measure the health outcomes. See Table 3.  
 
Table 3: Types of Economic Analysis 
 
Type of Analysis Outcome Measure Costs
Cost-Minimization Analysis (CMA) None $
Cost-Benefit Analysis (CBA) Monetary value (willingness to pay) $
Cost-Effectiveness Analysis (CEA) Natural units (e.g., life years saved, quality of life) $
Cost-Utility Analysis (CUA) Utility values (e.g., QALYs) $
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The Concept of Cost 
 
   From economic perspective, the resources consumed by an intervention reflect its 
cost.
36
 In cancer outcome research, the resources traditionally associated with the 
health care system are only one aspect of the costs associated with cancer and its 
interventions.
36
 A full analysis of the economic burden of cancer care takes direct, 
indirect and intangible costs of cancer into account. 
 
   Luce et al.
37
 explain direct costs in cost-effectiveness analysis of health and 
medicine as follows: 
 
   “Direct costs include the value of all the goods, services, and other resources that 
are consumed in the provision of an intervention or in dealing with the side effects or 
other current and future consequences linked to it. These costs are often thought of as 
involving - or potentially involving - a monetary transaction, although it is the use of 
the resource rather than a monetary exchange that defines the direct cost. Direct costs 
encompass all types of resource use, including the consumption of professional, 
family, volunteer, or patient time. Because the intervention (e.g., screening) can affect 
both current and future resource use and costs, these costs should be considered a 
stream of resource use that can span time, from a year or less for a simple procedure, 
to a lifetime for a preventive intervention or a chronic disease treatment regimen.” 
 
   In brief, direct costs comprise direct health care costs (e.g., diagnosis, laboratory 
tests, medical facilities, patient out-of-pocket expenses including co-payments), direct 
non-health-care costs (e.g., treatment-related transportation and child care), and 
patient time costs (e.g., the time a patient spends to seek care, the time of receiving 
treatment). 
 
   Indirect costs are related to productivity loss due to illness and its treatment. These 
costs are typically measured by morbidity and mortality-related cancer cost. 
Morbidity costs of illness refer to the lost or impaired ability to work (e.g., days lost 
from work, foregone wages). Economic output and the time lost or forgone by the 
patients‟ family and friends from usual activities (e.g., income lost by family members, 
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restricted leisure time) are also considered as the morbidity costs.
38
 Those related to 
the value of future income lost due to premature death are considered as the mortality 
costs of illness. 
 
   Intangible costs are pain and suffering from disease and its treatment, 
psychological costs (e.g., anxiety, grief), changes in social functioning/daily activities, 
or other effects on the patient‟s quality of life. They have no market prices, and are 
usually measured by the reduction in quality of life. 
 
Economic Analysis 
    
   Cost-minimization analysis (CMA) is applied to compare and find the lowest cost 
among different drug treatments. When conducting a cost-minimization study, all 
costs (resource expenditures) need to be measured and competing alternatives of drug 
treatments need to have equal efficacy and tolerability. However, it is rare to use 
cost-minimization analysis, because effectiveness, utility and safety of interventions 
must be identical, meanwhile only changes in costs of the intervention are taken into 
account. 
 
   Cost-benefit analysis (CBA) measures the costs and benefits in monetary units of 
different treatments to decide the least costly way of achieving any positive outcome. 
The approach is useful since it leads to a simple decision-making rule: if a treatment‟s 
net benefits exceed its net costs, then it should be adopted.
39
 However, CBA also 
raises measurement difficulties, because it requires the monetary valuation of health 
benefits. In practice, it is the most difficult and most criticized analysis. 
 
Cost-effectiveness analysis (CEA) compares the costs and effectiveness of two or 
more interventions, where only the costs are calculated in monetary units, while the 
effectiveness is defined by the health benefit or outcome achieved with the 
intervention and expressed in non-monetary or natural units. This effectiveness is 
defined by a summary measure that combines quantity of life (mortality) and quality 
of life (morbidity), weighted by the preference for that quality of life. It is calculated 
as the difference in costs between two alternatives divided by the difference in health 
effects. 
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Cost-effectiveness ratio = 
                    
                       
 
 
Here, all outcomes are defined by using natural units, including health endpoints 
(e.g., a case prevented), survival, quality of life etc. When compared with an 
alternative, cost-effectiveness ratio represents the incremental cost of obtaining a unit 
of health effect from a given intervention. However, it is difficult to use 
cost-effectiveness ratio to compare treatments with different outcomes because the 
health outcomes are difficult to express in a single effectiveness unit. Therefore 
cost-effectiveness analysis is best suited to measuring technical efficiency.
40
 
 
Cost-utility analysis (CUA) is a special case of cost-effectiveness analysis. It has 
its roots in expected utility theory, which describes a normative model of rational 
decision making under conditions of uncertainty.
39
 In cost-utility analysis, 
effectiveness is measured by a utility score derived from utilities measures.  
 
   Cost-utility ratio = 
                    
                                  
 
 
Cost-utility ratio indicates how much cost per quality-adjusted life year (QALY) 
gained. An intervention with a lower cost to QALY saved ratio is preferred over an 
intervention with a higher ratio. Cost-utility analysis provides a more complete 
analysis of total benefits because it takes into account the quality of life that an 
individual has. Therefore, it is most frequently used. 
 
   According to the health economics literature, a QALY measures the performance 
of medical treatments and interventions, and it encompasses both the quantity and 
quality of life generated by healthcare interventions. The quantity of life is expressed 
by survival or life expectancy, while quality of life contains different aspects of 
people‟s lives, including health status.23 A QALY is estimated by assigning every life 
year a weight between 0 and 1. A weight of 0 reflects a health status that is valued to 
be equal to being dead and a weight of 1 reflects perfect health. 
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Economic evaluations involve a comparison of costs and outcomes from 
alternative uses of resources to improve health. To be useful to decision-makers, the 
results must also be interpreted by attaching clinical meaning to numerical data. 
Outcomes take on a variety of forms. For making a meaningful comparison, they need 
to be measured or valued using the same metric. In economic evaluation, although 
measuring and calculating cost is fundamental and substantial, the key issue is 
choosing outcome measure. The suitability of an outcome measure depends on the 
type of treatment that is analysed as well. For example, chronic diseases are difficult 
to accommodate in the QALY context, because for them quality of life is a major 
issue while survival is less of an issue. Treatment of hormonal therapy in breast 
cancer could be an example of this. Both tamoxifen and Aromatase Inhibitors (AIs) 
are the most commonly used hormonal medicines for postmenopausal women, the 
comparison in terms of QALYs seems doubtful since both medicines demonstrate 
similar effectiveness in terms of survival rate, hence the patient 
HRQoL/satisfaction/preference for a reduction of side effects might be a more fruitful 
approach.  
 
1.1.3 The Application of Cancer Outcome Measures 
 
   Lipscomb J et al.
41
 evaluated the peer-reviewed literature in cancer outcome 
research, and employed a framework to categorize and characterize the applications of 
cancer outcome measures. This framework adopted three broad categories: macro, 
meso and micro-level. The specific explanation is as follows:
41
 
 
 Macro-level analyses, investigating current and potential trends in HRQoL of 
patients among large population, their satisfaction with the care received and 
the corresponding economic burden are also attached. 
 Meso-level analyses, consisting of a wide range of diversified studies on 
patient-reported outcomes. Those studies include: randomized trials on 
intervention efficacy; observational designs on intervention effectiveness; 
cancer impact (with an emphasis on cancer survival); differences of cancer 
care utilization, quality of cancer care; clinical decision modeling, economic 
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modeling (e.g., cost-effectiveness analysis), and evaluation existing 
interventions to help decision makers. 
 Micro-level analyses, emphasizing the performance and quality of cancer 
outcome measures. 
 
Table 4 presents these three categories of application for cancer outcome 
measures in detail and illustrates their potential uses in decision making.
 
 
   Macro-level studies examine population trends in cancer-related outcomes and the 
cancer burden,
41
 such as the changes in cancer-related mortality, morbidity, HRQoL 
and cost, by state and demographic subgroup. They are intended to provide 
information to policy makers on formation and research agenda, especially for those 
meso-level studies.
41
  
 
   Meso-level studies collect a wide range of sources like patients, families, payers 
and providers, agencies and organizations, evaluate their influences to decision 
making and therefore affect the judgements on the safety, efficacy or 
cost-effectiveness of the cancer care.
41
 Examples of meso-level studies are as follows: 
a) cross-sectional analysis of prevalence and quality-of-life impact of depression and 
anxiety among long-term survivors of breast cancer; b) randomized controlled trial 
comparing impact of two competing hormonal therapy regimens on survival and 
HRQoL in patients with early stage breast cancer; c) prospective cohort study of 
individuals newly diagnosed with breast cancer to examine the impact of alternative 
strategies for initial treatment and follow-up care on HRQoL, satisfaction with care, 
and economic burden; d) cost-effectiveness analysis of comparison with tamoxifen 
and with anastrozole (Arimidex®) used in postmenopausal patients to reduce breast 
cancer morbidity and mortality. Meso-level studies may be used to check the 
macro-level study hypotheses and results, and also to link the process-outcome to 
support micro-level specific problem solving.
10
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Table 4: Application for Cancer Outcome Measures 
 
 
   Micro-level studies use outcome measurement (e.g., generic, cancer-specific, 
and/or domain-specific HRQoL instruments) to truly reflect the quality of cancer care 
itself by improving the patient-provider communication quality and decision 
making.
41
 
 
   In recent years, there is an increasing interest in using macro-level measures to 
amend health policy by studying cancer disparities and economic burden against 
national objectives,
27
 because population health has become a principal subject in 
many developed countries. Several national and international organizations such as 
the World Health Organization (WHO) and the Organization for Economic 
Cooperation and Development (OECD), have sponsored national surveillance plans 
(e.g., the evaluation of cancer control programs).
27
 In the United States, some 
government departments, like the Agency for Healthcare Research and Quality 
Potential Uses in Decision Making
Macro Population trends in cancer-related outcomes and  the economic 
burden
Informs policy makers with information and the research 
agenda by revealing successes, shortcomings, and areas 
requiring in meso-level studies for intensive investigation
Meso Descriptive and analytical studies to understand the impact of 
cancer, variation in service use and performance, and effects of 
interventions on cancer-related outcomes. The examples of 
examinations are as follws:
Provides specific empirical research findings and 
recommendations to improve public and private decisions on 
safety and efficacy of cancer care, coverage and 
reimbursement, regulation (e.g., product approval and 
marketing), guidelines, and  support micro-level research to 
assess and improve cancer outcomes
A. Intervention efficacy (randomized controlled trial)
B. Intervention effectiveness (observational investigations on the 
burden of cancer patients and their families)
C. Cancer impact: observational studies analyzing the various 
effects of cancer on patients (e.g., depression), with an 
emphasis on cancer survivors.
D. Variations in utilication
1. Patterns of cancer care: identify significant population 
differences during the use of cancer services by cross-sectional 
or longitudinal studies.
2. Monitoring the quality of cancer care by examining patient 
satisfaction and adherence.
E. Intergrating and synthesizing information on outcomes 
through
1. Clinical decision modeling to select an optimal intervention
2. Economic modeling, such as cost-effectiveness analysis, 
cost-benefit analysis, cost-utility analysis.
3. Evaluating existing cancer interventions
Micro Use QoL instruments and other tools to monitor and predict 
outcomes, then help examine patient risk profile and behavioral 
characteristics, and select intervention.
Improve the quality of the information available for decision 
making, enhance the communication between patients and 
their providers. 
Domains
Adapted from: Lipscomb J, Donaldson MS, Hiatt RA. Cancer outcomes research and the arenas of application.
10  
Page 3.
 21 
 
(AHRQ) and the Centers for Disease Control and Prevention (CDC), have begun to 
develop national quality reports to help establish the priorities, monitor the 
improvement, and publicly report these findings by assessing national measurement 
systems related to cancer or other diseases.
27
 
 
Table 5: Cancer Performance Measures and Applications in Macro-level 
Studies in the United States 
 
 
   Table 5 lists the types of cancer performance outcome, the current or potential 
applications and data sources used for macro-level studies of cancer care in the United 
States. As the table illustrates, cancer registries or death certificate data normally 
captured clinical endpoint measures, such as cancer incidence, mortality and survival. 
Patient-defined endpoints (e.g., general health status, experience or satisfaction with 
care) are collected from population survey. In addition, cost information, including 
Measures Definition Data Source
Biomedical Outcomes Clinical Endpoint Measures Provider Sources
1. Total proportion of population diagnosed with cancer Cancer registries
2. Rate of newly diagnosed “avoidable” cancers in a year Cancer registries
1. Death rate of cancer Death certificates
2. Years of life lost: date of death from disease minus 
estimated date of death based on average life expectancy
Death certificates
1. Observed survival in a general population: time from 
diagnosis to death from cancer
Primarily death certificates
2. Relative survival: the ratio of the observed survival relative 
to the expected survival of a similar population group
Primarily death certificates
Quality-of-Life Outcomes Patient-Defined Endpoint Measures Patient Sources
Health Status Measures
Medical Outcomes Study Short 
Form 36 (SF-36)
Physical and emotional functioning Population survey
Responsiveness to patients Patient experience with care, satisfaction with care Population survey
Utility Measures
EQ-5D (EuroQoL)
Mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression
Population survey
Cancer Cost Economic Burden of Cancer Care Patient and Provider
Direct costs Health services and out-of-pocket costs attributable to cancer 
treatment
Population surveys
Indirect costs
Morbidity costs Lost productivity due to illness Population surveys
Mortality costs Lost productivity due to premature death Population surveys
Other Indirect costs Burden on family and individual life style Population surveys
Intangible costs
Pain and suffering, changes in social functioning/daily 
activities, anxiety, grief
Population surveys
Adapted from: Clauser SB. Use of Cancer Performance Measures in Population Health: A Macro-level Perspective.
27 
Page 144.
Incidence
Mortality
Survival
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direct, indirect and intangible costs, could also be collected from population survey. 
The macro application of burden-of-disease measures summarize disease burden for a 
nation, geographic area, entire population or demographic subgroup.
17 
Thus, 
macro-level studies are helpful in assisting researchers to examine cancer incidence 
and prevalence in the country, then determine whether certain demographic subgroups 
are disproportionately affected.  
 
   Overall, currently there are three broad categories of applying cancer outcome 
measures. Macro-level studies aim at a comprehensive view of the population trends 
in cancer-related outcomes from an economic point of view. Meso-level studies are 
more purpose specific to investigate the cancer impact and the corresponding 
interventions. Micro-level studies focus on the use of cancer outcome measures, risk 
and outcome prediction models, or other measurement, and help enhance the quality 
of information for patient-clinician decision making.
41 
These studies could help 
understand the outcomes of cancer and its treatment, as well as improve the process of 
cancer care decision making. 
 
1.2 Study Objectives 
 
   Due to the improved treatments, cancer survival rates have greatly increased in the 
past few decades. In particular, cancer drug therapy plays an important role in the 
treatment of patients with cancer in all stages of the disease. Although the currently 
available cancer drug treatments improve the survival and relieve some symptoms to a 
certain extent, at the same time they also produce some unexpected toxic side effects. 
It is noted that these side effects cause patients‟ health-related quality of life (HRQoL) 
and patient satisfaction with medication to decrease. Therefore, when considering the 
management of cancer patients, there is an increasing demand of recognition that 
patient-reported outcomes (PROs) – including treatment-related toxicity, the impact of 
treatments on HRQoL and patient satisfaction – can convey essentially additional 
information for assessing the overall burden of cancer and the effectiveness of 
interventions. In addition, the spending on cancer-related prescription medications 
increases substantially annually. This causes cancer patients exceptionally affected by 
high out-of-pocket expenditures and gives health economists a great cause for concern 
 23 
 
as well. Thus, it is more important now than ever to understand the pattern of 
cancer-related prescription drug expenditures. However, the studies assessing cancer 
patients‟ PROs and expenditures, particularly with respect to prescriptions are lacking 
and mostly out-of-date. To fill the void, this thesis attempts to attribute the PROs and 
expenditures of treatment of cancer patients with prescription medications through 
two empirical researches.  
 
   This first research will use the latest Medical Expenditure Panel Survey (MEPS) 
data to examine the association among factors related to cancer prescription 
medication use, HRQoL and prescription medication expenditures in the United States. 
It is intentionally designed to give a comprehensive and up-to-date understanding of 
HRQoL and expenditures aiding in managing cancer medical costs. By analysing 
quality of life data, the study will document how HRQoL is affected after taking 
cancer prescription medications. By analysing medical expenditure data, the study 
will document how the source of payments are affected, and help establish a 
framework for understanding the real medical expenses on cancer-related medications 
among cancer patients.  
 
   The second research focuses on breast cancer. It is conducted to examine patient 
satisfaction and subjective experiences of treatment with hormonal medications- 
tamoxifen and Aromatase Inhibitors (AIs). Both medications demonstrate similar 
effectiveness in terms of survival rate. In addition, currently available QoL studies 
show that although the side effect profiles of them vary significantly, there are no 
clinically important differences in overall QoL. Consequently, patient satisfaction is 
particular useful when differentiating these medications. This study will be based on 
the patient self-reported data collected from an Internet website www.askapatient.com. 
It will document what factors impact patient satisfaction with hormonal medications. 
It is carried out to give a deep understanding of the important issues in treatment 
decision making for postmenopausal women with breast cancer, and serve as the 
benchmark for policy makers to improve hormonal medication management.  
 
   The expected objective of this thesis is providing a new benchmark for these 
values which can be applied to the management of cancer medications, as well as a 
reference point for future research and baseline into clinical practice. 
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Chapter 2: Impact of Medication on Health-related Quality of Life 
and Expenditures for Cancer Patients in the United States 
 
2.1 Abstract 
 
Objective: To examine the association of factors related to cancer prescription 
medication use, health-related quality of life (HRQoL) and prescription medication 
expenditures in the United States. 
 
Methods: A cross-sectional study was performed using the year 2008 Medical 
Expenditure Panel Survey (MEPS) data. 392 cancer patients with age of 18 and above 
were extracted. HRQoL measures were used to provide different perspectives on 
health status of the patients. These measures included the 12-item Short Form Health 
Survey (SF-12), the Kessler Index (K-6) and the Patient Health Questionnaire 
(PHQ-2). Multivariate analyses were conducted to examine how certain patient 
characteristics were strongly associated with HRQoL and high financial burdens 
separately. 
 
Results: Cancer medication use was associated with significant impairment of 
HRQoL. Cancer population reported worse physical or mental health, more serious 
psychological distress and depression than age-matched non-cancer population. Less 
education attainment and experiencing chronic conditions were associated with poorer 
HRQoL. The multivariate analysis revealed that among the cancer patients the 
adjusted annual mean total and out-of-pocket expenditure associated with medications 
were $2,572.1 and $597.1, respectively. They significantly increased in elderly and 
Medicare cancer patients. In addition, patients with lower physical SF-12 scores, 
higher depression PHQ-2 scores were more likely to accrue higher prescription 
medication expenditures. 
 
Conclusions: An association with cancer medication use on patient health status and 
medication expenditures was observed. The study findings provide a comprehensive 
and up-to-date understanding of HRQoL and the real medical expenses on 
cancer-related medications among cancer patients. 
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2.2 Introduction 
 
   This section will introduce the background of the study first. Then study 
objectives and research questions will be presented. 
 
2.2.1 Background 
 
   According to American Cancer Society, in the U.S., men have slightly less than 
one in two lifetime risk of developing cancer; the risk is a little more than one in three 
for women.
4
 Today, millions of people are living with cancer or have had cancer.
4
 
Some of them were cancer-free, while others still had cancer and may be undergoing 
treatment. The treatment options for cancer patients are limited, because they depend 
mainly on the stage of cancer, the age and general health condition of the patients. 
Surgery, radiation therapy and cancer drugs are the most common cancer treatments. 
Surgery removes the tumor partially or completely, which depends on the type, size 
and location of the tumor, and how far advanced the cancer is. It offers the greatest 
chance for cure for many types of cancer, especially localized cancer. However, when 
the cancer has spread to other parts of the body before surgery, complete surgical 
removal is normally impossible. Aiming at these patients, radiation therapy and 
cancer drugs have been developed. Radiation therapy, also called radiotherapy, uses 
high-energy rays to kill cancer cells by damaging the DNA in their genes, and make 
them unable to grow and multiply. The main disadvantage of radiation therapy is that 
healthy cells are damaged as well during the process. Cancer drugs include 
chemotherapy, biologic therapy, immunotherapy, hormonal therapy and angiogenesis 
inhibitors. They can be used in both early and advanced stage, even before or along 
with surgery or radiotherapy. These anti-cancer drugs are taken orally, injected into 
the vein (intravenous, or IV), or applied to the skin (topically). 
 
   Although the currently available cancer drug treatment improves the survival rate, 
relieve some symptoms to a certain extent, at the same time they also produce some 
unexpected toxic side effects, such as damaged healthy cells and tissues, fatigue, fever, 
chills, nausea and so on. Thus, when considering the management of cancer patients, 
treatment-related toxicity and the effect of interventions on quality of life are also 
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taken into account. So far, the majority of outcome researches on cancer drug 
treatment focus on mortality and morbidity since these outcomes are relatively easy to 
observe and data are readily available. Studies examining quality of life of cancer 
patients have shown that cancer drug therapies have a detrimental effect on both short 
and long-term health-related quality of life (HRQoL). However, these studies were 
mostly localized to specified cancer population. The national impact of cancer 
prescription medications on quality of life has not yet been fully examined. Such 
information is absolutely essential when comprehensively assessing the impact of 
cancer drugs on patients‟ health and health care in the U.S. 
 
   In addition, cancer patients are particularly affected by high out-of-pocket 
expenditures. The burden of out-of-pocket expenses is an issue of growing concern to 
both medical and policy community. One of the key reasons is that spending on 
cancer-related prescription drugs rises faster than spending in many other areas of 
health care. Therefore, it is more important now than ever to understand the pattern of 
prescription drug expenditures. It is noticeable that the elderly are incurring more of 
the prescription spending than nonelderly; racial and ethnic minorities have lower 
out-of-pocket medication expenditures than the white population; individuals with 
lower socioeconomic status (SES) incurred greater health care expenditures. However, 
very few studies assess cancer patient expenditures on prescriptions. In particular, the 
studies examined the prescription expenditures associated with cancer among the 
groups of different age, race/ethnic, or socioeconomic characteristics are limited.  
 
2.2.2 Study Objectives 
 
   This study is a macro-level study. It uses the latest public-used data to examine 
the patient characteristics related to HRQoL and expenditures on prescription cancer 
medications among adult cancer patients. This study assesses HRQoL, the total and 
out-of-pocket expenditures attributable to the prescription medications taken by 
cancer patients. It is intended to give a comprehensive and up-to-date understanding 
of cancer and cancer prescription expenditures aiding in managing medical costs. By 
analysing quality of life data, the study will document how HRQoL is affected after 
taking cancer prescription medications. By analysing medical expenditure data, 
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especially out-of-pocket spending for medications, the study will document how the 
expenditures are affected by patient characteristics and health status, and help 
establish a framework for understanding the real medical expenses on cancer-related 
medications among cancer patients.  
 
   One study objective is to compare HRQoL of a large national sample of cancer 
patients with age-matched non-cancer patients, then examine the patient 
characteristics related to HRQoL. Although assessing quality of life is important in 
cancer outcome research, to date, only a few studies have compared the HRQoL of 
cancer patients taking prescription medications with that of the non-cancer population. 
National studies regarding this issue are also lacking. To meet the demand, this study 
quantifies the national impact of cancer patients taking prescription medications in the 
non-institutionalized population in the United States with different HRQoL measures. 
It also explores whether the effects of quality of life differ by patient characteristics, 
such as age, race or insurance coverage. 
 
   The other study objective is to estimate the total and out-of-pocket expenditures 
on prescription cancer medications, and examine how certain patient characteristics 
and health status strongly associated with high financial burdens. Although HRQoL 
also reveals the patients‟ thoughts about the efficacy of treatment, which may 
influence their utilization of medical services, relatively few studies have assessed 
costs and health status associated with cancer patients taking prescription 
medications.  
 
   The expected objective of this study is that by investigating HRQoL and economic 
burden incurred in cancer patients, especially in a specific group of patients, such 
information could be helpful for policy makers to determine the best strategy for 
cancer interventions, and perform efficient patient and medical cost management. 
 
2.2.3 Research Questions and Hypotheses 
 
   This study is based on the year 2008 public-used data drawn from Medical 
Expenditure Panel Survey (MEPS), which is by far the latest and most complete 
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dataset of this survey. The MEPS is a population-based survey for the U.S. civilian 
non-institutionalized population, which is designed to provide nationally 
representative estimates on the health care in terms to utilization, insurance coverage, 
expenditures, and payment sources.
42
 The research questions and their hypotheses are 
described below. 
 
Research Question one: 
“What effects do cancer prescription medications have on the health-related 
quality of life (HRQoL) of cancer patients?” 
 
The hypotheses to be tested are as follows: 
 
1. Cancer patients taking prescription medications show impaired HRQoL in 
comparison to non-cancer patients. 
2. Elderly cancer patients (65 years of age and older) taking prescription 
medications experience impaired HRQoL in comparison to nonelderly 
patients. 
3. Cancer patients with less education attainment are associated with impaired 
HRQoL in comparison to their counterparts. 
 
Research Question two: 
“What are the factors associated with prescription medication expenditures 
among cancer patients?” 
 
The hypotheses to be tested are as follows: 
 
1. Elderly cancer patients incur higher total/ out-of-pocket prescription 
medication expenditures in comparison to nonelderly patients. 
2. Female patients incur higher total/out-of-pocket prescription medication 
expenditures in comparison to male patients. 
3. Whites and non-Hispanics incur higher total/out-of-pocket prescription 
medication expenditures in comparison to blacks and Hispanics. 
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4. Patients with lower SES (classified as poor or having low income, uninsured) 
incur higher total/out-of-pocket prescription medication expenditures in 
comparison to their corresponding counterparts. 
5. Patients with worse physical or emotional health, more serious non-specific 
psychological distress, or greater tendency towards depression are more likely 
to incur higher prescription medication expenditures. 
 
2.3 Literature Review 
 
   This section will provide a systematically literature review related to this study. In 
order to make comparisons to the results of this study, an overview of the quality of life 
(QoL) research on cancer will be presented firstly. Secondly, a comprehensive review 
of the literature on prescription expenditures for cancer will be provided. 
 
2.3.1 Quality of Life (QoL) in Cancer 
 
   Unquestionably, traditional biomedical outcome measures, particularly survival and 
disease-free survival, remain the central topic in cancer decision making.
43
 
Nevertheless, when the clinicians must make a choice among available cancer therapies 
that have similar overall survival outcome, the determination is driven by QoL. The 
reason is that disease-related symptoms, toxic effects of therapy, and the emotional, 
functional and socioeconomic effects of living with cancer have profound effects on 
patients‟ quality of life. These effects can illustrate if the quality of life is improved or 
impaired.  
 
Quality of Life between Cancer and Non-Cancer Patients 
 
   Separating the effects of cancer on HRQoL from the effects produced by comorbid 
conditions and other life changes is difficult. Hence, in order to make a comparison, 
additional data on a comparable sample of non-cancer patients are needed. There are 
several studies comparing quality of life between cancer patients and healthy subjects. 
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   Baker et al.
44
 adopted the Medical Outcomes Study 36-item Short Form Health 
Survey (SF-36) to estimate the HRQoL of cancer survivors in comparison to a 
frequency age-matched cohort of non-cancer patients. In this study, cancer survivors 
had statistically significantly poorer scores than non-cancer patients on all eight 
subscales as well as on the Physical Component measures (PCS) and Mental 
Component summary measures (MCS) of SF-36 (all p < 0.0001). 
 
   Holzner et al.
45
 used the European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC QLQ-C30) to reveal that compared with 
healthy controls, chronic lymphocytic leukemia patients received chemotherapy 
experienced a lower QoL in almost all domains. Moreover, female chronic lymphocytic 
leukemia patients reported remarkably lower QoL scores in emotional and social 
functioning than male patients. 
 
   Two studies compared the HRQoL of hepatocellular carcinoma patients with the 
general population. The SF-36 and the Functional Assessment of Cancer 
Therapy-Hepatobiliary (FACT-Hep) were used respectively. It was suggested that 
patients with hepatocellular carcinoma had lower HRQoL scores than the general 
population,
46 , 47
 especially in physical, emotional, and functional well-being.
47 
In 
contrast, patients reported better scores in social/family well-being.
47 
 
   Botella-Carretero et al.
48
 compared 18 differentiated thyroid carcinoma women 
with 18 age-matched healthy women using four validated HRQoL questionnaires – the 
SF-36, the Nottingham Health Profile (NHP), the Profile of Mood States (POMS) and 
the Visual Analogical Mental Scales (VAMS). When compared with healthy controls, 
patients taking chronic suppressive levothyroxine therapy presented impairment in 
total score, emotional, sleep, energy and social domain of the Nottingham Health 
Profile; mental health, general health and social functioning of the SF-36 (p < 0.05 for 
all comparisons). 
 
   Pelttari et al.
49
 evaluated the impact of cured low-risk differentiated thyroid 
carcinoma on HRQoL after long-term follow-up by 15D instrument, which is a generic, 
15-dimensional self-administered measurement.
 
The HRQoL data obtained from the 
patients was compared to that of a large, representative sample of the general Finnish 
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population. It was found that the mean total 15D scores were similar between patients 
and control subjects. In dimensions of sleeping, speech and distress, differentiated 
thyroid carcinoma patients were significantly worse off (p = 0.001, 0.002 and 0.012, 
respectively), but in dimension of discomfort and symptoms, they were better off (p < 
0.001). Within the patient group, age was the only significant independent predictor of 
HRQoL at the time of the initial treatment (p < 0.001). 
 
   A longitudinal study used SF-36 to compare the effect of androgen deprivation 
therapy on quality of life between men with prostate cancer and healthy men.
50
 There 
were small differences in SF-36 Mental Component Summary (MCS) scores, but 
androgen deprivation therapy use was associated with declines in general health, bodily 
pain, vitality, physical functioning, and role limitations because of physical health 
problems. 
 
Factors affecting Quality of Life in Cancer Patients 
 
   Quality of life is the outcome of the disease and its treatment; meanwhile it also 
highly depends on each patient‟s demographic and socioeconomic status (SES) 
characteristics. Generally, demographic characteristics comprise age, gender, race, 
ethnicity, marital status and residence. SES is largely determined by education, income, 
insurance etc. Some studies produced a consistent findings suggesting that 
demographic and SES characteristics are related to the disparities in QoL of cancer 
patients. 
 
   A national survey was performed in Japan to investigate the relationships among 
cancer patients‟ SES, distress and their QoL after taking chemotherapy.51 This study 
used a semi-structured questionnaire composed of the subscales of the EORTC 
QLQ-C30 and the FACT-Sp (Spiritual well-being) questionnaire. A significant 
association between QoL and age, cancer type, occupation, and marital status was 
found. Specifically, patients having an occupation reported a better QoL in Physical 
Functioning (p = 0.014), but a change in occupation (e.g., layoff, retirement) was 
negatively correlated with Physical Functioning, Role Functioning, Emotional 
Functioning, Cognitive Functioning, Social Functioning and Financial Impact subscale 
of EORTC QLQ-C30 and the Spiritual well-being subscale of FACT-Sp (all p < 0.05). 
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Patients having a partner negatively correlated with Emotional Functioning (p = 0.005) 
and Spiritual well-being (p = 0.038). 
 
   There is a paucity of researches assessing the QoL of patients with various types of 
cancer in relation to their demographic characteristics and SES. 
 
   Penson et al.
52
 examined whether socio-demographic and clinical variables are 
predictive of QoL outcomes of prostate cancer patients. General QoL was measured 
using the SF-36. Disease-specific QoL was measured by the University of 
California-Los Angeles Prostate Cancer Index (UCLA-PCI). The health distress scale 
from the Medical Outcomes Study (MOS) and a scale measuring patient self-esteem 
were also used to measure general QoL. It was noted that prostate cancer patients with 
higher annual income had better QoL scores at baseline in comparison to those with 
lower income. For married patients, emotional well-being and family functioning 
scores were better at baseline, but family functioning scores declined over the nine 
month study period. Compared with younger patients, older patients had slightly better 
baseline performance in several domains of QoL, but experienced greater QoL decrease 
over time. Likewise, increasing comorbidity was associated with worse baseline 
general QoL. Furthermore, prostate cancer patients insured by health maintenance 
organizations (HMOs) appeared to have better QoL than those with certain other types 
of insurance. 
 
   Penson et al.
53
 further examined the effect of SES on QoL outcomes in men with 
prostate cancer by the instruments of the SF-36 and the UCLA-PCI. This study also 
confirmed that patients of lower SES tend to have worse quality of life at baseline and 
following treatment for their disease. Specifically, significantly lower baseline QoL 
scores were found in patients with lower annual income. No relationship was observed 
between annual income and QoL outcomes over time. Conversely, health insurance 
status has a unique effect on general QoL outcomes in patients after treatment for 
prostate cancer. 
 
   Another study described QoL in low-income men with prostate cancer.
54 
Subjects 
were drawn from a statewide public assistance prostate cancer program. The 12-item 
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Short Form Health Survey (SF-12) and UCLA-PCI were used to compare prostate 
cancer patients with normative age-matched men without cancer from the general 
population. This study revealed that compared with the age-matched general 
population controls, the low-income men had worse scores in every domain of 
prostate-specific and general QoL. It also indicated that among the low-income men, 
Hispanic ethnicity and income level were predictive of worse physical functioning, 
whereas only comorbidities predicted mental health. 
 
   Knight et al.
55
 did a research on prostate cancer by using SF-36 and PCI quality of 
life measures as well. This study showed that low-educated men experienced worse 
outcomes in most domains of QoL six months after treatment and less recovery of QoL 
over two years after diagnosis, compared with high-educated men. 
 
   Melmed et al.
56
 examined the additional factors such as marriage and education on 
QoL in patients with metastatic prostate cancer. The outcomes were measured with 
SF-36. It found a slower rate of physical decline in men who were married, 
well-educated and more affluent, while emotional decline appeared slightly slower in 
men with lower than a college education level.  
 
   Some studies described whether HRQoL differ by socio-demographic 
characteristics in breast cancer patients.
 
These studies suggested that women who are 
younger,
57 , 58 , 59 , 60 , 61 , 62 , 63
 married,
63
 unemployed,
63
 highly educated,
60, 63
 or 
religious,
63
 with higher monthly household income,
63
 or less comorbidities,
60
 had 
higher QoL. In addition, the psychological well-being domain scored the lowest among 
domains of QoL.
63
 African American women report better emotional well-being and 
mental health but lower levels of physical functioning than white women.
64, 65, 66, 67
 
 
   Likewise, there are two studies that examined how SES affects QoL in lung cancer 
patients. One study revealed that patients with lower SES reported more problems such 
as physical mobility, energy, role and physical functioning.
68
 The other study showed 
that a higher level of education was significantly correlated with a decreased risk of 
lung cancer.
69
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   These findings support the view that cancer patients with lower SES are more 
likely to report worse QoL than patients with higher SES. 
 
Summary 
 
From the above QoL reviews, the most commonly used quality of life instrument 
to compare cancer patients with non-cancer or general population is the Medical 
Outcomes Study 36-item Short Form Health Survey (SF-36).  
 
   The SF-36 is a generic HRQoL measure designed to examine a person‟s perceived 
health status over the past four weeks. It is a reliable well-validated questionnaire 
which has been used in a wide range of medical conditions.
70
 The SF-36 consists of 
36 items covering eight domains: physical functioning, role limitations because of 
physical health problems, bodily pain, general health, vitality, social functioning, role 
limitations because of emotional problems, and mental health.
71, 72
 Then physical 
component summary scores (PCS) and mental component summary scores (MCS) are 
calculated to provide a global assessment of physical and mental functioning, 
respectively. Items are scored and all scores are transformed to a 0 to 100 scale. A 
higher score represents a better health status. In addition, the PCS and MCS have been 
standardized on norm-based scores (Mean = 50, Standard Deviation = 10) for the 
general U.S. population. 
 
   The SF-36 measures is less sensitive and responsive to the changes when 
assessing QoL of specific patient groups
18 
and it is invaluable when comparing 
different diseases. However, it has strong practical advantages. Firstly, the SF-36 is a 
generic HRQoL measure, which can be applied to a wide range of diseases and health 
conditions including fatigue, physical and social activities, and not related to cancer. 
Secondly, it is applicable to many disease groups as well as the general population, 
and not limited to cancer. Therefore, it can be used to make comparisons between 
cancer patients and patients with other diseases as well as healthy populations. 
 
   In addition, the review of QoL literature revealed two key features regarding the 
health of cancer patients taking medications: a) cancer patients receiving medications 
experienced an impaired QoL compared with non-cancer patients; b) disparities such 
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as age, marriage, race/ethnicity, education, income, insurance and chronic conditions 
have been related to QoL in cancer patients.  
 
2.3.2 Disparities on Prescription Medication Expenditures 
 
   One of the American Cancer Society‟s 2015 goals is eliminating disparities in the 
cancer burden of the U.S. population among different gender, race/ethnicity, residence, 
socioeconomic status (e.g., income, education, employment status, insurance status) 
groups.
4
 The complex and interrelated causes of health disparities within each of these 
groups are likely due to different education, work, income, residence and overall 
standard of living levels.
4
 Social barriers to high-quality cancer prevention, early 
detection and treatment services may also cause the disparities.
4
 Unfortunately, the 
studies focusing on disparities on cancer medication expenditures are limited. For 
providing more adequate background related to this study, some literatures identified 
by Kholsa
73
 and Lines
74
 are also adopted in current study. This section will firstly 
introduce the effects of disparities on prescription medication expenditures based on 
identified studies. Then the studies focusing on out-of-pocket expenditures for cancer 
patients will be presented. 
 
Effects of Age and Gender on Prescription Medication Expenditures 
 
   The actual relationship of cost to age and gender is not clear. When studying 
health utilization and expenditures, age and gender are the most common covariates 
used to adjust for patient characteristics when testing hypotheses about cost, because 
they are almost always available and are reasonable proxies for a person‟s need for 
service.
75 
 
 
   Some studies show that more elderly patients (age 65 and older) than nonelderly 
patients incur prescription drug costs. Additionally, elderly patients incur more of the 
prescription medication expenditures, and pay more of these expenditures via 
out-of-pocket. Moreover, for elderly patients, their out-of-pocket proportion of total 
prescription expenditures is also larger. 
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   The estimates from the year 1996 Medical Expenditure Panel Survey (MEPS) 
revealed that more of the elderly population incurred prescription expenses in 
comparison to the nonelderly (elderly 87% vs. nonelderly 62%), and elderly had more 
than twice as large average prescription expenses than nonelderly did ($825 vs. 
$321).
76
 In addition, more of the elderly patients than nonelderly paid via 
out-of-pocket (52% vs. 41%).  
 
   Ezzati-Rice et al.
77
 did a MEPS research based on year 2000 data and discovered 
that elderly people were much more likely than people under age 65 to have 
prescription medicine expenses (elderly 88.3% vs. nonelderly 58.5%), and their 
median prescription medicine expenses were about five times as high ($695 vs. $136). 
 
   One MEPS study by Xu
78
 confirmed that the disparities of financial burdens still 
existed between elderly and nonelderly populations even after controlling for 
utilization or health care need. The results indicated that the elderly spent about three 
times as much of their incomes on out-of-pocket spending for prescription drugs as 
the nonelderly. They also had financial disadvantage in out-of-pocket proportion and 
income proportion. The comparisons of within-poverty-level revealed that with the
 
low income level (125 - 199% of poverty) elderly were worse off than nonelderly in 
the same poverty class and in other income groups.  
 
   McKercher and his colleagues examined prescription drug use among elderly and 
nonelderly families based on year 1996 MEPS data.
79
 They found that compared with 
nonelderly families, elderly families had greater prescription size, higher price and 
more drug use. Elderly families experienced almost twice increase in their 
out-of-pocket spending proportion of total expenditures (45.6% vs. 23.7%).  
 
   Likewise, some studies also analyzed the effect of gender on prescription 
medication expenditures.  
 
   Hodgson et al.
80 
used various national survey data sources to estimate the year 
1995 personal health care expenditures with regard to gender, age and diagnosis for 
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each type of health care service. This study indicated that male cancer patients paid 
less on prescription drugs than female patients (male $387 vs. female $597). 
 
   Ezzati-Rice et al.
77
 found that females were more likely to incur prescription 
medicine expenses than males (female 69.2% vs. male 54.9%). The median expense 
per person was $219 for females and $146 for males. 
 
   In Medicare Chartbook 2010, one section analyzed Medicare and prescription 
drugs through Medicare current beneficiary survey cost and use files.
81
 It indicated 
that the average per capita out-of-pocket spending by female Medicare beneficiaries 
was higher than that by male beneficiaries (female $4,490 vs. male $3,930). 
 
Effects of Race and Ethnicity on Prescription Medication Expenditures 
 
   In health care, the differences of race and ethnicity are prevalent. According to 
Cancer Facts & Figures of American Cancer Society, compared with any other racial 
or ethnic group, African Americans have a higher probability to develop and die from 
cancer,82 and Hispanics have lower incidence rates for either all cancers combined or 
for most common types of cancer when compared to whites.83
 
Additionally, there is 
also a greater amount of uninsured or public insured among African Americans or 
Hispanics.
84 
Furthermore, older minorities had lower overall health care utilization in 
contrast to non-Hispanic whites.
85
 Thus the frequency of health care utilization 
including prescription medicine is lower among blacks and Hispanics, since they rely 
more on public coverage. 
 
   Ezzati-Rice et al.
77
 used year 2000 MEPS data to analyze the healthcare expenses 
in the Unites States. It was found that minorities were less likely to incur prescription 
medicine expenses than whites/others. The percentages were 47.2% of Hispanics, 
50.8% of blacks and 66.6% of whites/others. Whites/others ($214) incurred higher 
median prescription medicine expense per person with an expense than blacks ($125) 
and Hispanics ($92). 
 
   Winter et al.
86
 pooled year 1996-2003 MEPS data to examine how race and 
health insurance impact on cardiovascular disease prescription medication use and 
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expense. It showed that the expenses for European Americans were significantly 
higher than those for African American, Hispanic Americans, or persons in the other 
racial group (mean $1,406 vs. $1,056, $1,169, $1,086 respectively; p < 0.01). Higher 
prescription medication expense was associated with being older, female, married, 
unemployed and living in the northeast. In addition, compared to participants with 
public or with dual public and private coverage, participants with private coverage 
spent less prescription medications (private coverage $1,194 vs. public coverage 
$1,931, dual public and private coverage $2,076, respectively; p   0.001). 
 
   Tseng et al.
87
 investigated insured diabetes adults‟ race/ethnicity in cost-related 
medication underuse.
 
They found that African Americans and Latinos had higher 
cost-related medication underuse rates, lower income, lower education level and 
higher out-of-pocket drug costs than other races. 
 
Effects of Socioeconomic Status (SES) on Prescription Medication Expenditures 
 
   Several researches showed that SES, including income, education, employment 
status and insurance status, was an important factor affecting prescription medication 
expenditures. 
 
   Using year 2001 MEPS data, Shin and Moon studied how prescription drug 
insurance related to prescription drug‟s use and spending.88  The mean of total 
prescription drug expenditure for respondents with drug insurance ($1,032.2) was 
significantly lower in comparison to those without drug insurance ($1,293.2). 
Significant difference in out-of-pocket prescription drug spending was also found 
between respondents with drug insurance (46% of out-of-pocket spending for all 
health care use, 40% of prescription drug expenditure) and those without drug 
insurance (64% of out-of-pocket spending for all health care use, 69% of prescription 
drug expenditure). 
 
   Stagnitti
89
 examined prescribed medicine expenditures in terms of sources of 
payment and insurance status by year 2003 data from MEPS. For those incurring a 
prescribed drug expense, the average prescription drug expense per Medicare 
beneficiary ($1,971) was almost three times as large as the average expense per 
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person in the non-Medicare population ($688). The average annual out-of-pocket 
prescription drug expense for Medicare beneficiaries was the highest for those people 
covered by Medicare only ($1,353) compared with those covered by Medicare and 
any private insurance ($892) or those covered by Medicare and public only insurance 
($796). The uninsured had the lowest average annual total expense ($488) but the 
highest average annual out-of-pocket expense ($428) when compared with those with 
public insurance only (total expense $768 and out-of-pocket expense $226, 
respectively) and those with any private insurance (total expense $697 and 
out-of-pocket expense $271, respectively). 
 
   Ezzati-Rice et al.
77
 indicated that the median prescription medicine expense per 
person was $174 for people living in metropolitan statistical area (MSA) and $239 for 
people not living in MSA in year 2000. People living in the West Region had the least 
probability to incur prescription medicine spending: 58.1% in the West versus 62.6% 
in the South, 64.1 % in the Midwest, and 64.3% in the Northeast. Those people also 
had the lowest median prescription medicine expenses: $135 in the West versus $172 
in the Northeast, $204 in the Midwest, and $223 in the South. In addition, poor people 
had a lower likelihood of having prescription medicine expenses than high income 
people (poor 58.6% vs. high income 64.8%), and the median expense was less among 
poor people than for people with high income ($139 vs. $205). 
 
Prescription Medication Expenditures and Quality of Life 
 
   The studies assessing prescription medication expenditures and patients‟ quality 
of life show that poor health status was associated with higher prescription 
expenditures. 
 
 
   Based on year 2000 MEPS data, Ezzati-Rice et al.
77
 reported that people with 
better perceived health status were less likely to incur prescription medicine expenses 
in comparison to people in poor health. 49.0% of people with excellent perceived 
health had prescription medicine expenses. In contrast, 92.2% of people with poor 
perceived health had prescription medicine expenses. 
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   A study demonstrated significantly worse health outcomes among middle-age and 
elderly Americans who reported restricted medications because of unaffordable cost.
90 
Among the responders who reported good to excellent health at baseline, the 
percentage of those who had cost-related medication restrictions reported a significant 
decline in their health status was higher than that of those who had not (32.1% vs. 
21.2%; adjusted odds ratio 1.76). Cardiovascular disease has the strongest association 
with cost-related medication restriction than diabetes, arthritis and depression. 
 
   Harman et al.
91
 used year 1999 MEPS data to indicate that older Americans with 
depression have relatively high out-of-pocket expenditures. Mean out-of-pocket 
expenditures for elderly Americans with depression were $1,835 in 1999. Most of the 
spending ($1,090) was on prescription drugs. Patients with depression had greater 
mean out-of-pocket spending than those with hypertension and arthritis. 
 
   Farmer and Ferraro examined the interactive relationship between race and SES 
on health for Americans with a 20-year period.
92
 This study indicated that blacks 
reported more serious illnesses and poorer self-rated health than whites when starting 
the study, and this disparity last 20 years. It was also found that race and education 
had significant associations with health outcomes: at the higher levels of SES, the 
racial disparity in self-rated health was the largest; blacks did not have the same 
improvement in self-rated health as whites did when education level increased. 
 
   Lee and Skrepnek
93
 used year 2006 MEPS data to examine the associations of 
out-of-pocket health care expenditure and quality-of-life (QoL) with physical activity 
in patients with hypertension. This study showed that patients had an average of 
$1,453 ± 47 out-of-pocket health care expenses. Average physical and mental QoL 
scores were 42.4 ± 0.2 and 50.2 ± 0.1 respectively. In addition, physical inactivity was 
associated with 14.9% ± 5.2% greater out-of-pocket health care expenses, 7.4% ± 0.8% 
lower physical QoL, and 3.3% ± 0.7% lower mental QoL (all p < 0.0001). 
 
   A study used population-based survey to examine the determining factors of 
out-of-pocket health expenditure in China. This study indicated that highest 
out-of-pocket health expenditure incurred among the persons who had perceived quite 
serious illness and self-reported poor health status.
94
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Out-of-Pocket Expenditures of Cancer Patients 
 
   There are seven studies assessing cancer patients‟ out-of-pocket expenditures in 
the U.S. Six studies conducted national estimates of medical costs by national survey 
data, which focusing on nonelderly, elderly cancer patients or cancer survivors. One 
study examined expenditures of breast cancer patients. 
 
   Hodgson et al.
80
 used various national survey data sources to estimate the year 
1995 personal health care expenditures. They found that male cancer patients paid 
less prescription drugs than female patients. Female cancer patients had an average of 
$567 on prescription drugs in year 1995, while the number for male cancer patients 
was $387. Elderly cancer patients had an average of $19,212 in year 1995 on 
expenditures ($366 for prescription drugs) while non-elderly counterparts had an 
average expenditure of approximately $21,964 ($588 for prescription drugs).  
 
   Howard et al.
95
 compared year 1996-1999 data from MEPS with year 1999 data 
from Marketscan database, which collects claims data from commercial, Medicare 
supplement and Medicaid populations. The total cancer treatment-related spending by 
nonelderly cancer patients was $20.1 billion in MEPS database (6.5% was spent via 
out-of-pocket expenditures), and $17.2 billion in Marketscan database (4.1% was 
spent via out-of-pocket expenditures). 
 
   One study used the same year 1996-1999 MEPS data to examine health insurance 
and spending among nonelderly cancer patients.
96
 This study revealed the uninsured 
patients spent less of the health care spending ($3,606) compared with Medicare 
($6,080), Medicaid ($5,943) and privately insured patients ($6,550). Additionally, 
uninsured patients paid more out-of-pocket than insured patients paid. 
 
   Using year 1996-2003 data from MEPS, Banthin et al.
97
 reported that individuals 
aged 55 to 64 years, with poor and low-income, without group coverage, living in a 
non-city area, in fair or poor health, having any type of limitation, or experiencing a 
chronic medical condition had higher-than-average risk of incurring high total 
burdens. 
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   Langa et al.98 did national estimates of elderly patients by using data from the 
year 1995 Asset and Health Dynamics Study, which is a nationally representative 
survey of non-institutionalized elderly population in the U.S. They found that 
prescription medications ($1,120 per year) accounted for most of the additional 
out-of-pocket expenditures associated with cancer treatment. Low-income cancer 
patients undergoing treatment spent about 27% of their yearly income on 
out-of-pocket expenditures; in contrast, high-income individuals with no history of 
cancer spent only 5%. Elderly cancer patients spent additional $670 (48% were 
attributed to prescription medication expenditures) per year on current cancer 
treatments, despite adjusting for contributing factors, such as demographic 
characteristics, socioeconomic status. 
 
   Another study used MEPS data from year 2001 to 2007 to estimate of medical 
expenditures for adult cancer survivors aged less than 65.
99
 It indicated that cancer 
increased the risk of high out-of-pocket expenditures. The mean annual expenditures 
on all services were higher for survivors who were newly diagnosed ($16,910) than 
long term survivors ($7,992) and other adults ($3,303). 
 
   Arozullah et al.
100
 examined the financial burden of insured breast cancer patients. 
In all, 156 patients received most or all cancer care at an academic hospital between 
October 1999 and November 2002 were interviewed by a questionnaire. The mean 
total out-of-pocket costs averaged $1,455 per month, of which about half was lost 
income ($727), 41% was for non-reimbursed direct medical costs ($597), and 9% for 
direct nonmedical costs ($131). The most commonly reported out-of-pocket 
expenditures were for medications (80%). The financial burden of breast cancer 
patients was 98% for those with annual household incomes less than $30,000, 41% 
for those with annual household incomes between $30,001 and $60,000, and 26% for 
those with annual household incomes more than $60,000, respectively. 
 
Summary 
 
   The studies examining expenditures associated with cancer disparities are limited; 
particularly the studies referring to cancer prescription medication expenditures are 
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scare. Yet the identified studies have shown that more elderly patients than nonelderly 
patients incur prescription drug costs and incur more of the prescription medication 
expenditures. Female patients pay more on prescription drugs than male patients. 
Compared with whites, more racial and ethnic minorities were covered by public 
health insurance and they spent lower out-of-pocket expenditures for health care 
including prescription expenditures. Furthermore, individuals with lower SES or 
poorer health status incur higher health expenditures. 
 
   Identifying the characteristics of patients who are probable to spend large amounts 
of out-of-pocket medication expenditures, as well as those services that are most 
likely to generate such expenditures is important. To summarize from the points 
above, out-of-pocket spending varies by age (especially the elderly), gender 
(especially female), income (especially low-income), insurance status (especially 
uninsured), chronic conditions, and the self-reported health status (especially poor 
health status). 
    
2.4 Methodology 
 
   This study is a cross-sectional analysis on health-related quality of life and 
expenditures of cancer patients with prescription medications. For better documenting 
the disparities affecting HRQol and cancer prescription medication expenditures, 
beyond the data analysis methods introduced by MEPS, some other methods in the 
studies of Xie et al.
101
 and Sung
102
 are considered as references as well. In this 
section, the data source used is described firstly, and then the data files chosen to meet 
the study‟s goals will be introduced. After that, the study sample, variables and 
statistical analytic methods will be presented. 
 
2.4.1 Data Source 
 
   The data from this study were collected from the Medical Expenditure Panel Survey 
(MEPS), which is administered by the Agency for Healthcare Research and Quality 
(AHRQ) under the U.S. Department of Health and Human Services (HHS) 
(http://www.meps.ahrq.gov/mepsweb). The MEPS is a set of large-scale surveys 
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designed for individuals and families, their medical providers (e.g., doctors, hospitals, 
and pharmacies) and employers across the United States.
42
 The primary care 
practice-based research networks are supported by AHRQ link information on health 
services with patient-reported outcomes data in community-based clinical care 
settings for more than 38,000,000 patients in 49 states.
103
 It provides nationally 
representative estimates on the utilization, insurance coverage, expenditures, and 
payment sources of health care for the U.S. civilian non-institutionalized population. 
 
   The core component data in the MEPS is the Household Component (HC) data. 
This data is based on questionnaires for individual household members and their 
medical providers.
42
 It contains the information of respondents‟ health status, 
demographic and socioeconomic characteristics, employment status, access to health 
care, satisfaction with health care and prescribed medication information. In addition, 
since year 2000, HC has included a Self-Administered Questionnaire (SAQ) that 
contains HRQoL measures for adults aged over 18 years. The overall response rate for 
this questionnaire is 92.7% in 2008.
104
 
    
   The sampling frame for the MEPS Household Component is randomly drawn 
from individuals who have responded to the previous year‟s National Health 
Interview Survey (NHIS). The NHIS follows a complex multi-stage probability 
design which samples in three stages: the first stage of sample selection is an area 
sample of Primary Sampling Units (PSUs), which consist of counties; in the second 
stage, blocks are selected; and in final stage, households are sampled.
104
 In each 
selected family, all civilians are key, in-scope and are surveyed. A key, in-scope 
person means that the person responded to MEPS for the full period of time (in this 
study, it is year 2008).
104
  
 
   The MEPS Household Component has an overlapping panel design. Each panel is 
interviewed totally five times covering two full calendar years.
105
 Every year a new 
MEPS panel that includes a nationally representative sample of households is 
introduced into the survey. Interviews last an average time of 90 minutes and are 
conducted with computer-assisted personal method. The first interview contains many 
detailed questions (e.g., respondents‟ health status, income, employment status, 
eligibility for Medicare, Medicaid or private insurance coverage, use of health care 
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services, payment for care, etc.). The subsequent interviews ask about the changes 
since the last interview, such as what employment status has changed, what medical 
care has occurred. In supplemental modules, relevant questions (e.g., access to health 
care, health status) are asked periodically.
105
 This design could help to determine how 
these changes are related.  
 
   The data used in this study pertain to calendar year 2008. They were collected in 
Rounds 1, 2, and 3 for MEPS Panel 13 and Rounds 3, 4, and 5 for MEPS Panel 12. 
Round 3 for a MEPS panel is designed to overlap two calendar years, as illustrated in 
Figure 4. 
 
Figure 4: Illustration of Panels and the Round Series in MEPS Survey Year 2008 
 
 
Adapted from: 2008 Full Year Consolidated Data File, Agency for Healthcare Research and Quality.104  Page 109. 
 
 
   This public use dataset contains 33,066 persons who participated in the MEPS 
Household Component in 2008.
104
 These persons were part of one of the two MEPS 
panels for whom data were collected in 2008: Rounds 4 and 5, and part of Round 3 of 
Panel 12 or Rounds 1and 2, and part of Round 3 of Panel 13. 
 
   For examining patients‟ HRQoL and prescription medication expenditures, the 
following three data sources are selected from 2008 household component files: 
 
 MEPS HC-118A: 2008 Prescribed Medicines File 
 MEPS HC-120:  2008 Medical Conditions File 
 MEPS HC-121:  2008 Full Year Consolidated Data File 
2007 2008
2009
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   The 2008 Prescribed Medicines public use data set (MEPS HC-118A) contains 
detailed prescription medicines information obtained from pharmacy providers that 
household sampled persons frequented. On this file, each record includes the 
following information: an identifier for each prescribed medicine; detailed medicine 
characteristics (e.g., national drug code (NDC), medicine name, quantity of the 
medication dispensed, form of the medications, unit of measure, and dosage strength); 
conditions associated with the medicine; the first date that the person start to use the 
medicine; total expenditure; payment sources; contact information of pharmacies that 
filled the prescriptions.
106
 To use this file for cancer patients, a list of reported use of 
prescription medications associated by all household with a primary diagnosis 
corresponding to the International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes of “140-239” was complied. The detailed ICD-9-CM 
codes for cancer in this study are listed in Appendix 1. 
 
   The MEPS HC-120, Medical Conditions File contains verified information about 
respondents‟ medical conditions. These conditions are transformed to fully-specified 
ICD-9-CM codes by professional coders based on the verbatim text recorded by the 
interviewers.
107
 All the codes were verified, and error rates were less than 2.5% for 
any coder.
108
 From these data, patients with cancer (ICD-9-CM codes from 140 to 
239) were first identified, and then comorbid conditions were identified for each 
person.  
 
   The MEPS HC-121, 2008 Full Year Consolidated Data File contains variables 
related to participants‟ demographics, income and tax filing, person-level condition, 
health status, disability days, access to care and quality of care, employment status, 
health insurance, patient satisfaction, and person-level medical care use, expenditures, 
and sources of payment.
104
 All patients‟ variables and health related information are 
extracted from this file. Demographic and socioeconomic status variables include age, 
gender, race/ethnicity, region, marital status, education attainment, personal total 
income and family poverty level. Metropolitan Statistical Area (MSA) status is also 
used as a geographic variation. With regard to health insurance status, this study used 
the summarized health insurance coverage indicators for the respondents in 2008: 
Medicare, Medicaid, other public insurance, private insurance and being uninsured. In 
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addition, patient-reported health status information was collected through 
Self-Administered Questionnaire (SAQ) in this data file.  
 
Reasons for Using MEPS   
 
   In the United States, there are many national survey databases conducted by the 
U.S. Department of Health & Human Services (HHS), such as MEPS, National 
Ambulatory Medical Care Survey (NAMCS), Healthcare Cost and Utilization Project 
(HCUP) etc.  
 
   The first reason for choosing MEPS data files for this research is that MEPS is a 
nationally representative survey data with high accuracy and reliability. Detailed 
information on prevalence and incidence along with comorbidities, medication, health 
utilization, medical services received, expenditures could be obtained from MEPS. In 
addition, there was a high percentage correlation between patient and 
provider-reported diagnoses.
109, 110
 
 
   The second reason is that MEPS allows researchers to identify the disease by 
ICD-9-CM codes instead from the answers to the questions. At first, the diagnoses of 
cancer were based on the verbatim text of each patient‟s self-reported medical 
condition. Subsequently, a professional coder assigned fully-specified ICD-9-CM 
codes to that verbatim text. Additionally, each code for self-reported medical condition 
was verified by medical providers and pharmacies that the respondents frequented. The 
error rate did not exceed 2.5% for any coder.
108
 Fully-specified ICD-9-CM codes were 
in three-digit form in order to protect the confidentiality of respondents.
 108
 
 
   The third reason is the reliability of drug use information. In order to avoid 
respondent underreporting prescription data, the MEPS relieves the household of the 
report burden by obtaining the computerized printouts from respondents‟ pharmacy 
providers that the respondents identified as their source of care under patients‟ 
permission.
111
 The computerized printouts contains detailed financial information on 
every prescription purchase, such as the date the drug dispensed or refilled, the NDC, 
the drug name including generic and/or brand name, the strength of the drug, the 
quantity of the drug dispensed, total charge, payment sources and the amount of 
 48 
 
payment made by each source.
111
 When computerized printouts are unavailable from a 
pharmacy provider, the survey staff attempt to secure written data forms when possible. 
The information collected from pharmacy providers has to be imputed or match to all 
the household drug mentions for public release of the household prescription data.
111
  
 
   The fourth reason is that MEPS collects data on specific health care services and 
captures all related costs, not just single payer costs. The data allows for basic 
descriptive statistics and behavioral analyses of the U.S. health care system, including 
detailed demographic, health status, behavior, and socioeconomic status information; 
conditions and diseases direction; utilization of health services, expenditures of health 
care, and payment sources for health care.
105
 It also support exporting the impact of 
health status on health care use, expenditures, choice of health insurance and household 
decision making.
105
  
 
   The final reason is that the data files released by MEPS are easy to access. There 
is no permission required for access to all public use data files, which are also freely 
downloadable. All public use files are sorted according to data year. In addition to the 
raw data, each data file includes a document file containing detailed technical and 
programming information (e.g., how the data were collected, how the variables were 
edited), survey sampling information and variable-source crosswalk; a codebook 
containing alphabetical and positional listing of variables, and unweighted and 
weighted frequencies; statistical program (SAS or SPSS) statements and 
programming examples; and the contents of questionnaires used in interviewing 
MEPS respondents.
42
 
 
2.4.2 Definitions of Study Sample and Variables 
 
This section will firstly introduce how the study sample is selected. Then a brief 
explanation about the dependent and independent variables will be presented, 
respectively. 
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2.4.2.1 Study Sample 
 
   Individuals were identified for inclusion in this study if they reported diagnosis of 
cancer (ICD-9-CM codes from 140 to 239). In addition, only individuals who were at 
least 18 years old and had positive personal weight were included. The reason for 
extracting patients with positive personal weight is that the current study only 
included in-scope persons who responded to MEPS during the full 2008 year. The 
detailed explained will be found in the next section - “statistical analytic methods”. 
Moreover, patients who did not have Self-Administered Questionnaire (SAQ) data 
were excluded, because only SAQ had HRQoL information. The selection process of 
the study sample is illustrated in Figure 5. 
 
Figure 5: Flow Chart of the Study Sample Selection 
 
 
 
Prescribed Medicines File Medical Conditions File Full Year Consolidated File
   N=18,595 N=26,028 N=33,066
Patients with Cancer 
Conditions
N=1,995
Cancer Patients
N=1,631
Cancer Patients with 
Prescription Medicines
N=428
Exclude:
Patients under 18 years of age
Personal weight < 0
Patients not eligible for SAQ
Sample Size
N=392
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   In 2008, 33,066 persons participated in the Household Component of the MEPS. 
There were 1,631 persons reported that they were diagnosed with cancer. 31,435 
persons were without cancer diagnosis. Among these cancer patients, only 428 (26%) 
patients were treated with prescription cancer medications during the full year of 2008. 
After excluding patients who were less than 18 years of old, with negative personal 
weight and not eligible for SAQ, the final sample included 392 cancer patients with 
prescriptions. Patients without cancer diagnosis were age-matched to cancer patients 
with prescription medications at 1:5 ratios. Hence, 1,960 age-matched persons 
without cancer diagnosis were identified from total population.  
 
2.4.2.2 Dependent Variables 
 
1) Patient-reported Outcomes from SAQ 
 
   The Self-Administered Questionnaire (SAQ) is a paper-and-pencil questionnaire. 
It is designed to collect a variety of health status and health care quality measures of 
adults. MEPS interviewers distribute hard copies of the SAQ to members of sampled 
households. Then completed SAQs are returned by mail. The pooled response rate of 
SAQ for the year 2008 is 92.7 %.
104
 The SAQ includes three Health-related Quality of 
Life (HRQoL) instruments: the Medical Outcomes Study 12-item Short Form Health 
Survey, Version 2 (SF-12v2) for measuring overall health status, the Kessler Index 
(K-6) for measuring non-specific psychological distress, and the Patient Health 
Questionnaire (PHQ-2) for measuring depression.  
 
a. Short-Form 12 Version 2 (SF-12v2) 
 
   The Medical Outcomes Study 12-item Short-Form Health Survey (SF-12) is a 
generic HRQoL measure with items derived from the 36-item Short Form Health 
Survey (SF-36). It is a brief and easy (usually takes two to three minutes to complete) 
HRQoL measure of overall health status.
112, 113
  
 
   SF-12 includes twelve questions covering the following eight multi-item 
subscales:  
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 physical functioning (2 questions); 
 role limitations because of physical health problems (2 questions);  
 bodily pain (1 question);  
 general health perceptions (1 question);   
 vitality (energy/fatigue) (1 question);   
 social functioning (1 question); 
 role limitations because of emotional problems (2 questions);  
 general mental health ( 2 questions: psychological distress and psychological 
well-being) 
    
   The two questions of physical functioning are scored from 1 to 3, higher score 
indicates less limitations. The other questions are scored from 1 to 5, higher score 
indicates better health. But for general health perceptions and bodily pain, higher 
score indicates poor general health and aggravating pain.  
 
   Then, physical and mental summary scales (Physical Component Summary 
[PCS-12] and Mental Component Summary [MCS-12]) from all twelve questions are 
generated by a scoring system. PCS-12 weighs more heavily on the response to the 
first four subscales, while MCS-12 weighs more heavily on the response to the last 
four subscales. Both summary scales are transformed to a scale of 0 (worst health) to 
100 (best health) by means of norm-based scoring. Higher scores represent better 
physical or emotional function. Norm-based PCS-12 and MSC-12 scores for the U.S. 
general population were scaled with a mean of 50 and standard deviation of 10. That 
is, a score of more or less than 50 indicated that physical / emotional health was better 
or worse, respectively, than the general U.S. average. Item level of SF-12 responses, 
PCS-12 scores and MCS-12 scores are available for adult respondents in the MEPS 
data files. In year 2001 and 2002, the SF-12 Version 1 was administered; starting in 
year 2003, the SF-12 Version 2 replaced Version 1. Compared with version 1, version 
2 improved a lot, such as increasing the precision of the eight health profiles, 
decreasing ambiguity in the phrasing of some questions, and providing normative 
comparisons.
114
 The evaluation of adequate validity and reliability of the SF-12v2 in 
the MEPS can be found in the publication by Cheak-Zamora et al
115
, which supports 
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the use of the SF-12v2 to evaluate the health status of the population and changes in 
health status over time. 
 
b. Kessler Index (K-6) 
 
The Kessler Index (K-6) was developed by Kessler and colleagues to measure 
non-specific, rather than disorder-specific psychological distress.
116  
The six-item 
questions assess a person‟s non-specific psychological distress during the past 30 days. 
Persons are asked to rate how often they felt 
 
 nervous; 
 hopeless; 
 restless or fidgety; 
 so sad that nothing could cheer you up; 
 that everything was an effort; 
 worthless; 
 
Each question uses the values 0 (none of the time), 1 (a little of the time), 2 (some 
of the time), 3 (most of the time) and 4 (all of the time). A summation of the six 
variables above provides an index score ranging from 0 to 24. Higher value of K-6 
index score indicates a greater tendency towards serious mental disability. K-6 
summary score   13 is the optimal cut point for the prevalence of serious mental 
illness in the national population.
117
 
 
c. Patient Health Questionnaire (PHQ-2) 
 
The PHQ-2 is made up of two items to assess the frequency of the person‟s 
depressed mood and decreased interest in usual activities.
118
 The two items are “Over 
the last two weeks, how often have you been bothered by 1) little interest or pleasure 
in doing things 2) feeling down, depressed, or hopeless?” For each item, the response 
scores are 0 (not at all), 1 (several days), 2 (more than half the days) and 3 (nearly 
every day), respectively. There is also a summation of the values of the two variables 
above ranging from 0 through 6. A higher score indicates more serious depression. 
The authors suggest a score of 3 as the optimal cut-point for screening purposes.  
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2) Prescription Medication Total and Out-of-Pocket Expenditure 
  
   In the MEPS Prescribed Medicines File, expenditures refer to actual money paid 
for prescribed medications. More specifically, expenditures defined as the sum of 
payments for health care received, including out-of-pocket payments and payments 
made by each source such as private insurance, Medicaid, Medicare and other 
sources.
106 
Expenditures for over-the-counter medications are not included. Such 
definition in MEPS represents improvements over the predecessors of MEPS (i.e., the 
year 1987 National Medical Expenditure Survey and the year 1977 National Medical 
Care Expenditure Survey), which included information on charges rather than sum of 
payments to measure expenditures.
106
 The reason of adopting this change is that the 
increasingly common practice of discounting charges causes charges gradually 
becoming an improper proxy for medical expenditures during the 1990s.
106 
 
Total Expenditure 
 
   The total expenditure is calculated from major twelve sources of payments 
categories. On page 15 of “MEPS HC-118A: 2008 Prescribed Medicines” document 
downloaded from the website of Agency for Healthcare Research and Quality,
 
these 
categories are introduced as follows:“ 
 Out-of-pocket by user (self) or family;  
 Medicare;  
 Medicaid;  
 Private Insurance;  
 Veterans Administration (VA) / Civilian Health and Medical Program of the 
Department of Veterans Affairs (CHAMPVA), excluding TRICARE (military 
health services);  
 TRICARE;  
 Other Federal sources, includes Indian Health Service, Military Treatment 
Facilities, and other care by the Federal government;  
 Other State and Local Source, includes community and neighborhood clinics, 
State and local health departments, and State programs other than Medicaid;  
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 Worker‟s Compensation;  
 Other Unclassified Sources, includes sources such as automobile, 
homeowner‟s and liability insurances, and other miscellaneous or unknown 
sources;  
 Other Private, any type of private insurance payments reported for persons not 
reported to have any private health insurance coverage during the year as 
defined in MEPS; and  
 Other Public, Medicaid/Medicaid payments reported for persons who were not 
reported to be enrolled in the Medicaid/Medicaid program at any time during 
the year. ”106  
 
   The last two are additional sources of payment variables (other private and other 
public). They were created to sort apparently inconsistent payments between 
insurance coverage and payment sources.
106
 
 
Out-of-Pocket Expenditure 
 
   In the MEPS Prescribed Medicines File, out-of-pocket expenditures are the 
prescribed medication spending paid by user or family.
106 
They also include cash 
payments for coinsurance and deductibles, services, supplies and other items not 
covered by health insurance, but the premiums of health insurance, whether directly 
paid or withheld by employers, were excluded in this study.
119
  
 
   It is important to note that the total number of prescription medications in MEPS 
data is not differentiated. That is, all refills are included. 
 
2.4.2.3 Independent Variables 
 
   In order to make the outcomes more explainable and understandable, this study 
modified a few variables and regrouped some values. All the independent variables 
still have the same names as those in the MEPS survey. Totally, there are five 
categories of independent variables: demographic variables (i.e., age, gender, race, 
ethnicity, marital status, and geographic variation), socioeconomic status (i.e., 
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education attainment, income, health insurance coverage, and prescription insurance 
status), currently smoke, chronic conditions and proxy report.  
 
1) Demographic Variables 
 
Age 
 
   Age was calculated from the date of birth and indicated age status as of 
12/31/2008. In order to analyze the differences between age groups, dummies were 
used to account for different age categories: 18-39 years, 40-64 years, and above 65 
years. 65 years and older category was the reference group. 
 
Gender 
 
   Gender was classified in to male and female. Male was the study reference group. 
 
Race 
 
   The race questions in the MEPS have been revised starting in year 2002. In the 
2008 survey, races included: 1. White; 2. black; 3. American Indian/Alaska Native; 4. 
Asian; 5. Native Hawaiian/Pacific Islander; 6. multiple race.
104
 This study recoded the 
race into three groups: white, black and other. White population was the study 
reference group. 
 
Ethnicity 
 
   Ethnicity included Hispanic and non-Hispanic, in which the latter was the study 
reference group. 
 
Marital Status 
 
   The MEPS interview had six categories to measure marital status in questionnaire: 
1. Married; 2. Widowed; 3. Divorces; 4. Separated; 5. Never married; 6. Under 16 - 
inapplicable.
104
 Individuals under 16 years old were considered as inapplicable data. 
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This study only extracted individuals who were older than the age of 18. A dummy 
was used to regroup marital status. The new code 1 was for married and 0 was for 
unmarried. Here, unmarried was the reference group. 
 
Geographic Variation - Census Region 
 
   Census region was collected for the main four areas of the U.S.: Northeast, 
Midwest, South, and West. West was the reference group. The states for each region 
will be introduced in Appendix 2. 
 
Geographic Variation - Metropolitan Statistical Area (MSA) 
 
   The code of the MSA was 1 and non-MSA was 0, in which the latter was the 
reference group. 
 
2) Socioeconomic Status (SES) 
 
Education Attainment 
 
   In 2008 survey, the number of years of completed education and the highest 
degree of education indicated personal education level.
104
 This study created four new 
levels according to the total years of education completed: 1. Less than 8 years; 2. 
High school diploma (including school grades from 9 to 12); 3. Some college 
(including college year from 1 to 3); 4. Bachelor‟s degree and other higher degrees. 
The last group was the reference group. 
 
Income – Total Person-level Income 
 
   The definitions of income and poverty categories used to construct the related 
variables in this file were taken from the 2008 poverty statistics developed by the 
Current Population Survey (CPS).
104
 Income variables included total person-level 
income and family income. Total person-level income was the sum of all income 
components with the exception of a person‟s tax refunds and capital gains.104 In this 
study, it was divided into low (< $15,000), middle (between $15,000 and $20,000) 
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and high categories (> $20,000). High person-level income category was the reference 
group. Family income was related to poverty status as follows. 
 
Income - Poverty Status 
  
   Page 30 of “MEPS HC-121: 2008 Full Year Consolidated Data File” defined 
family income as follows: “family income was derived by constructing person-level 
total income comprising annual earnings from wages, salaries, bonuses, tips, 
commissions; business and farm gains and losses; unemployment and workers‟ 
compensation; interest and dividends; alimony, child support, and other private cash 
transfers; private pensions, Individual Retirement Account (IRA) withdrawals, social 
security, and veterans payments; supplemental security income and cash welfare 
payments from public assistance, Temporary Assistance for Needy Families, and 
related programs; gains or losses from estates, trusts, partnerships, S corporations, 
rent, and royalties; and a small amount of “other” income.”104 Person-level incomes 
were summed over family members to yield the family-level total income. Then, 
family-income was divided by the applicable poverty line (i.e., based on family size 
and composition) and categorized as a percentage of the poverty line.
104
 The five 
categories were as follows: 1. negative or poor (i.e., less than 100%); 2. near poor (i.e., 
100% to less than 125%); 3. low income (i.e., 125% to less than 200%); 4. middle 
income (i.e., 200% to less than 400%); 5. high income (i.e., greater than or equal to 
400%).
104
 However, since less than 5% of the study sample were classified as near 
poor, the lowest two categories were combined. High family income group was the 
reference group. 
 
Health Insurance Coverage 
 
   In this study, health insurance coverage was re-categorized as Medicare, Medicaid, 
other public insurance, private insurance and uninsured. Each variable was binary 
coded. Value 1 indicated that the person was covered for at least one day of one 
month during year 2008; value 0 indicated that the person was not covered for a given 
type of insurance for all of year 2008. Patients covered by private insurance were the 
reference group. 
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Prescription Insurance Status 
 
   This study focused on the patients with cancer prescription medications; therefore 
prescription insurance was also an important independent variable. Patients not 
covered by prescription insurance were the reference group. 
 
3) Currently Smoke 
 
   According to the data from the American Cancer Society‟s Cancer Prevention 
Study II, the smoking-related cancer deaths continue to rise.
4
 Smoking accounts for at 
least 30% of all cancer deaths and 87% of lung cancer deaths.
4
 Hence, smoking was 
also considered as an independent variable. Former smokers were the reference group. 
 
4) Chronic Conditions 
 
   The chronic conditions: heart conditions (including hypertension, coronary heart 
disease, angina, and heart attack), high cholesterol, diabetes, joint pain, arthritis, 
asthma etc. were identified. A dummy was used. The reference group included those 
who did not have the condition of interest listed above. For example, for the group of 
patients experiencing heart conditions, the reference group is those who did not 
experience heart conditions. 
 
5) Self-Report 
 
   The code of the self-report was 1 and proxy-report was 0, in which the latter was 
the reference group. 
 
Independent Variables of Measuring Lost Productivity  
 
   Here, the independent variables of measuring lost productivity are presented as 
well, because as part of indirect cost, a simple descriptive analysis will be conducted. 
Lost productivity due to cancer prescriptions was measured by: 
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 whether the individual had a job in the past year (yes/no),  
 whether the individual had limitations to work in the past year due to health 
problems (yes/no),  
 number of days lost from work in the past year due to health problems,  
 number of days spent in bed in the past year due to health problems. 
 
2.4.3 Statistical Analytic Methods 
 
   The MEPS data is a complex survey design that used cluster and stratified 
sampling. Hence, all respondents in the database were assigned person-level weights 
to enable calculation of national estimates. In the database “MEPS HC-121: 2008 Full 
Year Consolidated Data File”, weight variables are provided to convert sample 
statistics to population parameter. Each record for each key, in-scope person was 
assigned with a single full year person-level weight (in year 2008, this variable is 
PERWT08F). A key person either was a member of a National Health Interview 
Survey (NHIS) household when doing the NHIS interview, or became a member of a 
household after being out-of-scope at the time of the NHIS interview (e.g., newborns, 
persons returning from military service, or living outside the United States).
104
 A 
person is in-scope means that he or she is a member of the portion of the U.S. civilian 
non-institutionalized population at any time.
104
 A single person-level weight variable 
(SAQWT08F) has been provided for use the data obtained from the SAQ. 
 
   The sample population represented in the current study had to be classified as a 
key, in-scope person who responded to MEPS for the full year of 2008, which means 
that the person should have a positive person-level weight in 2008 full-year 
(PERWT08F > 0).  
 
   In addition, the clustered nature of data that include both individual-level and 
area-level covariates requires that researchers use models to adjust the standard errors 
for the structure of the data. Several methodologies, including the Taylor-series 
linearization method, have been developed to deal with this problem. Various 
software packages permit analysts to implement these methodologies, such as SAS 
(version 8.2 and higher), Stata, SPSS (version 12.0 and higher), and SUDAAN. When 
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using these methods, sampling strata and Primary Sampling Units (PSUs) must be 
specified for the variance estimation. On MEPS data file, the variables VARSTR 
(Variance Estimation Stratum) and VARPSU (Variance Estimation PSU) are 
provided for the use in the variance estimation programs.
104  
 
   This study used SAS software version 9.2 (SAS Institute, Cary, NC) for statistical 
analysis. Due to the complex sample design of MEPS, PROC SURVEYFREQ, PROC 
SURVEYMEANS and PROC SURVEYREG procedures in SAS 9.2 which 
incorporated survey weights were used to calculate sampling errors of estimates. 5% 
level was used as cutoff for statistical significance. 
 
Univariate Analysis 
 
   Patient characteristics of cancer and age-matched non-cancer population, 
including demographics, insurance coverage and chronic conditions, were described. 
Weighted population estimates, mean HRQoL scores, mean expenditures of total and 
out-of-pocket, were tabulated using the survey weights. As part of indirect cost, a 
simple descriptive analysis was conducted about lost productivity. Descriptive 
statistics between key variables were computed based on frequencies and percentages 
for categorical variables, and mean and standard deviation for continuous variables. 
 
Bivariate Analysis 
 
   To assess the differences of patient characteristics between cancer and 
age-matched non-cancer population, categorical variables were compared using 
Chi-square test, while continuous variables were compared using T-test. Responses to 
the quality of life questions for the two groups were compared using the Pearson 
correlation coefficient. 
 
Multivariate Analysis 
 
   How certain patient characteristics strongly associated with HRQoL and high 
total/out-of-pocket prescription medication expenditures were examined by 
multivariate regression analyses, respectively. 
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1) Health-related Quality of Life (HRQoL) 
 
   To control for potential confounders, multivariate ordinary least squares (OLS) 
regressions were conducted to further investigate the differences in these HRQoL 
measures between cancer and non-cancer populations. The rationale for using OLS 
regression was that dichotomizing the QoL responses may cause information loss, 
variance reduction, and power loss.
120
 In addition, the QoL responses were normally 
distributed, which permitted the use of OLS regression.
 
The multivariate analysis was 
controlled for patient characteristics (age, gender, race, ethnicity, marital status, 
region, education, personal-level income and poverty level), prescription insurance 
status, currently smoke, chronic conditions and proxy reporting. 
 
   The regression model is: 
 
HRQoL = α + β1 (age) + β2 (education) +… βn (proxy reporting) 
 
   Where α is an intercept constant, and β is a non-standardized multiple regression 
coefficient to be estimated. The term HRQoL was a continuous dependent variable, 
which was measured as PCS-12, MCS-12, K-6 and PHQ-2. 
 
   The weighted model was constructed by the SAS SURVEYREG procedure, 
which was developed to perform regression analysis for complex survey sample 
designs, including unequal weighting.
121
 Therefore, incorporating the sampling 
weights in the weighted model was enabled. 
 
2) Total and Out-of-Pocket Prescription Medication Expenditures 
 
   To assess the factors affecting medication expenditures associated with cancer and 
estimate the predicted expenditures, least-squares regression was used. The factors 
included patients‟ demographics, socioeconomic status (SES), chronic conditions and 
HRQoL scores. The regression was weighted, and the standard errors were adjusted 
for the survey design. 
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Logarithmic Transformation of Expenditures 
 
   Because expenditure data in MEPS were found to be highly skewed, a logarithmic 
transformation of total/out-of-pocket prescription medication expenditures was used 
as the dependent variable.
75
 The logarithm of the expenditure variable can be 
presented by “log (prescription medication expenditures + 1)”. When calculating a 
logarithm for individuals with zero expenditure, one dollar was added to expenditures. 
 
Exponentiated Regression Coefficients, (   - 1)  100 
 
   The exponentiated regression coefficients, which provide the estimated ratios of 
expenditures, were used to explain the outcomes of logarithm scale of expenditures. 
“exponentiated regression coefficients (   - 1)   100” can be used to interpret 
logarithm scale of expenditures. For example, the expenditures in the group of 
population with high blood pressure were how much percentage higher or lower than 
that in the reference group without high blood pressure. 
 
Retransformations  
 
   In order to calculate the cost in economic analysis, the transformed results must be 
retransformed back to the original scale. For producing unbiased estimates of the 
mean expenditures, adjusted mean expenditures were calculated by exponentiating the 
least-squares means, and then multiplying the result by a “smearing” coefficient, 
which was the sum of the exponentiated residuals divided by the sample size.
122
 
 
   The regression model is: 
 
Expenditure = α + β1 (age) + β2 (insurance coverage) +… βn (SF-12 score) 
 
2.5 Study Results 
 
   In this section, results of describing and comparing the characteristics of cancer 
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population with prescription medications and age-matched non-cancer population are 
presented firstly. Secondly, the HRQoL outcomes between these two groups are 
provided, including the factors affecting HRQoL of cancer population with 
prescription medications. Thirdly, the mean distributions of total and out-of-pocket 
prescription drug expenditures of cancer patients by characteristics, and the results of 
multivariate analyses are presented.  
 
2.5.1 Descriptive Statistics 
 
   Table 6 describes the proportions for the individual characteristics of the 
population obtained by incorporating primary sampling units, strata and person 
weights. Patients without cancer diagnosis were age-matched to cancer patients with 
prescription medications at 1:5 ratios. The final sample, 392 cancer patients with 
prescription medications were derived from the 2008 MEPS with age of 18 and above, 
while 1,960 patients were without cancer diagnosed. 
 
   As shown in the table, the mean age for both groups was 62.7 years old. Most 
patients were aged 40 and above. Individuals with cancer were disproportionately 
more female. Both groups were predominately white and Non-Hispanic. The majority 
of individuals in both groups were currently married and living in MSA. Cancer 
participants had more years of education (13.2 years for cancer patients vs. 12.6 years 
for non-cancer patients; p < 0.0001) and greater percentage of high family income 
(45.4% for cancer patients vs. 38.7% for non-cancer patients; p = 0.0318) than 
participants without cancer. With regard to insurance, more cancer patients were 
covered by Medicaid than non-cancer patients. Oppositely, more non-cancer patients 
were uninsured (p < 0.0001). Furthermore, cancer patients trended to report more 
chronic conditions than non-cancer patients (3.2 vs. 2.7; p < 0.0001). They also had a 
much higher incidence rate of chronic bronchitis, join pain and asthma. In addition, 
both groups had high percentage of self-report on HRQoL. 
 
   In the group of cancer patients with prescriptions, most of the individuals were 
older than 65 years (49.1%), female (60.3%), white (89%), non-Hispanic (94.4%), 
living in the South (38.4%) and city area (81.7%), and with high school diploma 
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(37.9%).  
 
Table 6: Weighted Sample Characteristics of Cancer and Non-Cancer 
Populations: MEPS 2008 
 
 
 
 
Demographics
Age (%)
Mean (SE) Age, y 62.7 (0.76) 62.7 (0.51) 0.9997
18-39 y 8.1 8.2 0.9187  
40-64 y 42.8 43.0 0.9678  
65+ y 49.1 48.8 0.9237  
Gender (%)
Male 39.7 44.2 0.2098  
Female 60.3 55.8  
Race (%)
White 89.0 83.9 0.0074 **
Black 8.3 10.3 0.1894  
Other 
1 2.7 5.8 0.0064 **
Ethnicity (%)
Hispanic 5.6 9.5 0.0020 **
Non-Hispanic 94.4 90.5  
Marriage Status (%)
Married 57.7 57.7 0.9940  
Unmarried 
2 42.3 42.3  
Region (%)
Northeast 15.9 17.9 0.5375  
Midwest 24.8 22.2 0.3777  
South 38.4 39.4 0.7917  
West 20.9 20.5 0.8870  
Metropolitan Statistical Area (MSA) (%)  
MSA 81.7 81.9 0.9201  
Non-MSA 18.3 18.1  
Education (%)
Mean (SE) Education, y 13.2 (0.14) 12.6 (0.10) 0.0005 **
Less 8 years 5.8 9.6 0.0292 *
High School 37.9 42.8 0.1471  
College 26.0 22.8 0.2728  
Above Bachelor 29.9 24.2 0.0781  
Notes:
P values are based on Chi-square test for categorical variables, T-test for continous variable.
SE: Standard Error.
[1] Other race included American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander. 
[2] Not married included widowed, divorced, separated and never married.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Characteristics
Cancer                     Non-Cancer 
P-Value
(N = 392) (N = 1,960)
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Table 6 (continued): 
 
 
Income 
Personal Total Annual Income (%) 
3 
Low 31.0 32.0 0.6869  
Middle 7.0 9.6 0.1155  
High 62.0 58.4 0.2422  
Poverty Level (%)
Poor 17.1 16.1 0.6533  
Low income 12.3 13.5 0.4925  
Middle income 25.3 30.7 0.0344 *
High income 45.4 39.6 0.0604  
Health Insurance Coverage (%)
 4
Medicare 52.0 16.7 <.0001 **
Medicaid 11.1 9.7 0.3653  
Other Public Insurance 
5 6.6 3.4 0.0036 **
Private Insurance 64.9 66.6 0.5242  
Uninsured 2.3 16.3 <.0001 **
Prescription Insurance Status (%)
Yes 54.5 57.2 0.3447  
No 45.5 42.8  
Currently Smoke (%)
Yes 12.6 20.5 0.0025 **
No 86.8 77.9 0.0009 **
Chronic Conditions (%)
Mean (SE) Chronic Conditions 3.2 (0.12) 1.6 (0.02) <.0001 **
High Blood Pressure 54.0 30.6 <.0001 **
Coronary Heart Disease 15.9 5.5 <.0001 **
Angina 7.1 2.9 <.0001 **
Heart Attack 7.2 3.5 0.0018 **
Other Heart Disease 21.1 10.0 <.0001 **
Stroke 8.5 3.4 <.0001 **
Emphysema 6.0 2.3 <.0001 **
Chronic Bronchitis 8.8 2.2 <.0001 **
High Cholesterol 52.7 30.0 <.0001 **
Diabetes 19.7 9.3 <.0001 **
Joint Pain 54.3 31.5 <.0001 **
Arthritis 48.9 23.1 <.0001 **
Asthma 14.9 8.8 0.0008 **
Self Report (%) 91.2 90.0 0.4943  
Notes:
P values are based on Chi-square test for categorical variables, T-test for continous variable.
SE: Standard Error.
[4] These categories are not mutually exclusive and a patient might be in multiple categories.
Characteristics
Cancer Non-Cancer
P-Value
(N = 392) (N = 19,067)
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
[3] Personal total income less than $15,000 was classifed as low income, between $15,000 and $20,000 was classified as middle income, above 
$20,000 was classified as high income.
[5] Public insuracne included Tricare and Veterans.
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   Significant and consistent group differences by SES were also observed. Patients 
with higher personal annual income or lower poverty level were more likely to take 
medicines than patients with incomes below the poverty line. Half number of patients 
were Medicare beneficiaries (52%), and 64.9 percent had private insurance. Few of 
them were uninsured (2.3%), and less of them were non-prescription insurance 
beneficiaries (45.5%). As for chronic conditions, the most prevalent (almost above 
50%) were high blood pressure, high cholesterol, joint pain and arthritis.  
 
   Table 7 compares lost productivity between cancer and non-cancer population. 
Cancer patients were less likely than non-cancer patients to have been employed in 
the past 12 months (employment status 43.3% vs. 47.3%; p = 0.1731), more likely to 
have work limit because of health problems (22.3% vs. 16.3%; p = 0.0189). The mean 
days lost from work in the past 12 months due to health problems were 3.1 days for 
cancer patients, 0.9 day for non-cancer patients (p < 0.0001). The days spent in bed in 
the past 12 months due to health problems for cancer patients were more than that for 
non-cancer patients (1.9 days vs. 0.9 day; p < 0.0001).  
 
Table 7: Comparison of Lost Productivity Between Cancer and Non-Cancer 
Populations: MEPS 2008 
 
 
Cancer Non-Cancer
(N = 392) (N = 1,960)
Employment Status
Employed 43.3 47.3 0.1731  
Not Employed 56.7 52.7
Work Limit due to Health Problem
Yes 22.3 16.3 0.0189 *
No 4.1 3.7 0.7106  
Missing 73.6 80.0 0.0118 *
Days Lost from Work
Mean (SE) 3.1 (0.65) 0.9 (0.19) <.0001 **
 Number of Bed Days
Mean (SE) 1.9 (0.40) 0.9 (0.11) <.0001 **
Notes:
P values are based on Chi-square test for categorical variables, T-test for continous variable.
SE: Standard Error.
Lost Productivity P-Value
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
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2.5.2 Health-related Quality of Life (HRQoL) 
 
   Pearson correlations among SF-12, K-6 and PHQ-2 are displayed in Table 8. 
There are a few evident trends from this data. Firstly, SF-12, K-6 and PHQ-2 were 
statistically significantly inter-correlated (all p < 0.0001). Secondly, with respect to 
the relationship between SF-12 and K-6, K-6 correlated the greatest with MCS-12 
(coefficient r = - 0.67). Role emotional (accomplished less emotional) and mental 
health (felt downhearted) correlated highly with K-6 (r = - 0.56, r = - 0.60, 
respectively). Thirdly, the correlation between MCS-12 and PHQ-2 was higher than 
moderate (r = - 0.50). Finally, PHQ-2 and K-6 were highly correlated (r = 0.66). 
 
Table 8: Pearson Correlations for the SF-12, K-6 and PHQ-2 
 
Coefficient 
1
Coefficient 
1
SF-12
PCS-12 -0.40 <.0001 ** -0.27 <.0001 **
MCS-12 -0.67 <.0001 ** -0.50 <.0001 **
General Health 0.40 <.0001 ** 0.32 <.0001 **
Physical FunctioningLimit tions in Moderate 
Activities -0.31 <.0001 ** -0.18 <.0001 **
Limitations in Climbing  Stairs -0.29 <.0001 ** -0.15 <.0001 **
Role Physical 
Accomplished Less Physical -0.44 <.0001 ** -0.26 <.0001 **
Limited in Work -0.42 <.0001 ** -0.25 <.0001 **
Bodily Pain 0.41 <.0001 ** 0.29 <.0001 **
Vitality Scale 0.44 <.0001 ** 0.33 <.0001 **
Social Functioning -0.48 <.0001 ** -0.31 <.0001 **
Role Emotional 
Accomplished Less Emotional -0.56 <.0001 ** -0.35 <.0001 **
Work Less Carefully -0.47 <.0001 ** -0.30 <.0001 **
Mental Health 
Felt Calm 0.43 <.0001 ** 0.31 <.0001 **
Felt Downhearted -0.60 <.0001 ** -0.40 <.0001 **
PHQ-2 0.66 <.0001 ** - - -
Notes:
[2] P-Values are determined using Pearson correlation.
SF-12: Short Form-12; PCS: Physical Component Summary; MCS: Mental Component Summary; K-6: Kessler 
Index; PHQ-2: Patient Health Questionnaire.
[1] Coefficient larger than 0 indicates positive correlation; less than 0 indicates negative correlation; equal to 0 
means no correlation.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
K-6 PHQ-2
P-Value 
2
P-Value 
2
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   Table 9 reports weighted mean SF-12, K-6 and PHQ-2 scores for demographic 
and socioeconomic characteristics.  
 
Table 9: Weighted HRQoL Scores in Cancer and Non-Cancer Populations by 
Characteristics: MEPS 2008 
 
 
Cancer Non-Cancer Cancer Non-Cancer Cancer Non-Cancer Cancer Non-Cancer
Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE)
Overall 41.3 (0.77) 45.4 (0.39) 49.8 (0.62) 51.3 (0.33) 4.3 (0.29) 3.4 (0.11) 1.2 (0.12) 0.9 (0.05)
Age 
18-39 y 46.8 (1.49) 53.8 (0.62) 44.8 (1.36) 50.7 (0.62) 5.3 (0.91) 2.9 (0.26) 1.6 (0.28) 0.7 (0.07)
40-64 y 44.2 (1.07) 47.9 (0.51) 49.6 (0.80) 50.6 (0.44) 3.9 (0.33) 3.6 (0.15) 1.2 (0.18) 0.9 (0.06)
65+ y 37.9 (1.05) 41.8 (0.56) 50.9 (0.85) 51.9 (0.49) 4.5 (0.42) 3.4 (0.16) 1.2 (0.14) 0.9 (0.07)
Gender
Female 42.2 (0.93) 44.3 (0.52) 49.7 (0.68) 50.5 (0.45) 4.2 (0.34) 3.7 (0.16) 1.2 (0.12) 0.9 (0.07)
Male 40.0 (1.22) 46.8 (0.47) 50.1 (1.11) 52.2 (0.41) 4.5 (0.44) 3.1 (0.15) 1.3 (0.22) 0.8 (0.06)
Race
White 41.5 (0.84) 45.5 (0.43) 50.1 (0.68) 51.5 (0.37) 4.2 (0.31) 3.3 (0.12) 1.2 (0.13) 0.8 (0.05)
Black 39.6 (1.29) 44.2 (0.74) 47.4 (1.10) 50.0 (0.54) 5.2 (0.55) 4.3 (0.22) 1.8 (0.21) 1.5 (0.15)
Other 
5
40.4 (2.00) 46.1 (0.71) 48.6 (1.06) 50.5 (0.77) 5.0 (0.84) 3.5 (0.32) 1.2 (0.29) 0.9 (0.08)
Ethnicity
Hispanic 41.0 (1.41) 46.5 (0.75) 47.0 (1.20) 50.0 (0.60) 6.1 (0.51) 3.9 (0.23) 2.1 (0.33) 0.9 (0.07)
Non-Hispanic 41.4 (0.79) 45.3 (0.41) 50.0 (0.63) 51.4 (0.34) 4.2 (0.30) 3.4 (0.11) 1.2 (0.12) 0.9 (0.06)
Marriage Status
Married 42.8 (1.09) 46.6 (0.44) 50.8 (0.75) 52.6 (0.39) 3.7 (0.33) 3.0 (0.13) 1.0 (0.14) 0.6 (0.05)
Unmarried 
6
39.3 (1.01) 43.7 (0.60) 48.4 (0.99) 49.5 (0.51) 5.2 (0.48) 4.1 (0.18) 1.6 (0.20) 1.2 (0.09)
Region
Northeast 40.4 (1.88) 47.4 (0.69) 50.7 (0.99) 51.3 (0.77) 4.7 (0.76) 3.3 (0.21) 1.3 (0.28) 0.9 (0.12)
Midwest 40.7 (1.07) 45.4 (0.91) 48.5 (1.33) 52.2 (0.50) 4.7 (0.50) 3.4 (0.23) 1.5 (0.22) 0.8 (0.10)
South 41.8 (1.37) 44.4 (0.64) 49.3 (0.88) 50.8 (0.49) 4.0 (0.49) 3.5 (0.16) 1.1 (0.21) 0.9 (0.09)
West 41.8 (1.60) 45.5 (0.55) 51.5 (1.22) 51.1 (0.67) 4.1 (0.54) 3.5 (0.22) 1.1 (0.16) 0.9 (0.08)
Metropolitan Statistical Area
MSA 41.7 (0.87) 45.6 (0.40) 50.2 (0.72) 51.2 (0.34) 4.1 (0.31) 3.4 (0.11) 1.2 (0.15) 0.8 (0.06)
Non-MSA 39.6 (1.19) 44.3 (0.86) 48.2 (0.95) 51.6 (0.75) 5.6 (0.57) 3.6 (0.28) 1.4 (0.15) 1.0 (0.12)
Education
Less 8 years 33.5 (1.37) 41.1 (0.64) 50.2 (1.47) 47.6 (0.69) 4.8 (0.56) 5.2 (0.32) 1.3 (0.25) 1.4 (0.11)
High School 40.2 (1.21) 43.6 (0.51) 49.7 (0.96) 50.8 (0.49) 4.6 (0.47) 3.8 (0.17) 1.4 (0.14) 1.0 (0.08)
College 39.4 (1.18) 46.3 (0.81) 47.7 (1.34) 51.9 (0.59) 5.2 (0.53) 3.0 (0.17) 1.2 (0.22) 0.7 (0.09)
Above Bachelor 45.7 (0.89) 49.3 (0.50) 51.7 (0.73) 52.7 (0.50) 3.2 (0.37) 2.5 (0.17) 1.0 (0.18) 0.6 (0.05)
Income 
Personal Total Annual Income 
7
Low 37.5 (1.20) 41.3 (0.61) 47.5 (1.27) 49.7 (0.52) 5.5 (0.53) 4.5 (0.22) 1.7 (0.19) 1.2 (0.09)
Middle 41.0 (1.54) 44.1 (0.94) 47.7 (1.22) 50.7 (0.82) 5.1 (0.50) 3.7 (0.27) 1.2 (0.14) 1.0 (0.13)
High 43.3 (0.96) 47.8 (0.46) 51.2 (0.68) 52.2 (0.40) 3.7 (0.32) 2.8 (0.13) 1.0 (0.15) 0.7 (0.06)
Poverty Level
Poor 35.1 (1.21) 40.5 (0.74) 47.0 (0.99) 49.6 (0.66) 6.4 (0.43) 4.6 (0.28) 1.9 (0.17) 1.4 (0.13)
Low income 40.0 (1.58) 42.2 (0.89) 49.7 (1.37) 49.6 (0.77) 4.3 (0.52) 4.2 (0.26) 1.1 (0.22) 1.2 (0.11)
Middle income 41.8 (1.34) 45.9 (0.56) 50.4 (1.09) 51.1 (0.51) 4.1 (0.45) 3.6 (0.19) 1.2 (0.16) 0.9 (0.09)
High income 43.8 (1.02) 48.0 (0.57) 50.6 (1.03) 52.7 (0.51) 3.7 (0.40) 2.5 (0.14) 1.0 (0.16) 0.5 (0.06)
[1] Possible range for PCS-12 is from 0 to 100 with a higher score indicating a more impaired quality of life.
[2] Possible range for MCS-12 is from 0 to 100 with a higher score indicating a more impaired quality of life.
[3] Possible range for K-6 summary index is from 0 to 24 with a higher score indicating a more serious distress.
[4] Possible range for PHQ-2 summary score is from 0 to 6 with a higher score indicating a more serious depression.
[5] Other race included American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander. 
[6] Not married included widowed, divorced, separated and never married.
Notes:
SF-12: Short Form-12; PCS: Physical Component Summary; MCS: Mental Component Summary; K-6: Kessler Index; PHQ-2: Patient Health Questionnaire; SE: Standard Error.
[7] Personal total income less than $15,000 was classifed as low income, between $15,000 and $20,000 was classified as middle income, above $20,000 was classified as high income.
All were significant between cancer and non-cancer populations based on Z tests (P < 0.05).
Characteristics
PCS-12 
1
MCS-12 
2
K-6 
3
PHQ-2 
4
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Table 9 (continued): 
 
 
   As expected, individuals with cancer prescription medications had worse HRQoL 
than those without cancer. Specifically, cancer patients reported poorer physical or 
mental health, more serious physiologic distress or depression.  
 
   In this table, cancer patients with medications had significantly lower average 
overall component summary scores of SF-12 than patients without cancer (cancer 
41.3 vs. non-cancer 45.4 for PCS-12; cancer 49.8 vs. non-cancer 51.3 for MCS-12, 
respectively), but the average K-6 and PHQ-2 scores were significantly higher (4.3 vs. 
3.4 for K-6 scores; 1.2 vs. 0.9 for PHQ-2 scores, respectively). Similar results were 
found in most characteristics in each population subgroup, such as age, gender, race, 
ethnicity, marriage status, region, income, prescription insurance, currently smoking 
status and proxy report. In addition, cancer patients experiencing chronic conditions 
Cancer Non-Cancer Cancer Non-Cancer Cancer Non-Cancer Cancer Non-Cancer
Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE)
Health Insurance Coverage
Medicare 37.6 (1.05) 41.4 (0.55) 50.5 (0.81) 51.5 (0.49) 4.7 (0.40) 3.6 (0.16) 1.3 (0.14) 1.0 (0.08)
Medicaid 37.0 (1.15) 37.9 (0.68) 43.8 (0.94) 45.0 (0.90) 6.9 (0.37) 6.3 (0.39) 2.1 (0.16) 1.9 (0.17)
Other Public Insurance 
8
42.0 (1.00) 39.5 (1.23) 51.7 (0.82) 49.7 (1.15) 3.9 (0.46) 4.4 (0.17) 1.3 (0.53) 1.3 (0.12)
Private Insurance 42.7 (0.94) 47.9 (0.45) 49.7 (0.83) 52.0 (0.40) 4.0 (0.37) 2.8 (0.13) 1.2 (0.16) 0.7 (0.05)
Uninsured 44.1 (1.62) 46.6 (0.76) 49.4 (1.85) 50.3 (0.45) 3.7 (0.64) 4.2 (0.24) 1.0 (0.29) 1.1 (0.12)
Prescription Insurance Status
Yes 42.6 (1.01) 48.2 (0.49) 49.3 (0.87) 51.6 (0.44) 4.2 (0.38) 2.8 (0.12) 1.2 (0.17) 0.7 (0.05)
No 39.8 (1.10) 42.5 (0.55) 50.5 (0.84) 50.9 (0.44) 4.5 (0.41) 4.0 (0.17) 1.2 (0.16) 1.1 (0.08)
Currently Smoke
Yes 40.6 (1.32) 45.3 (0.74) 47.7 (1.23) 49.3 (0.65) 6.0 (0.64) 4.4 (0.34) 1.4 (0.17) 1.1 (0.11)
No 41.4 (0.85) 45.5 (0.42) 50.1 (0.67) 51.7 (0.36) 4.1 (0.30) 3.2 (0.11) 1.2 (0.13) 0.8 (0.06)
Chronic Conditions
High Blood Pressure 37.8 (0.97) 41.5 (0.54) 50.2 (0.78) 50.1 (0.51) 4.8 (0.41) 3.9 (0.17) 1.3 (0.15) 1.1 (0.08)
Coronary Heart Disease 33.0 (1.17) 37.5 (0.71) 48.0 (1.57) 47.7 (0.91) 6.4 (0.52) 5.2 (0.30) 2.0 (0.28) 1.5 (0.17)
Angina 31.4 (1.04) 36.7 (0.57) 47.5 (1.55) 48.0 (0.72) 5.9 (0.69) 5.8 (0.32) 1.6 (0.17) 1.6 (0.13)
Heart Attack 32.5 (1.46) 36.6 (0.69) 47.0 (2.22) 49.4 (0.75) 6.7 (0.58) 4.4 (0.23) 1.9 (0.33) 1.5 (0.08)
Other Heart Disease 38.0 (1.29) 40.4 (0.86) 51.0 (1.02) 49.4 (0.64) 4.8 (0.46) 4.6 (0.27) 1.5 (0.23) 1.2 (0.12)
Stroke 33.9 (1.21) 37.1 (0.90) 48.1 (1.43) 49.1 (0.51) 6.8 (0.55) 5.4 (0.28) 1.6 (0.18) 1.4 (0.13)
Emphysema 30.4 (1.04) 33.7 (0.82) 48.7 (0.86) 47.6 (0.79) 6.6 (0.67) 6.5 (0.49) 1.4 (0.23) 1.7 (0.20)
Chronic Bronchits 30.3 (1.66) 38.7 (1.23) 44.7 (1.12) 49.4 (0.93) 7.2 (0.54) 5.0 (0.29) 2.2 (0.18) 1.9 (0.26)
High Cholesterol 39.9 (1.08) 42.7 (0.50) 50.4 (0.91) 50.8 (0.48) 4.7 (0.46) 3.7 (0.15) 1.3 (0.17) 1.0 (0.07)
Diabetes 36.7 (1.48) 39.0 (0.82) 49.0 (1.33) 49.0 (0.75) 5.5 (0.58) 4.7 (0.31) 1.6 (0.20) 1.4 (0.13)
Joint Pain 37.9 (1.05) 40.8 (0.57) 49.3 (0.87) 49.8 (0.57) 4.8 (0.45) 4.3 (0.18) 1.3 (0.17) 1.1 (0.08)
Arthritis 36.7 (1.00) 39.2 (0.56) 49.7 (0.89) 50.0 (0.55) 5.1 (0.43) 4.3 (0.18) 1.4 (0.16) 1.1 (0.08)
Asthma 37.7 (1.18) 39.7 (0.87) 48.0 (0.59) 47.2 (1.00) 5.9 (0.38) 5.7 (0.30) 1.6 (0.13) 1.7 (0.21)
Self Report 42.3 (0.80) 45.9 (0.39) 50.4 (0.57) 51.5 (0.35) 4.0 (0.27) 3.3 (0.10) 1.1 (0.13) 0.8 (0.05)
[1] Possible range for PCS-12 is from 0 to 100 with a higher score indicating a more impaired quality of life.
[2] Possible range for MCS-12 is from 0 to 100 with a higher score indicating a more impaired quality of life.
[3] Possible range for K-6 summary index is from 0 to 24 with a higher score indicating a more serious distress.
[4] Possible range for PHQ-2 summary score is from 0 to 6 with a higher score indicating a more serious depression.
Notes:
SF-12: Short Form-12; PCS: Physical Component Summary; MCS: Mental Component Summary; K-6: Kessler Index; PHQ-2: Patient Health Questionnaire; SE: Standard Error.
[8] Other public insuracne were public insurance excluding Medicare and Medicaid.
All were significant between cancer and noncancer populations based on Z tests (P < 0.05).
Characteristics
PCS-12 
1
MCS-12 
2
K-6 
3
PHQ-2 
4
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reported worse physical health, more serious psychological distress or greater 
tendency towards physiologic depression. 
 
   For cancer patients with prescription medications, PCS-12, K-6 and PHQ-2 scores 
declined monotonically among older age groups, but MCS-12 scores did not. It was 
found that blacks, Hispanics, unmarried persons, persons not living in city area, 
persons with low income and persons currently smoking were more likely to report 
poor physical or mental health and had greater tendency towards physiologic distress 
and depression. For region, education or health insurance coverage, the pattern was 
less clear. Patients with prescription insurance had lower physical health scores and 
higher mental health and K-6 scores.  
 
   Table 10 shows significant differences between these two groups for SF-12, K-6, 
or PHQ-2 scores. All the mean scores were weighted. For the entire sample, cancer 
patients had lower mean scores on PCS-12 and MCS-12, higher mean scores on K-6 
and PHQ-2 than the non-cancer subjects. All the differences were statistically 
significant (p < 0.05).  
 
   The weighted mean PCS-12 of cancer patients with medications was 41.3 
(Standard Error (SE) = 0.77), which were significantly lower than those without 
cancer (45.4, SE = 0.39), that meant, medication use was associated with worse 
physical health. The same trend was noted for MSC-12, physical functioning, role 
physical, social functioning, role emotional scales and mental health (felt 
downhearted). But the different trend was noted for vitality scale and mental health 
(felt calm). The weighted mean general health and bodily pain scores of cancer 
patients with medications were higher than non-cancer patients (cancer 3.0 vs. 
non-cancer 2.7 for general health, 2.4 vs. 2.1 for bodily pain, p < 0.0001, respectively), 
which meant that cancer patients experienced worse general health and more pain. 
Among the eight domains, the differences observed in the role physical scales (limited 
in work) and bodily pain were particularly salient. Overall, these impairments were 
greater in physical than mental health. 
 
   It was also noted that cancer patients with medications experienced more serious 
psychological distress, and had greater tendency towards depression. The weighted 
 71 
 
mean K-6 summary index score was 4.3 (SE = 0.29) for cancer patients, and 3.4 (SE 
= 0.11) for patients without cancer. The weighted mean summary score of PHQ-2 was 
1.2 (SE = 0.12) for cancer patients, which was higher than that of non-cancer patients 
0.9 (SE = 0.05). The same trend was noted for six subscales of K-6 and two subscales 
of PHQ-2. 
 
Table 10: Differences in HRQoL Measures Between Cancer and Non-Cancer 
Populations: MEPS 2008 
 
 
Mean SE Mean SE Mean SE Mean SE
Short Form-12 (SF-12) 
2
Physical Health Score (PCS-12) 41.3 0.77 45.4 0.39 -4.06 0.81 <.0001 ** -3.31 0.72 <.0001 **
Mental Health Score (MCS-12) 49.8 0.62 51.3 0.33 -1.44 0.68 0.0364 * -1.34 0.67 0.0483 *
General Health 3.0 0.07 2.7 0.04 0.32 0.08 <.0001 ** 0.32 0.07 <.0001 **
Physical Functioning
Limitations in Moderate Activities 2.3 0.06 2.5 0.03 -0.24 0.07 0.0003 ** -0.20 0.07 0.0029 **
Limitations in Climbing  Stairs 2.2 0.06 2.5 0.03 -0.23 0.08 0.0031 ** -0.18 0.08 0.0235 *
Role Physical 
Accomplished Less Physical 3.6 0.08 3.9 0.03 -0.32 0.09 0.0003 ** -0.23 0.09 0.0067 **
Limited in Work 3.6 0.08 4.0 0.04 -0.39 0.09 <.0001 ** -0.29 0.09 0.0012 **
Bodily Pain 2.4 0.07 2.1 0.05 0.35 0.09 <.0001 ** 0.27 0.08 0.0016 **
Vitality Scale 3.0 0.08 2.7 0.04 0.32 0.08 0.0002 ** 0.27 0.08 0.0008 **
Social Functioning 4.2 0.07 4.5 0.04 -0.28 0.08 0.0008 ** -0.24 0.08 0.0037 **
Role Emotional 
Accomplished Less Emotional 4.1 0.07 4.4 0.03 -0.27 0.08 0.0009 ** -0.26 0.08 0.0029 **
Work Less Carefully 4.2 0.07 4.4 0.04 -0.26 0.08 0.0011 ** -0.24 0.08 0.0040 **
Mental Health 
Felt Calm 2.5 0.07 2.4 0.04 0.09 0.08 0.2309  0.06 0.08 0.4286  
Felt Downhearted 4.1 0.07 4.2 0.03 -0.11 0.08 0.2054  -0.09 0.08 0.2865  
Kessler Index (K-6)
 3
Summary Index 4.3 0.29 3.4 0.11 0.91 0.31 0.0034 ** 0.86 0.28 0.0028 **
Felt Nervous 1.2 0.11 0.9 0.03 0.33 0.11 0.0028 ** 0.29 0.11 0.0074 **
Felt Hopeless 0.8 0.10 0.5 0.03 0.28 0.11 0.0140 * 0.27 0.11 0.0149 *
Felt Restless or Fidgety 1.2 0.10 0.9 0.04 0.25 0.11 0.0244 * 0.22 0.11 0.0378 *
Felt Sad 0.7 0.11 0.4 0.03 0.25 0.11 0.0296 * 0.25 0.11 0.0236 *
Felt that Everything was an Effort 1.2 0.11 0.9 0.04 0.34 0.11 0.0023 ** 0.31 0.11 0.0047 **
Felt Worthless 0.7 0.10 0.5 0.04 0.20 0.11 0.0770  0.19 0.11 0.0809  
Patient Health Questionnaire (PHQ-2) 
4
Summary Score 1.2 0.12 0.9 0.05 0.37 0.13 0.0049 ** 0.36 0.13 0.0048 **
Decreased Interest 0.8 0.10 0.5 0.04 0.29 0.11 0.0094 ** 0.28 0.11 0.0108 *
Depressed Mood 0.8 0.11 0.5 0.03 0.29 0.11 0.0101 * 0.28 0.11 0.0110 *
[3] Possible range for K-6 summary index is from 0 to 24 with a higher score indicating a more serious distress.
[4] Possible range for PHQ-2 summary score is from 0 to 6 with a higher score indicating a more serious depression.
SE: Standard Error.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Notes:
[1] Adjusted differences were estimated from multivariate regression models controlling for sociodemographic variables, current smoking status, prescription insurance 
status, chronic conditions, and proxy reporting.
[2] Possible range for PCS-12 is from 0 to 100 with a higher score indicating a more impaired quality of life. Possible range for MCS-12 is from 0 to 100 with a higher 
score indicating a more impaired quality of life. Possible range for physical functioning is from 1 to 3 with a higher score indicating less limitations. Possible range for the 
other subscales is from 1 to 5 with a higher score indicating better health. For general health perceptions and bodily pain, higher score indicates poor general health and 
aggravating pain. 
HRQoL Instruments
Cancer Non-Cancer Unadjusted Difference Adjusted Difference 
1
P-Value P-Value
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   The differences in the HRQoL scores became smaller after controlling for 
socio-demographic characteristics, prescription insurance status, current smoking 
status, chronic conditions, and proxy reporting. After adjustment, the marginal impact 
of patients with medications was highly statistically significant across all three 
HRQoL measures and all seemed to be clinically significant. Compared with mental 
function-related domains measured by the MCS-12, physical function-related 
domains measured by the PCS-12 showed a greater decrease in HRQoL (unadjusted 
difference: -4.06 for PCS-12 vs. -1.44 for MCS-12). The adjusted differences between 
cancer patients with prescription medications and non-cancer patients were -3.31 for 
PCS-12 (7.3% of the score in the non-cancer population), -1.34 for MCS-12 (2.6%), 
0.86 for K-6 (25.3%), and 0.36 for PHQ-2 (40%). 
   
   Additionally, this study explored if differences arose in HRQoL scores of cancer 
patients with prescriptions across socio-demographic groups and categories 
dichotomized by health behaviors and chronic conditions. See Table 11.  
 
   It showed that younger age, more education, no prescription insurance coverage, 
no experience of chronic conditions, and self-reporting were significant predictors of 
a higher PCS-12 score. Younger age, Hispanic, less education, and lower income were 
significant risk factors, and self-reporting was a significantly mitigating factor for the 
MCS-12 score in the regression equation. Younger age, Hispanic, living in non-city 
area, less education, currently smoking, and experience of high cholesterol, and not 
self-reporting were significant predictors of higher K-6 scores, which indicated that 
these patients with greater tendency towards mental disability. White, Non-Hispanic 
and married, and self-reporting were significant predictors of lower PHQ-2 scores, 
which indicated that these patients had less serious depression. Overall, old age, less 
education attainment and chronic conditions were risk factors of HRQoL. Hispanics 
were more likely to report worse mental problems or more serious depression than 
non-Hispanics.  
 
 
 
 
 
 73 
 
 
Table 11: Results of Multivariate Analysis of HRQoL on Cancer Patients with 
Prescription Medications 
1
 
 
 
 
 
 
 
 
 
 
Coefficient SE Coefficient SE Coefficient SE Coefficient SE
Age    
18-39 y 2.97 2.17 0.1763  -6.29 1.87 0.0013 ** 1.58 0.72 0.0322 * 0.62 0.34 0.0733  
40-64 y 3.27 1.40 0.0222 * -1.60 1.37 0.2455  -0.01 0.48 0.9887  0.31 0.16 0.0547  
65+ y 
reference
- - - - - - - - - - - -
    
Gender
Female 1.03 1.19 0.3872  0.46 1.12 0.6819  -0.22 0.44 0.6274  -0.28 0.19 0.1427  
Male 
reference
- - - - - - - - - - - -
Race     
Black 0.16 1.64 0.9223  -2.60 1.41 0.0704  0.89 0.65 0.1785  0.56 0.27 0.0424 *
Other 
2
-0.12 1.56 0.9390  0.01 1.43 0.9935  0.67 0.92 0.4682  -0.41 0.53 0.4392  
White 
reference
- - - - - - - - - - - -
    
Ethnicity
Hispanic 1.19 1.38 0.3926  -3.29 1.23 0.0093 ** 2.41 0.81 0.0042 ** 0.99 0.28 0.0007 **
Non-Hispanic 
reference
- - - - - - - - - - - -
Marriage Status     
Married 1.78 1.30 0.1736  1.94 0.99 0.0547  -0.84 0.48 0.0861  -0.64 0.19 0.0013 **
Unmarried 
3
 
reference
- - - - - - - - - - - -
    
Region
Northeast 0.42 1.93 0.8300  -1.34 1.62 0.4103  0.76 0.88 0.3914  0.06 0.24 0.8203  
Midwest 1.39 1.94 0.4744  -1.07 1.34 0.4263  -0.40 0.55 0.4691  0.10 0.27 0.7123  
South 0.59 1.66 0.7247  -1.55 1.41 0.2777  -0.36 0.48 0.4587  -0.07 0.20 0.7289  
West 
reference
- - - - - - - - - - - -
Metropolitan Statistical Area     
MSA -1.57 1.25 0.2117  1.11 1.12 0.3248  -1.33 0.50 0.0095 ** -0.16 0.21 0.4530  
Non-MSA 
 reference
- - - - - - - - - - - -
    
Education     
Less 8 years -7.65 2.62 0.0048 ** 1.44 1.91 0.4550  -0.84 0.94 0.3752  -0.30 0.25 0.2348  
High School -3.37 1.16 0.0048 ** -1.29 1.10 0.2468  0.74 0.56 0.1894  0.22 0.22 0.3069  
College -4.64 1.60 0.0050 ** -3.96 1.64 0.0187 * 1.75 0.49 0.0006 ** 0.12 0.21 0.5759  
Above Bachelor 
 reference
- - - - - - - - - - - -
    
Income     
Personal Total Annual Income 
4
Low -1.51 1.97 0.4464  -4.43 1.93 0.0251 * 0.75 0.66 0.2603  0.60 0.37 0.1045  
Middle 0.25 2.35 0.9170  -5.06 2.29 0.0307 * 1.45 0.83 0.0837  0.36 0.25 0.1506  
High  
reference
- - - - - - - - - - - -
    
Poverty Level     
Poor -2.99 2.01 0.1428  1.87 2.31 0.4217  0.53 0.83 0.5222  -0.05 0.42 0.9059  
Low income 0.97 1.81 0.5918  2.66 1.99 0.1843  -1.09 0.75 0.1542  -0.55 0.36 0.1353  
Middle income 0.49 1.29 0.7049  1.36 1.17 0.2480  -0.69 0.47 0.1495  0.01 0.21 0.9647  
High income 
 reference
- - - - - - - - - - - -
[2] Other race included American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander. 
[3] Not married included widowed, divorced, separated and never married.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
P-Value P-Value
Independent Variables
PCS-12 MCS-12 K-6 PHQ-2
P-Value P-Value
Notes:
[4] Personal total income less than $15,000 was classifed as low income, between $15,000 and $20,000 was classified as middle income, above $20,000 was classified as high income.
SF-12: Short Form-12; PCS: Physical Component Summary; MCS: Mental Component Summary; K-6: Kessler Index; PHQ-2: Patient Health Questionnaire; SE: Standard Error.
[1] Adjusted for socio-demographic variables, prescription insurance status, current smoking status, chronic conditions and self-reporting.
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Table 11 (continued): 
 
 
2.5.3 Total and Out-of-Pocket Prescription Medication Expenditures 
 
   This section includes the mean distributions of total and out-of-pocket prescription 
medication expenditures of cancer patients by characteristics. Then the results of 
multivariate analysis will be presented.  
 
2.5.3.1 Mean Expenditures by Patient Characteristics 
 
   Table 12 presents weighted mean total and out-of-pocket expenditures by cancer 
patient characteristics. For cancer patients, the weighted mean total and out-of-pocket 
prescription medication expenditures were $3,169.1 (SD = 203.3) and $744.6 (SD = 
59.8), respectively. Nonelderly patients had lower total and out-of-pocket spending 
than the elderly. 
 
 
 
 
Coefficient SE Coefficient SE Coefficient SE Coefficient SE
Prescription Insurance Status
Yes -2.81 1.21 0.0231 * -1.18 1.08 0.2792  0.48 0.50 0.3404  0.23 0.15 0.1273  
No 
reference
- - - - - - - - - - - -
Currently Smoke
Yes -0.79 1.63 0.6321  -0.18 1.02 0.8628  2.10 0.51 0.0001 ** -0.05 0.24 0.8259  
No 
reference
- - - - - - - - - - - -
Chronic Conditions     
High Blood Pressure
Yes -4.36 1.21 0.0006 ** 0.95 1.08 0.3840  0.05 0.47 0.9103  0.03 0.15 0.8199  
No  
reference
- - - - - - - - - - - -
High Cholesterol
Yes 1.22 1.12 0.2781  0.08 1.20 0.9490  1.11 0.45 0.0162 * 0.05 0.17 0.7809  
No  
reference
- - - - - - - - - - - -
Joint Pain
Yes -3.98 1.35 0.0045 ** -2.31 1.17 0.0524  0.69 0.42 0.1001  0.27 0.17 0.1326  
No  
reference
- - - - - - - - - - - -
Arthritis
Yes -5.46 1.54 0.0007 ** 0.43 1.08 0.6892  0.72 0.36 0.0508  0.19 0.15 0.2242  
No  
reference
- - - - - - - - - - - -
   
Self Report
Yes 7.14 2.10 0.0011 ** 6.40 1.86 0.0010 ** -3.17 0.88 0.0006 ** -0.75 0.29 0.0117 *
No  
reference
- - - - - - - - - - - -
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Notes:
SF-12: Short Form-12; PCS: Physical Component Summary; MCS: Mental Component Summary; K-6: Kessler Index; PHQ-2: Patient Health Questionnaire; SE: Standard Error.
Independent Variables
PCS-12 MCS-12 K-6 PHQ-2
P-Value P-Value P-Value P-Value
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Table 12: Weighted Total and Out-of-Pocket Expenditure in Cancer 
Population with Prescription Medications by Characteristics: MEPS 2008 
 
 
 
 
Mean SD Mean SD
Overall 3,169.1 203.3 744.6 59.8
Age 
18-39 y 1,797.8 466.5 428.0 121.3
40-64 y 2,418.5 324.1 579.0 79.9
65+ y 4,049.9 288.0 941.2 84.5
Gender
Female 2,771.5 232.8 770.0 86.1
Male 3,772.3 361.9 706.0 62.1
Race
White 3,265.0 223.4 766.1 65.4
Black 2,647.9 324.3 653.7 159.4
Other 
1
1,612.0 191.8 316.0 35.2
Ethnicity
Hispanic 4,699.5 418.9 1,073.4 116.9
Non-Hispanic 3,078.0 213.0 725.0 63.3
Marriage Status
Married 3,335.8 259.4 813.7 88.6
Unmarried 
2
2,941.5 313.1 650.3 63.0
Region
Northeast 3,022.1 197.3 901.6 80.5
Midwest 3,304.5 346.6 656.2 77.8
South 3,616.6 446.1 728.6 102.5
West 2,298.8 263.0 759.4 193.2
Metropolitan Statistical Area
MSA 3,203.5 219.8 680.7 51.5
Non-MSA 3,015.7 531.2 1,029.4 245.1
Education
Less 8 years 4,545.7 619.2 866.5 231.5
High school 2,652.9 312.3 712.1 117.3
College 2,606.2 276.5 703.5 81.3
Above bachelor 4,015.7 388.2 794.6 75.9
[1] Other race included American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander. 
Characteristics
Out-of-Pocket ExpenditureTotal Expenditure
Notes:
[2] Unmarried included widowed, divorced, separated and never married.
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Table 12 (continued): 
 
Mean SD Mean SD
Income
Personal Total Annual Income 
3
Low 3,509.9 376.7 841.9 130.7
Middle 2,977.0 542.9 729.1 199.5
High 3,020.4 225.0 697.7 50.9
Poverty Level
Poor 2,619.2 278.7 541.6 41.3
Low income 3,476.2 488.1 1,022.9 291.2
Middle income 3,530.3 369.8 923.8 93.7
High income 3,091.2 296.3 645.6 61.3
Health Insurance Coverage
Medicare
Yes 4,189.4 305.4 961.6 88.4
No 2,061.9 200.0 509.1 53.0
Medicaid
Yes 3,044.0 347.8 356.5 127.8
No 3,184.8 219.2 793.2 64.8
Other Public Insurance 
4
Yes 3,502.2 1,252.9 652.2 132.0
No 3,145.6 198.6 751.1 63.3
Private Insurance
Yes 3,389.8 297.5 736.5 86.2
No 2,760.7 205.2 759.6 68.0
Uninsured
Yes 2,083.6 1,103.0 487.9 190.4
No 3,195.0 208.4 750.7 61.2
Prescription Insurance Status
Yes 3,623.4 311.4 678.4 65.7
No 2,625.7 186.6 823.7 91.4
Currently Smoke
Yes 2,550.7 535.3 515.4 112.0
No 3,258.3 209.4 777.7 64.4
Chronic Conditions
High Blood Pressure
Yes 4,204.4 329.4 1,007.7 93.5
No 1,952.9 189.3 435.5 50.6
High Cholesterol
Yes 3,697.7 285.7 896.3 66.1
No 2,580.5 206.5 575.7 92.0
Joint Pain
Yes 3,356.3 301.2 798.5 64.1
No 2,946.8 204.1 680.6 95.2
Arthritis
Yes 3,630.8 347.8 849.8 73.4
No 2,727.5 184.7 644.0 87.6
[4] Other public insuracne were public insurance excluding Medicare and Medicaid.
[3] Personal total income less than $15,000 was classifed as low income, between $15,000 and $20,000 was classified 
as middle income, above $20,000 was classified as high income.
Notes:
Characteristics
Total Expenditure Out-of-Pocket Expenditure
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   As shown in Table 12, of the total expenditures, elderly, male, white, Hispanic, 
married, and living in city area persons had higher expenditures than young, female, 
black or other races, non-Hispanic, unmarried, and living in non-city area persons did. 
For region, education or income, the pattern of mean total spending was less clear.  
 
   Mean total expenditures paid by different source of payments were quite different. 
Patients covered by Medicare, private, other public or prescription insurance paid 
higher than those without Medicare, private, other public or prescription insurance 
coverage. Medicare patients paid higher total money for prescription medications in 
comparing with other insurance groups. Non-Medicaid beneficiaries spent more 
money for their medicine treatments in comparison to those of Medicaid covered. 
Uninsured individuals had much higher payment than those having insurance did.  
    
   Currently smokers had lower mean total prescription expenditure than former 
smokers. But patients reported chronic conditions had higher mean total prescription 
expenditure than their counterparts.  
 
   The same situations were also found in out-of-pocket spending, except that female 
or persons living in non-city area, patients covered with private, other public or 
prescription insurance had higher payment than their corresponding counterparts did. 
 
2.5.3.2 Multivariate Analysis 
 
   As a result of the non-normal distribution of expenses, a logarithmic 
transformation was applied for correction to determine total and out-of-pocket 
prescription expenditures. Table 13 and Table 14 present the results of the multivariate 
regression of logarithmic transformation of expenditures. 
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Table 13: Factors Affecting Total Prescription Medication Expenditures by 
Cancer Patients: MEPS 2008 
1
 
 
 
Exponent Regression 
Coefficient 
Intercept 5.67 0.98  (3.71 - 7.62) <.0001 **
Age 0.0553  
18-39 y -0.37 0.33 -30.93  (-1.03 - 0.28) 0.2578  
40-64 y -0.54 0.22 -41.73  (-0.98 - -0.10) 0.0167 *
65+ y 
 reference
- - - - -
Gender 0.1295  
Female 0.20 0.13 22.14  (-0.06 - 0.47) 0.1295  
Male 
reference
- - - - -
Race 0.5172  
Black -0.03 0.16 -2.96  (-0.35 - 0.29) 0.8476  
Other 
2
-0.24 0.21 -21.34  (-0.67 - 0.19) 0.2662  
White 
reference
- - - - -
Ethnicity 0.3624  
Hispanic 0.19 0.21 20.92  (-0.23 - 0.61) 0.3624  
Non-Hispanic 
reference
- - - - -
Marriage Status 0.8516  
Married -0.02 0.12 -1.98  (-0.26 - 0.21) 0.8516  
Unmarried 
3  reference
- - - - -
Region 0.0302 *
Northeast 0.62 0.23 85.89  (0.17 - 1.08) 0.0077 **
Midwest 0.60 0.21 82.21  (0.19 - 1.02) 0.0054 **
South 0.52 0.22 68.20  (0.09 - 0.96) 0.0183 *
West
  reference
- - - - -
Metropolitan Statistical Area 0.5366  
MSA 0.12 0.19 12.75  (-0.26 - 0.49) 0.5366  
Non-MSA 
reference
- - - - -
Education 0.0704  
Less 8 years 0.11 0.23 11.63  (-0.36 - 0.57) 0.6526  
High School -0.31 0.16 -26.66  (-0.63 - 0.02) 0.0630  
College -0.40 0.20 -32.97  (-0.80 - -0.00) 0.0492 *
Above Bachelor 
reference
- - - - -
Income
Personal Total Annual Income 
4
0.0264 *
Low 0.50 0.18 64.87  (0.14 - 0.85) 0.0074 **
Middle 0.05 0.18 5.13  (-0.31 - 0.42) 0.7719  
High 
 reference
- - - - -
Notes:
[2] Other race included American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander. 
[3] Not married included widowed, divorced, separated and never married.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Log (Total Expenditures +1) 
Parameter Regression 
Coefficient
SE 95% CI
P-Value
T-Test
P-Value
Wald F
[1] Adjusted for socio-demographic variables, insurance coverage, prescription insurance status, current smoking status, chronic conditions and HRQoL scores.
[4] Personal total income less than $15,000 was classifed as low income, between $15,000 and $20,000 was classified as middle income, above $20,000 was 
classified as high income.
SF-12: Short Form-12; PCS: Physical Component Summary; MCS: Mental Component Summary; K-6: Kessler Index; PHQ-2: Patient Health Questionnaire; SE: 
Standard Error; CI: Confidence Intervals.
   -1) *100
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Table 13 (continued): 
 
 
 
 
 
 
Exponent Regression 
Coefficient 
Poverty Level 0.0002 **
Poor -0.65 0.22 -47.80  (-1.10 - -0.21) 0.0044 **
Low income -0.35 0.21 -29.53  (-0.77 - 0.07) 0.1015  
Middle income 0.16 0.15 17.35  (-0.14 - 0.46) 0.2986  
High income  
reference
- - - - -
Health Insurance Coverage 0.0563  
Medicare 0.31 0.22 36.34  (-0.13 - 0.76) 0.1619  
Medicaid -0.15 0.30 -13.93  (-0.74 - 0.44) 0.6136  
Other Public Insurance 
5
-0.37 0.29 -30.93  (-0.96 - 0.21) 0.2074  
Uninsured -0.42 0.59 -34.30  (-1.60 - 0.76) 0.4768  
Private Insurance 
 reference
- - - - -
Prescription Insurance Status 0.0029 **
Yes 0.45 0.14 56.83  (0.16 - 0.74) 0.0029 **
No  
reference
- - - - -
Currently Smoke 0.4640  
Yes -0.27 0.31 -23.66  (-0.89 - 0.34) 0.3802  
No  
reference
- - - - -
Chronic Conditions
High Blood Pressure <.0001 **
Yes 0.75 0.18 111.70  (0.39 - 1.10) <.0001 **
No  
reference
- - - - -
High Cholesterol 0.0093 **
Yes 0.41 0.15 50.68  (0.10 - 0.71) 0.0093 **
No  
reference
- - - - -
Joint Pain 0.0136 *
Yes 0.39 0.15 47.70  (0.08 - 0.69) 0.0136 *
No  
reference
- - - - -
Arthritis 0.1254  
Yes -0.22 0.14 -19.75  (-0.50 - 0.06) 0.1254  
No  
reference
- - - - -
HRQoL
PCS-12 -0.03 0.01 -2.96  (-0.04 - -0.02) <.0001 **
MCS-12 0.02 0.01 2.02  (-0.00 - 0.05) 0.0689  
K-6 0.04 0.02 4.08  (-0.00 - 0.09) 0.0692  
PHQ-2 0.08 0.04 8.33  (-0.01 - 0.17) 0.0843  
Notes:
SE: Standard Error; CI: Confidence Intervals.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
T-Test Wald F
[5] Other public insuracne were public insurance excluding Medicare and Medicaid.
Parameter
Log (Total Expenditures +1) 
Regression 
Coefficient
SE 95% CI
P-Value P-Value
   -1) *100
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Factors Affecting Total Prescription Medication Expenditures by Cancer 
Patients  
 
   After adjusting for differences in patients‟ age, gender, race, ethnicity, marital 
status, education, income, insurance coverage status, currently smoking status, 
chronic conditions and HRQoL scores in regression model, age was significantly 
associated with total prescription medication expenditures. Patients above 65 years 
old were the reference group. The total expenditures paid in patients between 40-64 
years old were 41.73% (p = 0.0167) lower than that in elderly group (age > 65). It 
meant that total expenditures increased with age groups after controlling all the other 
variables. Total expenditures for patients living in the Northeast, Midwest, or South 
were higher than patients living in the West (p < 0.05). Total expenditures spent on 
patients with college-level education were 32.97% (p = 0.0492) lower than patients 
with the highest education level (above bachelor). Patients with poor family poverty 
level paid 47.8% (p = 0.0044) lower total expenditures than those with high income 
family poverty level, while patients with low personal total annual income paid 64.87% 
(p = 0.0074) higher total expenditures than those with high personal total annual 
income. 
 
 As shown in Table 13, patients covered with prescription insurance, their 
expenditures paid for prescription medicines were 56.83% higher than those for 
patients without prescription insurance (p = 0.0029). With regard to HRQoL, only 
PCS-12 was significantly associated with total medication expenditures (coefficient 
-0.03; p < 0.0001). It meant that patients who reported lower physical SF-12 scores 
paid higher medicine spending. 
 
   Seven variables presented significant association with total prescription medicine 
expenditures by Wald F statistic method, which tested the main effect of each 
predictor in regression mode. They were region (p = 0.0302), personal total annual 
income (p = 0.0264), poverty level (p = 0.0002), prescription insurance status (p = 
0.0029), high blood pressure (p < 0.0001), high cholesterol (p = 0.0093) and joint pain 
(p = 0.0136). After controlling for contributing factors in regression model, region 
was significantly associated with total expenditures. Cancer patients who lived in the 
West had significantly lower prescription medicine total spending than those who did 
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not live there. Income was also significantly associated with expenditures in the 
predictive model. For patients whose total personal income was low, they paid much 
more total prescription medicine expenditures than that of higher personal income 
patients. Patients experienced high cholesterol, joint pain and arthritis had higher 
prescription medicine total spending that those without these chronic conditions. 
 
Factors Affecting Out-of-Pocket Prescription Medication Expenditures by 
Cancer Patients 
 
   Table 14 shows that region, education, health insurance coverage, chronic 
conditions and HRQoL scores were significantly associated with out-of-pocket 
prescription medication expenditures, after adjusting for confounding factors in 
regression model. Patients living in the West had significantly lower medication 
out-of-pocket spending than those in other regions. The difference was greatest in 
patients living in the Northeast, who paid 105.44 percent higher out-of-pocket 
prescription medicine expenditures than patients living in the West (p = 0.0018). 
Patients with college education level paid 30.93 percent lower out-of-pocket 
expenditures than those with above bachelor level degrees (p = 0.0408). Patients 
covered with Medicaid, their expenditure paid for prescription medicines via 
out-of-pocket was 79.4% lower than that of the patients who purchased private 
insurance (p < 0.0001). The difference was even greater in other public insurance 
groups; it was 83.96 percent less (p = 0.0058). Patients experienced high blood 
pressure, high cholesterol and joint pain paid more out-of-pocket prescription 
medicines than those without these conditions (p < 0.005). Oppositely, patients 
reported arthritis had 27.39% lower out-of-pocket spending than those without 
arthritis (p = 0.0484). 
 
   The coefficients for the PCS-12 and the MCS -12 for this model were -0.03 (p < 
0.0001) and 0.03 (p = 0.0073), respectively. The coefficient for the PHQ-2 for this 
model was 0.12 (p = 0.005).  
 
   By Wald F statistic method, region, poverty level, health insurance coverage, 
currently smoking status and chronic conditions presented significant association with 
out-of-pocket prescription medication expenditures. Patients with poor/low family 
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income paid lower out-of-pocket expense than those with the high family income. 
Former smokers paid much more than current smokers. 
 
Table 14: Factors Affecting Out-of-Pocket Prescription Medication Expenditures 
by Cancer Patients: MEPS 2008
1 
 
 
 
 
Exponent Regression 
Coefficient 
Intercept 5.32 0.82  (3.69 - 6.95) <.0001 **
Age 0.2401  
18-39 y 0.05 0.26 5.13  (-0.47 - 0.58) 0.8354  
40-64 y -0.25 0.19 -22.12  (-0.63 - 0.14) 0.2109  
65+ y 
 reference
- - - - -
Gender 0.2439  
Female 0.16 0.13 17.35  (-0.11 - 0.42) 0.2439  
Male 
reference
- - - - -
Race 0.9393  
Black 0.01 0.20 1.01  (-0.40 - 0.41) 0.9705  
Other 
2
-0.07 0.21 -6.76  (-0.49 - 0.35) 0.7413  
White 
reference
- - - - -
Ethnicity 0.6404  
Hispanic 0.09 0.20 9.42  (-0.30 - 0.49) 0.6404  
Non-Hispanic 
reference
- - - - -
Marriage Status 0.4809  
Married 0.07 0.11 7.25  (-0.14 - 0.29) 0.4809  
Unmarried 
3  reference
- - - - -
Region 0.0183 *
Northeast 0.72 0.22 105.44  (0.28 - 1.17) 0.0018 **
Midwest 0.45 0.22 56.83  (0.02 - 0.88) 0.0418 *
South 0.53 0.22 69.89  (0.09 - 0.96) 0.0176 *
West
  reference
- - - - -
Metropolitan Statistical Area 0.2729  
MSA -0.19 0.17 -17.30  (-0.53 - 0.15) 0.2729  
Non-MSA 
reference
- - - - -
Education 0.1665  
Less 8 years -0.28 0.30 -24.42  (-0.87 - 0.31) 0.3419  
High School -0.26 0.15 -22.89  (-0.57 - 0.05) 0.0948  
College -0.37 0.18 -30.93  (-0.72 - -0.02) 0.0408 *
Above Bachelor 
reference
- - - - -
Notes:
[2] Other race included American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander. 
[3] Not married included widowed, divorced, separated and never married.
SE: Standard Error; CI: Confidence Intervals.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Log (Out-of-Pocket Expenditures +1) 
Regression 
Coefficient
SE 95% CI
Parameter P-Value P-Value
T-Test Wald F
[1] Adjusted for socio-demographic variables, insurance coverage, prescription insurance status, current smoking status, chronic conditions and HRQoL scores.
[4] Personal total income less than $15,000 was classifed as low income, between $15,000 and $20,000 was classified as middle income, above $20,000 was 
classified as high income.
   -1) *100
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Table 14 (continued): 
 
 
 
 
 
Exponent Regression 
Coefficient 
Income
Personal Total Annual Income 
4
0.8827  
Low 0.11 0.23 11.63  (-0.35 - 0.58) 0.6301  
Middle 0.05 0.21 5.13  (-0.37 - 0.48) 0.7977  
High 
 reference
- - - - -
Poverty Level 0.0307 *
Poor -0.28 0.24 -24.42  (-0.77 - 0.20) 0.2429  
Low income -0.39 0.26 -32.29  (-0.90 - 0.12) 0.1312  
Middle income 0.28 0.14 32.31  (-0.01 - 0.56) 0.0585  
High income  
reference
- - - - -
Health Insurance Coverage <.0001 **
Medicare -0.25 0.25 -22.12  (-0.75 - 0.25) 0.3178  
Medicaid -1.58 0.29 -79.40  (-2.16 - -1.00) <.0001 **
Other Public Insurance 
5
-1.83 0.64 -83.96  (-3.11 - -0.55) 0.0058 **
Uninsured -0.17 0.50 -15.63  (-1.17 - 0.84) 0.7402  
Private Insurance  
 reference
- - - - -
Prescription Insurance Status 0.0687  
Yes -0.23 0.12 -20.55  (-0.47 - 0.02) 0.0687  
No  
reference
- - - - -
Currently Smoke 0.0490 *
Yes -0.35 0.25 -29.53  (-0.84 - 0.14) 0.1609  
No  
reference
- - - - -
Chronic Conditions
High Blood Pressure 0.0020 **
Yes 0.49 0.15 63.23  (0.19 - 0.80) 0.0020 **
No  
reference
- - - - -
High Cholesterol 0.0024 **
Yes 0.41 0.13 50.68  (0.15 - 0.68) 0.0024 **
No  
reference
- - - - -
Joint Pain 0.0117 *
Yes 0.35 0.14 41.91  (0.08 - 0.62) 0.0117 *
No  
reference
- - - - -
Arthritis 0.0484 *
Yes -0.32 0.16 -27.39  (-0.63 - -0.00) 0.0484 *
No  
reference
- - - - -
HRQoL
PCS-12 -0.03 0.00 -2.96  (-0.04 - -0.03) <.0001 **
MCS-12 0.03 0.01 3.05  (0.01 - 0.04) 0.0073 **
K-6 0.01 0.02 1.01  (-0.03 - 0.05) 0.6635  
PHQ-2 0.12 0.04 12.75  (0.04 - 0.21) 0.0050 **
Notes:
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
[5] Other public insuracne were public insurance excluding Medicare and Medicaid.
T-Test Wald F
Parameter
Log (Out-of-Pocket Expenditures +1) 
Regression 
Coefficient
SE 95% CI
P-Value P-Value
SF-12: Short Form-12; PCS: Physical Component Summary; MCS: Mental Component Summary; K-6: Kessler Index; PHQ-2: Patient Health Questionnaire; SE: 
Standard Error; CI: Confidence Intervals.
   -1) *100
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2.5.3.3 Mean Predicted Total and Out-of-Pocket Prescription Medication 
Expenditures 
 
   Table 15 describes the results from multivariate regression models of predicted 
prescription medication expenditures associated with cancer patients. There was a 
strong relationship among predicted direct expenditure and demographic 
characteristics, insurance coverage, currently smoking status and chronic conditions. 
 
   After adjustment, the predicted annual mean total and out-of-pocket prescription 
medication expenditures associated with cancer were $2,572.1 and $597.1 
respectively. Total and out-of-pocket expenditures significantly increased with age (p 
< 0.0001). Elderly patients (age   65) spent an average of $4,480.8 total expenditure 
($873.5 for out-of-pocket prescription expenditure) compared with $1,205.5 for 
patients between 18-39 years old ($322.2 for out-of-pocket prescription expenditure) 
and $1,684.8 for patients between 40-64 years old ($456.1 for out-of-pocket 
prescription expenditure). With regard to race, whites had higher out-of-pocket 
spending than blacks and other races. More specifically, it was found that whites had 
a decrease in out-of-pocket spending by $102.5 in comparison to blacks, and $176.9 
in comparison to other races. Compared with patients living in the Midwest, South or 
West, patients living in the Northeast paid almost twice as much as the total and 
out-of-pocket prescription expense. Among the four regions, patients living in the 
West incurred least prescription expense. Patients living in the Northeast paid an 
average of $4,374.1 (p < 0.0001) total expenditures, compared with $1,588.7 for the 
patients living in the West, In addition, patients living in MSA paid less total 
expenditures than those living non-MSA ($2,495.7 vs. $2,495.7; p = 0.0415). The 
same trend was found in out-of-pocket expenditures.  
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Table 15: Results of Regression Analysis to Estimate Predicted Total and 
Out-of-Pocket Prescription Medication Expenditures: MEPS 2008 
 
 
 
 
 
Estimate Estimate
Overall 2,572.1 597.1
Age 
18-39 y 1,205.5 <.0001 ** 322.2 <.0001 **
40-64 y 1,684.8 <.0001 ** 456.1 <.0001 **
65+ y 4,480.8 <.0001 ** 873.5 <.0001 **
Gender
Female 2,469.4 0.1404  572.0 0.0778  
Male 2,751.2  641.1
Race
White 2,630.2 0.2845  625.1 0.0347 *
Black 2,510.3 0.4588  522.6 0.0969  
Other 
1
1,898.2 0.1690  448.2 0.1037  
Ethnicity
Hispanic 2,651.1 0.4345  494.0 0.1917  
Non-Hispanic 2,561.7  612.5
Marriage Status
Married 2,449.0 0.1398  613.3 0.3321  
Unmarried 
2
2,738.8  577.1
Region
Northeast 4,374.1 <.0001 ** 1,025.2 <.0001 **
Midwest 2,770.7 0.1709  588.0 0.4794  
South 2,665.3 0.3245  652.0 0.0708  
West 1,588.7 <.0001 ** 370.6 <.0001 **
Metropolitan Statistical Area
MSA 2,495.7 0.0415 * 561.6 0.0005 **
Non-MSA 2,925.5  776.3
Education
Less 8 years 4,705.7 <.0001 ** 694.2 0.0506  
High school 2,532.4 0.4577  589.3 0.4085  
College 2,217.7 0.0474 * 528.9 0.0824  
Above bachelor 2,419.5 0.1627  644.4 0.3054  
Notes:
[1] Other race included American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander. 
[2] Unmarried included widowed, divorced, separated and never married.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Parameter
Out-of-Pocket ExpendituresTotal Expenditures
[3] Personal total income less than $15,000 was classifed as low income, between $15,000 and $20,000 was classified as middle 
income, above $20,000 was classified as high income.
P-Value P-Value
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Table 15 (continued): 
 
Estimate Estimate
Income
Personal Total Annual Income 
3
Low 3,043.0 0.0046 ** 557.0 0.2899  
Middle 2,087.3 0.1276  447.7 0.0299 *
High 2,379.7 0.0310 * 655.9 0.0531  
Poverty Level
Poor 2,421.9 0.3689  517.4 0.1551  
Low income 2,715.0 0.3134  492.8 0.0399 *
Middle income 3,229.1 0.0023 ** 812.2 <.0001 **
High income 2,180.1 0.0031 ** 554.5 0.0420 *
Health Insurance Coverage
Medicare
Yes 4,365.0 <.0001 ** 870.2 <.0001 **
No 1,499.1 406.6
Medicaid
Yes 2,721.0 0.2914  399.0 0.0019 **
No 2,541.1 651.2
Other Public Insurance 
4
Yes 2,557.9 0.4985  412.7 0.0400 *
No 2,573.1 612.5
Private Insurance
Yes 2,348.9 0.0046 ** 653.4 0.0876  
No 2,947.2 521.7
Uninsured
Yes 660.6 <.0001 ** 370.4 0.0106 *
No 2,715.8 608.7
Prescription Insurance Status
Yes 2,423.3 0.0624  605.9 0.3284  
No 2,730.0  588.5  
Currently Smoke
Yes 1,707.7 0.0003 ** 386.5 <.0001 **
No 2,789.0  653.0  
Chronic Conditions
High Blood Pressure
Yes 4,443.1 <.0001 ** 899.8 <.0001 **
No 1,314.1 360.9
High Cholesterol
Yes 3,914.2 <.0001 ** 842.1 <.0001 **
No 1,660.7 417.4
Joint Pain
Yes 3,477.9 <.0001 ** 729.6 <.0001 **
No 1,866.1 482.6
Arthritis
Yes 3,407.0 <.0001 ** 682.3 0.0028 **
No 1,947.3 523.3
Notes:
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
[4] Other public insuracne were public insurance excluding Medicare and Medicaid.
Parameter
Total Expenditures Out-of-Pocket Expenditures
P-Value P-Value
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   Low education level (less than 8 years) and low personal-income patients spent an 
average of $4,705.7 (p < 0.0001) and $3,043 (p = 0.0046) total expenditures, 
respectively, compared with $2,217.7 (p = 0.0474) for the patients with college 
education level, and $2,379.7 (p = 0.0310) for high personal-income patients. Patients 
with middle income poverty level paid much higher than those with other poverty 
levels. For total expenditures, patients with high income poverty level spent less than 
those with poor/low poverty level. But for out-of-pocket expenditures, the trend was 
opposite.  
 
   With regard to health insurance, persons covered by Medicare insurance paid 
higher total and out-of-pocket money for prescription medicine in comparing with 
other insurance groups. Medicare beneficiaries spent much higher average expense 
than those in the non-Medicare population (Medicare $4,365 vs. non-Medicare 
$1499.1 for total spending, $870.2 vs. $406.4 for out-of-pocket; p < 0.0001). Patients 
covered with private insurance paid less total prescription spending than their 
counterparts ($2348.9 vs. $2947.2; p = 0.0046). Other public insurance beneficiaries 
had a lower average out-of-pocket prescription spending than those with other public 
insurance ($412.7 vs. $612.5; p = 0.04). In addition, patients enrolled under Medicaid 
had a lower average out-of-pocket prescription spending than those without Medicaid 
($399 vs. $651.2; p = 0.0019). Uninsured patients had a predicted average total 
expenditure of $660.6 ($370.4 for out-of-pocket) compared with $2,715.8 ($608.7 for 
out-of-pocket) for insured patients. Although the total prescription expenditures in 
prescription insurance beneficiaries ($2,423.3) was lower than that in non-prescription 
insurance population ($2,730), it was not significant (p = 0.0624). 
 
   Patients who were current smokers spent less than those who were former 
smokers ($1,707.7 vs. $2,789 for total expenditure, p = 0.0003; $386.5 vs. $653 for 
out-of-pocket expenditure, p < 0.0001). Patients experienced high blood pressure, 
high cholesterol, joint pain or arthritis had higher mean predicted total and 
out-of-pocket expenditures than patients without these chronic conditions (p < 0.005). 
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2.6 Discussion  
 
   This cross-sectional study examined the association of factors related to cancer 
prescription medication use, health-related quality of life (HRQoL), and prescription 
medication expenditures in the United States. Due to the differences in statistical 
analyses, HRQoL measures, socio-demographic characteristics of the sample and 
medical conditions selected, the findings of this study are not directly comparable to 
prior literature review. Nevertheless, a few differences and common findings are 
noteworthy. This section begins by presenting the major findings based on the 
outcomes obtained from the current study. Then the limitations and health policy 
implications will be discussed. 
 
2.6.1 Major Findings 
 
Firstly, this study examined the difference of HRQoL measures between cancer 
patients with prescription medications and age-matched non-cancer patients. The 
dependent variable - HRQoL, was measured by using self-reported scores on the 
measures of the 12-item Short Form Health Survey (SF-12), the Kessler Index (K-6) 
for general psychological distress, and the Patient Health Questionnaire (PHQ-2) for 
depression. It was found that compared with age-matched non-cancer patients, cancer 
patients with medications had impaired HRQoL. It was also found that cancer patients 
with medications had considerably lower subscale scores for the SF-12 and higher 
subscale scores in the K-6 and the PHQ-2, compared with the age-matched 
non-cancer patients. Specifically, cancer patients reported worse physical or mental 
health, more serious psychological distress and depression. These impairments were 
greater in physical than mental health. 
 
It is generally believed that the small differences in HRQoL may be statistically 
significant but unimportant.
123
 The clinically important difference (CID) reflects the 
amount of change in HRQoL that is meaningful to patients and their health care 
providers, this change could be either improvement or decline.
124
 Minimal clinically 
important difference (MCID) is generally linked to the smallest difference in a HRQoL 
score that is considered to be clinically important.
123
 The estimate of CID depends on 
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the assessment method and may possibly change for different questionnaires, 
population and context.
124
 The 3 to 5 point difference in SF-36 scale scores is noted as 
the MCID translates into a 0.09 - 0.28 effect size range,
123
 and it is considered large 
enough to be important. The current study revealed that of the summary measures of 
SF-12, only the PCS-12 showed a small effect. The effect size for MCS-12 did not 
indicate any practical significance. It was also noted that for cancer patients with 
prescriptions, the mean K-6 summary index score was 4.3, which was well below the 
optimal cut point (13) for the prevalence of serious mental illness in the national 
population.
117
 It was the same with PHQ-2 score when the mean score 1.2 was well 
below the optimal cut point (3) for screening purposes.
118 
Nevertheless, these data 
support the view that cancer is a traumatic event producing negative impact on various 
dimensions of a patient‟s HRQoL.44  
 
   In this study, the HRQoL was measured by three generic HRQoL measurements, 
the SF-12, the K-6 and the PHQ-2. All of them are suitable to a wide range of diseases 
and health conditions. The SF-12, the K-6 and the PHQ-2 measure a person‟s health 
status over the past four weeks, 30 days and two weeks, respectively. The advantage 
of the SF-12 includes its broad coverage of HRQoL dimensions; the advantages of the 
K-6 and the PHQ-2 are that they are simple, easy to complete, and could be used to 
compare different populations. In addition, the K-6 could sensitively measure the 
general distress severity in the range that are commonly found in clinical data.
112
 
Correlations among the SF-12 , the K-6 and the PHQ-2 were reported to be less than 
0.50 (a high correlation
125
), except for the correlations between K-6 summary index 
and MCS-12 (0.67) / accomplished less emotional (0.56) / felt downhearted (0.60), 
PHQ-2 summary index and K-6 summary index (0.66) / MCS-12 (0.50). Due to the 
different attributes of these instruments, it was evident that the measurement of 
HRQoL using the SF-12, the K-6 and the PHQ-2 presented more meaningful 
information than only using one of the instruments. This study showed that compared 
with age-matched non-cancer population, all instruments reported impairments in 
comparable dimensions for cancer patients with prescription medications. Specifically, 
cancer patients with prescriptions had a significantly lower score in each summary 
score of the SF-12, and a significantly higher score in the K-6 and the PHQ-2 than 
age-matched non-cancer population. 
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The associations between patient characteristics variables and the HRQoL were 
mostly aligned with literature. Better HRQoL was reported by patients who were 
younger 
52, 63 
and with higher education.
55, 56, 63, 69 
The effect of age on worse physical 
health could be partially explained by the fact that about 78% of all cancers are 
diagnosed in persons with 55 years and older.
4
 In addition, cancer patients with 
chronic diseases have a worse physical health,
52, 60
 and Hispanics were more likely to 
report worse mental problems than non-Hispanics.  
 
   Secondly, this study calculated the expenditures for prescribed medications 
associated with cancer. After controlling for different confounding factors, the 
predicted annual mean total and out-of-pocket expenditures associated with cancer 
medications were $2,572.1 and $597.1, respectively. Both the medical and policy 
communities increasingly concern the burden of out-of-pocket expenses on cancer 
patients. This analysis also examined how certain demographic and socioeconomic 
characteristics are strongly associated with high financial burdens. There is a lack of 
studies which has examined the prescription expenditures associated with cancer 
among groups of different demographic and socioeconomic characteristics. Yet the 
current study findings mirror general trends reported in the literature. This 
multivariate analysis revealed that patient characteristics such as age, region, 
insurance status, chronic conditions and HRQoL had significant impact on cancer 
prescription drug expenditures.  
 
   Total and out-of-pocket expenditures significantly increased with age. Elderly 
cancer patients had a higher level of spending on cancer prescription medications than 
nonelderly, especially those in the age category of 18 - 39. This result mirrors general 
trends reported in the literature.
76, 77, 78, 79, 80, 86
 Similar to the results obtained by Ezzati 
et al.
77
 and McKercher et al.
79
, there were large differences of total and out-of-pocket 
expenditure between elderly and nonelderly patients. 
 
   Previous studies have consistently found that male paid less for their prescription 
medications expense than female.
77, 80, 81, 86 
However, in current analysis this 
difference was not evident. Hence the hypothesis 2 was not supported. 
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   With regard to race/ethnicity, this study found that whites had higher total and 
out-of-pocket spending than blacks. Although Hispanics spent higher total and 
out-of-pocket expenditures than non-Hispanics, these differences were not significant. 
Nevertheless whites actually incurred higher expenditures, which is similar to 
previous literature findings.
77 
Therefore, the hypothesis 3 was supported.  
 
   Among the socioeconomic status, it was shown that patients living in the West or 
MSA predict a lower prescription spending than patients living in other regions.
77, 86
 
In this study, out-of-pocket expenditures for patients living in the Northeast were 
105.44% higher than patients living in the West, while patients living in MSA paid 
17.3% lower out-of-pocket expenditures than patients living in non-MSA. However, 
MSA is not a significant factor. 
 
   With respect to hypothesis 4 - “Patients with lower SES (classified as poor or 
having low income, uninsured) experience greater total/out-of-pocket expenditures 
associated with prescription cancer medications in comparison to their corresponding 
counterparts.” The finding of effect of income level did not support it. 
 
   In terms of income levels, this study revealed that patients with poor or low family 
income had lower total and out-of-pocket prescription cancer spending than those 
who were with high family income (p < 0.05). Only patients with low personal 
income had higher total prescription expenditure than those with high personal 
income.  
 
   When considering prescription medication expenditures, clarifying the influence 
of patients‟ health insurance status is important for making a health policy. In this 
study, persons covered by Medicare insurance paid higher total and out-of-pocket 
money for prescription medicine in compared with other insurance groups. Similar to 
the results from Stagnitti et al.,
89
 Medicare beneficiaries spent much higher average 
expense than those in the non-Medicare population, and uninsured had the lowest 
average annual total expense. Patients enrolled under Medicaid or uninsured patients 
paid less for their medicines by out-of-pocket compared with their counterparts. This 
difference gives the researchers and policy makers an alarm to pay attention to those 
vulnerable people regarding their access to health care. 
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   In addition, this study also revealed that patients who were current smokers 
incurred less total and out-of-pocket expenditures for prescription medication than 
those who were former smokers. Patients experienced high blood pressure, high 
cholesterol, joint pain or arthritis had higher predicted mean total and out-of-pocket 
expenditures than patients not experienced these chronic conditions. 
 
   Furthermore, this study tried to associate HRQoL scores and medical expenditures. 
Previous literature reported that poor HRQoL was associated with higher prescription 
expenditures.
77, 90, 93, 94
 The hypothesis in this study to be tested was whether cancer 
patients with lower physical or mental SF-12 scores, higher K-6 or PHQ-2 scores are 
more likely to accrue higher prescription medicine expenditures. The present study 
findings provide the evidence that higher out-of-pocket medicine expenditures 
incurred by patients with worse physical health or more serious depression. However, 
patients with better mental health also had higher out-of-pocket medicine spending. 
One explanation maybe that patients‟ mental health was greatly improved by these 
medications. The other explanation was that the information of HRQoL measured by 
these instruments is not obtained at a regular interval after taking cancer medications.  
 
2.6.2 Study Strengths and Limitations 
 
   This study used the latest public use data drawn from the year 2008 Medical 
Expenditures Panel Survey (MEPS) for research. The MEPS is an annually nationally 
representative survey of the civilian non-institutionalized population in the U.S. Due to 
the secondary use of a pre-existing data, all independent and dependent variables were 
not exclusively designed for the objectives of this study. Detecting the time sequence 
of cancer patients taking prescription medications is difficult. An alternative method is 
to review medical-chart individually. However, performing this kind of study is very 
costly and time-consuming compared with using secondary data. In this section the 
discussions include the strengths and limitations of using secondary administrative 
dataset in this study. 
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Study Strength 
 
   Firstly, MEPS data has high accuracy and reliability. The MEPS is an annual set of 
large-scale surveys on the utilization of health care, insurance coverage, expenditures 
and payment sources for the U.S. civilian non-institutionalized population. It has a 
high-level agreement with physicians, and allows researchers to identify the disease by 
ICD-9-CM codes rather than from the answers to questions. Furthermore, MEPS 
collects information from pharmacy providers frequented by the survey respondents, 
and it takes measures to address the underreporting issues by relieving the household of 
the report.
111
 Hence, the accurate and detailed information on medications could be 
helpful for deeply understanding the factors affecting cancer patients‟ quality of life 
and expenditures.  
 
   Secondly, MEPS survey improves the validity and breadth of self-reported response. 
The response rate for the 2008 Self-Administered Questionnaire (SAQ) is relatively 
high, which is 92.7%.
104
 All the HRQoL measures in SAQ – the SF-12v2, the K-6 for 
general psychological distress and the PHQ-2 for depression, are proved to be valid 
and reliable. To my knowledge, this study is the first study to examine cancer patients‟ 
health status by using of these three different instruments. This study conducts a 
comprehensive comparison of patient-reported health status between the cancer and 
non-cancer populations and provides important information on the impact of cancer 
risk factor clusters on HRQoL. 
 
   Thirdly, the literature which has examined cancer patients treated with prescription 
medications by using nationally representative database such as MEPS are lacking 
and mostly outdated. This study uses year 2008 MEPS data, which is by the time the 
latest and most complete dataset available from MEPS website. Furthermore, to my 
knowledge, this study is also the first attempt to assess costs and health status 
associated with cancer patients taking prescription medications by using a nationally 
representative database. HRQoL assessment could provide information that is not 
available from diagnoses or other health record information resources. Meanwhile, it 
also reveals the patients‟ thoughts about the efficacy of treatment, which may 
influence their utilization of medical services. In the models of predicting medical 
expenditures, relatively few studies have used self-reported health status as a variable. 
 94 
 
Fleishman et al.
126
 used a nationally representative sample to estimate predictive 
models that included the SF-12 health status measure, and pointed out that the SF-12 
summary scores were significantly associated with expenditures, after controlling for 
demographic characteristics and specific chronic conditions. In the current study, 
lower physical SF-12 scores and higher depression (PHQ-2) scores were significantly 
associated with higher prescription medication expenditures. 
 
Study Limitations 
 
   Generally, administrative datasets are likely to cause potential errors in data 
collection, editing, or difficulty in evaluation of imputation. This study used 
administrative dataset. Without doubt, this leads to some limitations. 
 
   Firstly, a main limitation of this study is the observational design. Self-report does 
not provide a gold standard; it may potentially bias the results. In addition, because 
the data are cross-sectional, the causal relationship between medication therapy and 
HRQoL cannot be determined. However, the findings of this study provide an 
estimate of the potential impact of prescription medications on HRQoL of cancer 
adult patients.  
 
   Secondly, MEPS does not include certain measures that are more responsive to 
HRQoL among patients with cancer (e.g., the functional assessment of cancer 
therapy-General (FACT-G)). The SF-12, K-6 and PHQ-2 are generic instruments 
which could be used to assess outcomes across many medical conditions, as well as 
with healthy population. They are less sensitive and responsive to the changes when 
assessing quality of life in specific patient groups.  
 
   Thirdly, the estimates obtained in this study do not represent the HRQoL and 
prescription expenditures of all cancer patients in the U.S. because the study 
population excludes institutionalized population. In addition, the expenditures used in 
this study included only the spending for prescription medications, while many cancer 
patients are more likely to have expenditures of hospital inpatient stay, emergency 
room visits and other medical services. Moreover, the total number of cancer patients 
sampled may be comparatively small in MEPS, since MEPS is not designed to 
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provide statistically robust, population-based information on health status by types of 
cancer.
43
 Hence, the small sample size of this study will influence its representation of 
national estimates. 
 
2.6.3 Health Policy Implication 
 
   Based on the findings, there are a few suggestions for the implication of health 
policy. First of all, this study provides additional empirical evidence to demonstrate 
socio-demographic differences assessed by HRQoL measures. Healthcare researchers 
and clinicians need to be aware that persons between 18-39 years of age, unmarried, 
Hispanics, not living in city area, less education attainment or currently smoking had 
greater tendency towards physiologic distress or depression. There is a need to 
emphasize screening physiologic problem in cancer patients taking with prescription 
medications, because such problems could cause adverse effects and increase health 
care costs. 
 
   Moreover, this study is designed to document how the patient characteristics affect 
cancer prescription medication expenditures among adult cancer patients. It helps 
establish a framework for understanding the real cancer-related medication spending 
among cancer patients and gives a comprehensive and up-to-date understanding of 
cancer medication treatment and expenditures to assist manage medical costs. 
 
   The MEPS data include a crucial component of health expenditures - health 
insurance coverage. It is necessary to examine the relationship between health 
insurance status and out-of-pocket expenditures among vulnerable patients with 
prescription medications. Vulnerable patients are elderly, female, blacks, Hispanics, 
uninsured, or with low income. They particularly have the restrictions of insurance 
coverage and access to health service utilization, including prescription medications. 
Hence, health policy makers should develop more specific interventions to help these 
disadvantaged people. 
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2.6.4 Suggestions for Future Studies 
 
   Since the study has some limitations, there are some suggestions for future 
research. Firstly, the current study had a cross-sectional design, that‟s why it is not 
possible to determine causal relationships of socio-demographics against HRQoL or 
socio-demographics against prescription expenditures. Further longitudinal studies 
will be required to test the presence of associations and fully interpret their clinical 
significance.  
 
Additionally, the findings of this study did not support the following hypothesis – 
“female patients or patients classified as poor or having low income experience 
greater total/out-of-pocket expenditures associated with prescription cancer 
medications in comparison to their counterparts”. In this study, the impact of gender 
was not evident. And it was found that patients with poor or low family income had 
lower total and out-of-pocket prescription spending than those who were with high 
family income. The differences indicated that cancer patients with higher income had 
higher level of expenditures, which contradicted the hypothesis. Thus, further studies 
are needed to examine such differences. 
 
   Finally, a full estimation of the economic burden of cancer prescription 
medications should also include the indirect costs, which have important economic 
value as well. Morbidity cost of illness is the most common indirect cost. It is related 
to the lost or impaired ability to work or reduced productivity due to illness (e.g., days 
lost from work, foregone wages), as well as the economic output and the time lost or 
forgone by the patients‟ family and friends from usual activities (e.g., income lost by 
family members, restricted leisure time).
38
 In addition, mortality costs as part of 
indirect costs and intangible costs are also of considerable interest to policymakers. 
Since this study only focused on direct prescription expenditures of treating cancer, 
overall predicted expenditure associated with cancer was underreported. A simple 
descriptive analysis about the lost productivity was performed in this study. However, 
a more detailed analysis is needed to capture both direct and indirect expenditures 
associated with lost productivity, premature mortality, or pain and suffering, which 
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will provide a more precise overall predicted prescription medication expenditure for 
cancer.  
 
2.6.5 Conclusion 
 
   This study comprehensively examined the patient characteristics related to 
HRQoL and expenditures on prescription cancer medications among adult cancer 
patients by using the latest and most complete MEPS dataset. The results revealed that 
cancer population with prescription medications had impaired HRQoL and lost more 
productivity compared with age-matched non-cancer population. It also indicated that 
the disparities existed among HRQoL and prescription cancer expenditures. 
Specifically, older age, Hispanics, less education attainment and chronic conditions 
were risk factors for HRQoL. Differences existed in the total and out-of-pocket cancer 
prescription spending between elderly and nonelderly, black and white population, 
living in the West and living in the other regions. Insurance status, smoking status and 
chronic conditions also had significant impact. Moreover, patients with worse physical 
health or greater tendency towards depression were more likely to incur higher 
prescription medication expenditures. Findings from this study might assist health 
professionals to pay more attention to primary cancer care from the patient‟s 
perspective. Further research is needed to determine causal relationships to test the 
associations between the demographics/SES and the HRQoL/prescription medication 
expenditures by longitudinal studies. Additionally, a more detailed analysis is needed 
to capture both direct and indirect costs to provide more precise overall predicted 
prescription medication expenditures for cancer. 
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Chapter 3: Patient Satisfaction and Subjective Experiences of 
Treatment with Breast Cancer Hormonal Medications 
 
3.1 Abstract 
 
Objective: To examine patient satisfaction and subjective experiences of breast 
cancer treatment with hormonal medications – tamoxifen and Aromatase Inhibitors 
(AIs), by using patient self-reported data. 
 
Methods: The data used for this study were collected from the website 
www.askapatient.com, which invites patients to rate their medications and comment 
on their drug experience. 1,121 female breast cancer patients with age of 40 and 
above taking hormonal medications were extracted. Multivariate analyses were used 
to compare side effects, and evaluate both individual and condition characteristics that 
affect satisfaction with hormonal medications among breast cancer patients. 
 
Results: Patients receiving AIs experienced significantly more arthralgia/myalgia, 
bone events, carpal tunnel syndrome, vaginal dryness, sexual dysfunction and sleep 
disorders, while patients receiving tamoxifen experienced significantly more hot 
flashes, night sweats, vaginal discharge/bleeding and other serious gynecologic side 
effects. Side effects, especially musculoskeletal symptoms and nervous system 
problems, significantly and negatively affected patient satisfaction with hormonal 
medications. Long-term medication treatment and currently consistent use of 
medications were also important determinants of medication satisfaction. In addition, 
anastrozole and letrozole patients had a higher probability of experiencing satisfaction 
than tamoxifen patients.  
 
Conclusions: This self-reported-data study found that the majority of the patients on 
current hormonal medications incurred significant side effects, which negatively 
affected patient satisfaction. Additionally, long-term and currently consistent uses of 
medications were also important factors affecting patient satisfaction with medication.  
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3.2 Introduction 
 
   Study background, objectives, research questions and hypotheses will be 
presented in this section. 
 
3.2.1 Background 
 
   According to year 2008 World Cancer Report, breast cancer is the most frequently 
diagnosed type of cancer among women. And today, after lung cancer, it is the second 
leading cause of cancer death in women.
2 
Breast cancer is a cancer that starts in the 
breast. Usually, the tumor begins in the cell of the lobules that are the glands for 
milk-producing, in the cell of the ducts as well, which are the passages draining milk 
from the lobules to the nipple.
127
 In the United States, breast cancer is the most 
commonly diagnosed cancer for women after skin cancer, accounting for nearly one 
in four cancer cases diagnosed in women.
128
 Men are generally at low risk for 
developing breast cancer. Each year more than 190,000 new cases are diagnosed and 
cause more than 40,000 deaths.
129 
The American Cancer Society (ACS) estimates that 
192,370 new cases of invasive breast cancer would be diagnosed among women and 
approximately 40,170 would die of breast cancer in the U.S. in year 2010.
128
 The most 
significant risk factors for developing breast cancer are age and gender (female). 
Incidence and death rates of breast cancer generally increase with age. According to 
the ACS, 95% of new cases and 97% of breast cancer deaths occurred in women aged 
40 and older during year 2002 to 2006.
128
 
 
   Over the past few decades, the incidence of breast cancer has increased steadily in 
the United States, but breast cancer mortality has declined, indicating an increased 
survival rate. The predominant reason is the improved treatments. Generally, the 
choice of treatment depends on the stage of breast cancer, whether the tumor is 
positive for certain receptor, the overall health condition of the patient, as well as the 
risks and benefits associated with treatment. Conceptually, treatment options for 
breast cancer patients include local and systemic treatments. Local therapy treats a 
tumor at the site without affecting the rest of the body. In the case of metastatic 
disease, local treatment still could be applied to specific places where cancer might 
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have spread, such as bones or ovary. Surgery and radiation therapy are examples of 
local therapies. Systemic therapy is directed at the whole body. It uses anti-cancer 
drugs that are injected into the vein or taken orally. These drugs travel through the 
bloodstream and affect cells in all parts of the body.
128
 Systemic therapy could be 
given to patients before or after surgery. It could also be used in treating metastasis 
breast cancer. In such conditions, complete surgical excision is not possible, and 
therefore systemic therapies are the main treatment option.
128
 Systemic treatment 
includes chemotherapy, biologic therapy and hormonal therapy.  
 
   Approximately 75% of all breast cancers occur in postmenopausal women in 
Western countries, among which about 80% are hormone-receptor-positive.
130,131
 
Hormonal therapy, also called endocrine therapy or hormone therapy, is the best 
treatment choice for these breast cancer patients. It could be used in both early and 
advanced stages. Currently, the most widely used daily oral hormonal medications 
include tamoxifen and Aromatase Inhibitors (AIs) - anastrozole (Arimidex®), 
letrozole (Femara®) and exemestane (Aromasin®). Tamoxifen has been considered 
the standard hormonal treatment for premenopausal and postmenopausal breast cancer 
patients for decades, while AIs are the newest class of drugs, which can potentially be 
effective to postmenopausal women who become refractory or may become resistant to 
tamoxifen. All of these medications are approved by the U.S. Food and Drug 
Administration (FDA). The role of each hormonal therapy depends on woman‟s stage 
of disease, menopausal status, overall medical condition, and personal considerations. 
These medications are used to lower the risk of early-stage breast cancer recurrence 
after surgery, shrink or slow the growth of advanced-stage breast cancer, or lower the 
risk of patients who are at high risk but have not been diagnosed with breast cancer.  
 
   Although tamoxifen and AIs demonstrate a superior therapeutic efficacy in both 
early and advanced disease stages of postmenopausal women, they produce different 
toxic side effects. The most common side effects associated with tamoxifen are 
vasomotor symptoms, vaginal discharge, and vaginal itching or dryness.
129
 Patients 
who receive AIs experience vaginal dryness, sexual dysfunction, arthralgia, 
cardiovascular disease, and bone disease such as decreased bone mineral density or 
fractures.
132
 In addition, tamoxifen will cause some serious life-threatening side 
effects (i.e., thromboembolic and cerebrovascular events, endometrial cancer).
129 
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These side effects deleteriously effect the patients‟ quality of life and influence drug 
compliance. Therefore, when considering the management of breast cancer hormonal 
medications, in addition to assess the impact of the medication on patients‟ 
health-related quality of life (HRQoL), it is also essential to assess patient satisfaction 
with that medication. Currently available quality of life (QoL) studies show that 
although the side effect profiles of tamoxifen and AIs vary significantly, there are no 
clinically important differences in overall QoL. Consequently, patient satisfaction is 
particular useful when differentiating these treatments. 
 
   Patient satisfaction with medication mainly evaluates the patient‟s experience after 
taking the medication.
26
 It also reflects patients‟ treatment-related behaviours, such as 
correct use of the medication, the likelihood of continuing to use medication, and 
adherence with medication.
30
 It is influenced by the outcomes of the treatment, 
especially HRQoL and symptom status. Evidence has also shown that in randomized 
controlled clinical trials for patients with chronic disease including cancer, satisfaction 
outcomes can be more sensitive to the changes than outcomes of quality of life.
133
 
Hence, medication satisfaction information is potentially useful for deeply 
understanding the cancer patients‟ perspective on their current treatment and can 
differentiate among alternative treatments. However, to date, there have been no 
empirical studies which systematically explore this topic on breast cancer hormonal 
medications. 
 
3.2.2 Study Objectives 
 
   This study attempts to attribute treatment related toxicity and satisfaction with 
hormonal medications by using patient self-reported data. It is carried out to give a 
better understanding of the important issues in treatment decision making for 
postmenopausal women with breast cancer.  
 
   One objective of this study is to assess and compare the side effects reported by 
breast cancer patients with different hormonal medications. Monitoring of side effects 
after taking hormonal therapy is crucial in medical oncology practice, because it could 
be balanced against a minimal survival advantage to make the optimal choice of 
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treatment.
134
 As known from several publications, physician-guided symptom 
assessment is not sufficient to give a full picture of the real side effects produced by 
hormonal treatments, it normally underestimates the real treatment burden.
134,135,136 
Therefore, there is an increasing recognition of the importance of obtaining breast 
cancer patients‟ views about their problems and their treatments.  
 
   The other objective of this study is to examine patient satisfaction with the 
different hormonal medications. Tamoxifen and AIs have been demonstrated to have 
similar survival rates in postmenopausal patients,
137
 but differ with respect to side 
effects. Nevertheless, there were no clinically important differences in overall QoL. 
Consequently, patient satisfaction is particular useful when comparing the benefits of 
these hormonal medications. This information can be served as the baseline for the 
policy makers on how to best improve breast cancer outcomes over time. Currently, 
the published literature on cancer treatment satisfaction has been scarce, without clear 
indication of whether breast cancer patients are indeed satisfied with their hormonal 
medications, and what their subjective experiences are.  
 
   The expected objective of this study is that by examining patient satisfaction and 
subjective experiences of treatment with breast cancer hormonal medications, the 
findings will provide a new benchmark for these values which can be applied to the 
management of breast cancer hormonal medications. 
 
3.2.3 Research Questions and Hypotheses 
 
   This study is based on the patient self-reported data collected from an Internet 
website www.askapatient.com, which is a database providing patients‟ opinions and 
ratings of medicine effectiveness.
138
This database includes the FDA approved 
medications. It also includes patients‟ opinion polls on healthcare topics, and a section 
of health care research assistance.
138
 The research questions and their hypotheses are 
described below. 
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Research Question one: 
“What are the most common side effects reported by breast cancer patients after 
taking hormonal medications?” 
 
The hypotheses to be tested are as follows: 
 
1. Breast cancer patients taking tamoxifen reported more vasomotor symptoms 
and vaginal discharge/bleeding. 
2. Breast cancer patients taking AIs reported more arthralgia/myalgia, carpal 
tunnel syndrome, vaginal dryness and bone events. 
 
Research Question two: 
“What are the factors associated with breast cancer patients’ satisfaction after 
taking hormonal medications?” 
 
The hypotheses to be tested are as follows: 
 
1. The side effects have negative impact on patients‟ rating on satisfaction. 
2. The duration of medication treatment is longer, the probability of being 
satisfied or the likelihood of rating a higher score is higher. 
3. Patients who persist as current users of medication are more likely to rate a 
higher score on satisfaction. 
4. Patients with concurrent drug use are more likely to rate a higher score on 
satisfaction. 
5. AIs patients had a higher probability of experiencing satisfaction than 
tamoxifen patients. 
 
3.3 Literature Review 
 
This section will provide a systematically literature review related to this study. The 
topics include an overview of the quality of life (QoL) research on breast cancer 
hormonal medications. QoL research including disease-related symptoms, toxic effects 
of therapy, emotional, socioeconomic and functional effects of living, could affect the 
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patients‟ experience with treatment. In addition, a comprehensive review on patient 
satisfaction with medication is provided.  
 
3.3.1 Quality of Life (QoL) Studies on Breast Cancer Hormonal Medications 
 
A comprehensive literature search in PubMed was conducted to identify 
English-language studies assessing quality of life (QoL) in breast cancer patients with 
hormonal therapy. Publications through year 2010 were searched for. The key words 
“breast neoplasms”, “tamoxifen”, “anastrozole”, “letrozole”, “exemestane”, “quality of 
life” and “outcome assessment” were included in the search. After scanning titles and 
abstracts, studies that appeared to be relevant were reviewed in detail. Additionally, 
reference lists of selected papers were used to find articles that did not appear in the 
primary search.  
 
QoL Studies of Tamoxifen 
 
The effects of tamoxifen on QoL are collected from two randomized trials: the 
Wisconsin Tamoxifen Trial and the National Surgical Adjuvant Breast and Bowel 
Project P1 (NSABP-P1) Trial. See Table 16. 
 
Table 16: Randomized Trials Evaluating QoL of Tamoxifen 
 
Trial Timing Intervention Size Instrument Outcomes
Wisconsin (postmenopausal)
Love et al. 1991 
139  post surgery
Placebo × 2y  
Tamoxifen × 2y
140
Symptom 
questionnaires 
 No difference in overall 
QoL; Vasomotor and 
gynecologic symptoms↑ 
with tamxifen
NSABP-P1 (premenopausal and postmenopausal)
Day R et al. 1999 
140 prevention
Placebo × 5y 
Tamoxifen × 5y
11064
CES-D, SF-36,  
sexual functioning 
scale, SCL
 No difference in overall 
QoL; Vasomotor, 
gynecologic symptoms 
and sexual dysfunction ↑ 
with tamoxifen
Day R et al. 2001 
141 prevention
Placebo × 5y 
Tamoxifen × 5y
11064 CES-D No difference
Notes:
NSABP: National Surgical Breast and Bowel Project; CES-D: Center for Epidemiological Studies-Depression Scale; SF-36: Medical 
Outcomes Study 36-Item Short Form Health Status Survey; SCL: Symptom Check List.
↑ means "increase", ↓ means "decrease".
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    Wisconsin Tamoxifen Trial is a randomized, double-blind, placebo-controlled trial 
which included 140 postmenopausal women with axillary node negative breast 
cancer.
139
 Patients were randomly assigned to receive tamoxifen or placebo. Data on 
symptoms and overall QoL were collected over 24 months by symptom questionnaires. 
Women receiving tamoxifen had increased hot flashes (tamoxifen 67.2% vs. placebo 
45.4% at 6 months, p < 0.01). Gynecologic symptoms (one or more of the following: 
vaginal discharge, irritation, or bleeding) were also more common (29.7% vs. 15.1% at 
6 months; p < 0.05) in tamoxifen users. No differences were detected with regard to 
QoL, bone pain, joint pain, nausea, difficulty sleeping, irritability, depression, fatigue, 
or heartburn. 
 
The National Surgical Adjuvant Breast and Bowel Project P1 (NSABP-P1) Trial 
recruited 11,064 women who were randomized to receive tamoxifen or placebo with 36 
months follow-up period.
140
 HRQoL assessment was performed by the Center for 
Epidemiological Studies-Depression Scale (CES-D), the Medical Outcomes Study 
(MOS) 36-item Short Form Health Survey (SF-36), the MOS sexual functioning scale, 
and a Symptom Check List (SCL). No differences were found between tamoxifen and 
placebo for CES-D and SF-36. Tamoxifen use was associated with an increase in 
vasomotor symptoms, gynecologic symptoms and sexual functioning problems.  
 
   A sub-study of NSABP-P1 used CES-D to examine the psychological effects of 
tamoxifen for breast cancer patients.
141
 CES-D scores of 16 or higher indicated 
affective distress. This study showed no difference in the women who scored 16 or 
higher of tamoxifen and placebo. 
 
   All the above studies found no differences in QoL between tamoxifen and placebo, 
despite that significant increase in vasomotor and gynecologic symptoms with 
tamoxifen was observed. 
 
QoL Studies of Aromatase Inhibitors (AIs) 
 
   Aromatase Inhibitors (AIs) in postmenopausal women have successfully increased 
survival rates and disease-free survival rates. However, treatment with AIs seems to 
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produce a lot of side effects. The most common short-term adverse events include hot 
flashes, fatigue, arthralgia, muscle pain, and increases in osteoporosis.
132
 Up to now, 
quite a number of randomized trials about AIs are implemented; however the studies of 
QoL evaluation are limited. 
 
   Eight studies about randomized trials evaluating QoL of AIs with tamoxifen have 
been identified, including the Arimidex, Tamoxifen, Alone or in Combination trial 
(ATAC), the Intergroup Exemestane Study (IES), the National Surgical Adjuvant 
Study of Breast Cancer (NSAS BC), the Tamoxifen Exemestane Adjuvant 
Multinational (TEAM) trial, and the National Cancer Institute of Canada Trial (MA.17). 
Another two QoL studies were carried out with regard to head-to-head comparing 
anatrozole with letrozole. One was about adjuvant treatment, and the other was about 
metastatic treatment. See Table 17.  
 
  QoL studies of the Arimidex, Tamoxifen, Alone or in Combination trial (ATAC) 
were reported for two and five years follow-up. In the ATAC QoL sub-protocol over a 
period of two years, 1,021 of 9,366 patients were randomized to receive anastrozole, 
tamoxifen, or a combination.
142
 The Functional Assessment of Cancer Therapy for 
Breast Cancer (FACT-B) with an additional Endocrine Subscale (ES) questionnaire 
was used. The primary endpoint was the Trial Outcome Index (TOI) of the FACT-B. It 
is the summary scores from the Physical Well-Being (PWB), Functional Well-Being 
(FWB) and the breast cancer subscales.
138
 Secondary endpoints were the total ES score 
and the Emotional Well-Being (EWB) and Social Well-Being (SWB) subscales of the 
FACT-B. In this sub-study, response rates were approximately 85% for all time points. 
Overall QoL improved over time, and no significant differences between groups in TOI 
scores, ES, EWB or SWB scores were observed. Endocrine symptoms increased 
between baseline and three months for all groups and stabilized or improved slightly 
thereafter. Compared with sole tamoxifen users, anastrozole users only reported 
significantly fewer frequencies of cold sweats, but the same occurrence of hot flashes. 
Vaginal discharge was reported less often by patient receiving anastrozole. Conversely, 
vaginal dryness, painful intercourse and loss of libido were significant more common 
on anastrozole. There were no significant differences of neuropsychological, 
gastrointestinal symptoms and related symptoms in all treatment groups. 
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Table 17: Randomized Trials Evaluating QoL of Aromatase Inhibitors 
 
 
  
 
Trial Timing Intervention Size Instrument  Endpoints Outcomes
ATAC
Fallowfield L et al.2004 
142 Post-surgery or 
chemotherapy
Anastrozole × 5y 
Tamoxifen × 5y 
Combination ×  5y
1021 FACT-B+ES
Primary: TOI   
Secondary: total ES 
score, EWB and SWB 
subscales of the FACT-B
No difference in overall 
QoL or the endocrine 
subscale
Cella D et al.2006 
143 Post-surgery or 
chemotherapy
Anastrozole × 5y 
Tamoxifen × 5y
1105 FACT-B+ES
Primary: TOI   
Secondary:  ES score, 
EWB and SWB 
subscales of the FACT-B
No difference in overall 
QoL or the endocrine 
subscale
IES
Fallowfield L et al.2006 
144 Following 
tamoxifen × 2-3y
Exemestane × 2-3y 
Tamoxifen × 2-3y
582 FACT-B+ES
Primary: TOI   
Secondary: total FACT-
B + ES score, ES score
No difference in overall 
QoL or the endocrine 
subscale
NSAS BC 03
Ohsumi S et al. 2010 
145  
Post-surgery and 
Following 
tamoxifen × 1-4y
Anastrozole × 5y 
Tamoxifen × 5y
706
FACT-B+ES; 
CES-D
Primary: DFS, adverse 
events                
Secondary: HRQoL, 
psychological distress
Better QoL in tamoxfien 
group; hot flashes and 
vaginal discharge with 
anastrozle ↑; dizziness, 
diarrhea and headache 
with tamoxifen ↑
NSAS BC 04 (sub-study of TEAM)
Takei H et al. 2006 
146 N/A
Anastrozole × 5y 
Exemestane × 5y 
Tamoxifen × 5y 
247
FACT-B+ES; 
CES-D
Primary: Adverse events 
Secondary: HRQoL
No difference in overall 
QoL, endocrine subscale, 
or psychological distress
DUTCH TEAM TRIAL
 van Nes JGH et al .2009 
147 Following 
tamoxifen × 2-3y
Exemestane       
Tamoxifen          
742
EORTC QLQ- 
C30, EORTC 
QLQ-BR 23, 
FACT-ES
Not specified
No difference in overall 
QoL; insomnia ↑, sexual 
functioning ↓ with 
exemestane
MA-17
Whelan TJ et al.2005 
148
Letrozole 
Following 
tamoxifen × 5y
Letrozole × 5y 
Placebo × 5y 
3612
SF-36; 
MENQOL
Not specified
No difference in overall 
QoL; small differences in 
bodily pain and 
vasomotor symptoms
Muss B et al. 2008 
149
Letrozole  
Following 
tamoxifen × 5y
Letrozole × 5y 
Placebo × 5y 
5169
SF-36; 
MENQOL
Not specified
No difference in overall 
QoL among letrozole- and 
placebo-treated
patients age ≥ 70 years
ALIQUIT
Dixon JM et al. 2010 
150 N/A
Letrozole to 
Anastrzole × 3m 
Anastrozle to 
Letrozole × 3m
181 FACT-B+ES
QoL, toxicity, patient 
preference
No difference in overall 
QoL
Advanced Breast Cancer
Thomas R  2003 
151 Following 
tamoxifen
Anastrozole  × 1m      
Letrozole × 1m
72 FACT-B+ES
QoL, toxicity, patient 
preference
Overall QoL ↑ with 
letrozole; lethargy, joint 
pain, nausea, hot falshes, 
abdominal discomfort ↓ 
with letrozole
Notes:
QoL: Quality of Life; ATAC:Arimidex,Tamoxifen,Alone, or in Combination;  IES: Intergroup Exemestane Study; NSAS BC: National Surgical Adjuvant in Study of Breast Cancer; 
FACT-B: FunctionalAssessment of Cancer Therapy-Breast; ES: Endocrine Subscale; SF-36: Medical Outcomes Study 36-Item Short Form Health Status Survey; MENQOL: 
Menopause SpecificQuality of Life Instrument; CES-D: Center for Epidemiologic Studies Depression scale; EORTC QLQ-C30: European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire Core 30; BR: Breast; ALIQUIT: Anastrozole vs. Letrozole, an Investigation of Quality Of Life and Tolerability; TOI: Trial 
Outcome Index; ES:Endocrine Subscale; EWB: Emotional Well-Being; SWB: Social Well-Being.
↑ means "increase", ↓ means "decrease".
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   Cella D et al.
143
 studied HRQoL of 1,105 patients over the full five-year adjuvant 
treatment period. The findings were consistent with the results from the two-year 
follow-up analysis. No statistically significant differences were noted in the TOI scores 
between treatments at five years, and the mean TOI scores showed continued slight 
improvement in both the treatment groups from two years to five years. Statistically, 
total ES, SWB or EWB scores were not significantly different between treatment 
groups. However, differences in patient-reported side effects existed: compared to 
tamoxifen, anastrozole was associated with significantly more occurrences of diarrhea 
(anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), decreased 
libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%), while significantly less 
occurrences of dizziness (anastrozole 3.1% vs. tamoxifen 5.4%) and vaginal discharge 
(1.2% vs. 5.2%). 
 
   The Intergroup Exemestane Study (IES) trial recruited 582 of 4,742 women to a 
QoL sub-study with 24 months of follow-up.
144  
Both the FACT-B and ES 
questionnaires were used. The primary endpoint was the TOI. Secondary endpoints 
included the total ES score and individual endocrine symptoms. In this study, response 
rates were 85% for all time points. The overall QoL (measured by TOI and total 
FACT-B+ES), and total ES change scores were noted not statistically different, but 
endocrine symptoms, especially vasomotor symptoms, improved over time. Hot flashes 
(46% vs. 45% for exemestane and tamoxifen respectively) decreased over time in both 
groups. Except for vaginal discharge was reported less frequently in exemestane group 
(p < 0.001), between the groups there were no significant differences for any other 
gynecologic symptoms, neuropsychological or gastrointestinal symptoms. 
 
   In the National Surgical Adjuvant in Study of Breast Cancer (NSAS BC 03) trial, 
postmenopausal breast cancer patients were with a slightly better HRQoL with further 
tamoxifen treatment after adjuvant tamoxifen compared with those switching to 
anastrozole.
145 
In this trial, 706 patients who had been on adjuvant tamoxifen for one to 
four years without recurrence were randomized to either five years of anastrozole or an 
additional five years of tamoxifen. Patients were asked to complete FACT-B and ES 
questionnaires, and Center for Epidemiologic Studies Depression scale (CES-D) at 
baseline, three months, one and two years. The tamoxifen group reported statistically 
significantly better total scores of FACT-G, FACT-ES and the scores of Physical 
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Well-Being (PWB) subscale than the anastrozole group. Total FACT-B scores were 
marginally better in the tamoxifen group. There were no statistically significant 
differences between the two treatment groups for the scores of CES-D, or the scores of 
the endocrine symptom subscale of FACT-ES. However, some items in the endocrine 
symptoms showed statistically significant differences. Hot flashes and vaginal 
discharge were worse in the tamoxifen group than in the anastrozole group, while 
dizziness, diarrhea and headache were worse in the anastrozle group than in the 
tamoxifen group. 
 
   The NSAS BC 04 trial compared the effects of five-year exemestane, anstrozole and 
tamoxifen on HRQoL and psychological distress in Japanese postmenopausal women 
with hormone responsive early-stage breast cancer after receiving adjuvant therapy.
146
 
Patients were asked to complete FACT-B, FACT-ES and psychological distress 
(CES-D) at baseline, 3 months, and 1 year after the randomization. There were no 
significant differences for any of the scales used to assess QoL among the three 
treatment groups. The mean scores of all the patients increased significantly over the 
period in FACT-G total, FACT-B total, and breast cancer subscale of FACT-B (P ≤ 
0.01 for all), whereas the mean scores of all the patients became significantly worse in 
the endocrine subscale of FACT-ES (P = 0.04) but did not change in CES-D.  
 
   The Dutch Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial included 
2,754 patients, in which 742 patients were invited onto the QoL sub-protocol.
147
 
Patients were asked to fill in the European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire Core 30 (EROTC QLQ-C30), the European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
Breast Cancer (EORTC BR 23), and FACT-ES. After one and two years of hormonal 
treatment, there were no significant differences in global health status/QoL between 
treatments. Exemestane use was associated with significantly more insomnia and worse 
sexual functional problems than tamoxifen use. There were no significant differences in 
physical functioning, role functioning, cognitive or emotional functioning and 
endocrine symptoms between the two treatment groups. 
 
   The National Cancer Institute of Canada Trial (MA.17) assigned 3,612 of 5,187 
women to the QoL sub-study with the median follow-up of 30 months.
148
 The Medical 
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Outcomes Study 36-item Short Form Health Survey (SF-36) and the Menopause 
Specific Quality of Life (MENQOL) questionnaire
 
were completed at baseline, 
six-month and annually. The primary and secondary endpoints were not specified. The 
SF-36 summarized subscales into two global scores: the physical and mental 
component summary scores (PCS and MCS). MENQOL summarized subscales into 
four domains: vasomotor, physical, psychosocial and sexual. In the sub-study, 
compliance with the QoL assessment was over 90% for all time points. No significant 
differences were seen between letrozole and placebo arms in mean change scores from 
baseline for SF-36 PCS and MCS scores. Small but statistically significant differences 
were detected on physical functioning, bodily pain and vitality scales of SF-36 domains, 
and MENQOL sexual and vasomotor domains. In the response analysis, a significant 
difference was noted for the bodily pain domain (percentage of patients reporting worse 
QoL, placebo 47% vs. letrozole 51%; p = 0.009) and the vasomotor domain (22% vs. 
29%; p = 0.001). On the symptom analysis, letrozole use resulted in a significant 
increase in hot flashes (placebo 17% vs. letrozole 22%; p = 0.0002) and sweating (14% 
vs.18%, p = 0.003). An increase in muscle and joint aches, vaginal dryness, night 
sweats, and sleeping difficulty in the letrozole group was observed. There were no 
differences in sexual desire, avoiding intimacy, poor memory, depression or weight 
gain. Although a small number of patients suffered from adverse effects, no major 
impact of letrozole therapy was seen on overall QoL. 
 
   Muss B et al.
149
 studied the QoL in early-stage breast cancer older women treated 
with letrozole or placebo after five years of tamoxifen. In this study, patients were 
divided into three age groups: younger than 60 years, 60 to 69 years, and age 70 years 
and older. The SF-36 and the MENQOL questionnaire
 
were used to measure QoL. 
Compared with placebo receivers, patients receiving letrozole treatment showed only a 
modest decrease of QoL. In the oldest group (age 70 years and older), patients receiving 
letrozole had significantly worse QoL than those receiving placebo on the vitality, 
bodily pain, and physical scale at 6 months, and MENQOL vasomotor domain at 12 
months. At 24 months, only a mild increase of MENQOL vasomotor symptoms was 
noted for the age group – age 70 years and older (p = 0.02), while it became similar to 
placebo at 36 months. 
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   Anastrozole vs. Letrozole, an Investigation of Quality Of Life and Tolerability 
(ALIQUOT) study was an open-label crossover study of postmenopausal women with 
breast cancer receiving adjuvant AI therapy.
150
 Patients were randomized to receive 
either three months of letrozole followed by three months of anastrozole or three 
months of anastrozole followed by three months of letrozole. QoL was assessed by 
FACT-B and FACT-ES. At the end of the six months study period, there was no 
significant change in overall QoL score or endocrine symptoms subscale score between 
anastrozole and letrozole. No differences in side effects were seen between the two 
drugs and patients receiving these two drugs had similar preference. 
 
   A multicenter, randomized, single-blind study compared QoL of metastatic breast 
cancer patients receiving anastrozole and those resceiving letrozole by the FACT-ES 
questionnaire.
151
 After four-week follow-up, patients receiving letrozole showed a 
significant improvement compared with anastrozole in overall QoL scores. The sub 
score of endocrine symptoms and additional concerns (including hair loss, weight 
change, sexual attractiveness and self-awareness) also showed significant improvement 
for letrozole treatment. Furthermore, letrozole showed better tolerability than 
anastrozole. Letrozole induced less lethargy (letrozole 8% vs. anastrozole 19%), nausea 
(10% vs. 22%), joint pain (3% vs. 11%), abdominal discomfort (3% vs. 11%), appetite 
(2% vs. 14%) and headache (5% vs. 14%). And more than twice as many patients 
preferred to continue with letrozole therapy than with anastrozole at the end of the trial 
(letrozole 68% vs. anastrozole 32%). 
 
   In general, clinical trials of AIs have failed to show a significant deterioration in 
QoL for patients on AIs compared with tamoxifen or placebo. The head-to-head QoL 
comparison of AIs showed that letrozole provides better QoL than anastrozole for 
patients with metastatic breast cancer. 
 
Other QoL Studies Focusing on Side Effects 
 
   Besides those randomized trials mentioned above, there are some studies focusing 
on the side effects reported by the patients receiving hormonal therapies, such as 
menopausal symptoms, cognitive functioning, etc. See Table 18. 
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Table 18: Other QoL Studies Focusing on Side Effects 
 
 
Author Timing Intervention Size Instrument Primary endpoint Outcomes
Early-stage Brease Cancer
Asmar L et al. 2004 
152 Post-surgery or 
chemotherapy
Exemestane 
Tamoxifen  
997 Symptom checklist
Menopausal 
symptoms
Vaginal dryness and bone/muscle 
aches with exemestane ↑
Francini G et al. 2006 
153 Following 
tamoxifen × 2y
Exemestane   
Tamoxifen 
60 EORTC QLQ-C30
Body composition, 
lipid profiles 
No difference in overall QoL;fat 
mass, triglycerides, high-density 
lipoprotein cholesterol ↓with 
exemestane; FFM/FM ratio,low-
density lipoprotein cholesterol ↑ 
with exemestane
Jones SE et al. 2007 
154 Following 
tamoxifen × 2-3y
Exemestane    
Tamoxifen 
1614
self-report menopausal 
symptoms questionnaire
Menopausal 
symptoms
Vaginal dryness, bone/muscle 
aches, difficulty sleeping↑ with 
exemestane; vaginal discharge, 
hot flashes ↓with exemestane
Schilder CM et al. 2009 
155 Following  A/C
Exemestane   
Tamoxifen       
Controls 
128
FACT-B+ES, EORTC 
QLQ-C30, HSCL, CFQ, 
MFI-20
Neuropsychological 
functioning
No statistically significant 
differences of cognitive testing.
Schilder CM et al. 2010 
156 Following 
tamoxifen × 2-3y
Exemestane   
Tamoxifen      
Controls 
299
FACT-B+ES, EORTC 
QLQ-C30, HSCL
Cognitive 
functioning
Verbal memory and executive 
functioning ↓with tamoxifen.
Thomas R et al. 2008 
157 Following 
tamoxifen × 3m
Exemestane    
Letrozole 
184
FACT-B+ES, HFD,  
MRS,patient preference
questionnaire, Arthralgia 
grading system
Hot flashes score
QoL ↑; hot flashes, mood, 
arthralgia↑ with AI.
Mamounas EP et al.2008 
158 Following 
tamoxifen × 5y
Exemestane     
Placebo  
454 MENQOL 
Menopausal 
symptoms
No statistically significant 
differences in MENQOL.
Boehm DU et al. 2009 
159 Following 
tamoxifen 
N/A 136
50-item self-administered 
questionnaire
Side effects and 
level of influence on 
the physical, 
emotional and social 
functioning caused 
by tamoxifen
QoL ↓
Crew KD et al. 2007 
160 Following               
a AI × > 3m 
Anastrozole  
Letrozole  
Exemestane 
200
self-administered 
questionnaire
Joint symptoms
More that 45% patients having 
AI-related joint pain and 
stiffness.
Henry NL et al. 2008 
161 Following               
a AI × > 6m 
Letrozole  
Exemestane          
100 HAQ, VAS
Musculoskeletal 
symptoms
45.4% patients met criteria for 
rheumatologic referral; referred 
patients had higher HAQ and 
VAS scores
Ruhstaller T et al. 2009 
134 Following 
hormonal therapy
Adjuvant       
Metastatic 
373 C-PET
Symptoms of 
hormonal therapy
Hot flashes/sweats, low energy, 
fluid retention, vaginal dryness↑ 
with this study than in pivotal 
trials
Ochayon L et al. 2010 
162 Following 
hormonal therapy
N/A 132
FACT-B+ES 
sociodemographic and 
medical information 
questionnaire
QoL, symptoms of 
hormonal therapy
Adjuvant hormonal therapy did 
not affect the QoL; A reduced 
number of symptoms indicarted 
a higher QoL; mood swings and 
irritability had a negaive impact 
on QoL
Advanced Breast Cancer
Mouridsen H et al. 2004 
163 Following               
a AI 
Letrozole     
Tamoxifen 
907 KPS scale Not specified
Time to worsening of at least 20 
points in KPS was significantly 
longer in letrozole group; more 
tamoxifen patients with mainly 
lung metastasese experienced 
worsening KPS scores by  at 
least 20 points
Notes:
C-PET: Checklist for Oatients with Endocrines Therapy; A/C: Doxorubicin/Cyclophosphamide; CFQ: Cognitive Failures Questionnaire; HSCL: Hopkins Symptom Checklist-25; MFI-20: 
Multidimensional Fatigue Inventory; BCPT: Breast Cancer Prevention Trial; HFD: Hot Flushes Diary ; MRS: Mood Rating Scale; HAQ: Health Assessment Questionnaire; VAS: Visual 
Analog Scale; KPS: Karnofsky Performance Status; FFM/FM: Fat-Free Mass/Fat Mass.
↑ means "increase", ↓ means "decrease".
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     Asmar L et al.
152
 used a 10-menopausal-symptom questionnaire to compare 
menopausal symptoms during the first year in 997 postmenopausal women who were 
randomized to tamoxifen or exemestane.
 
Results showed that vaginal discharge (p < 
0.001) was more common with tamoxifen, but vaginal dryness (p = 0.0021) and bone or 
muscle aches (p < 0.001) were more common with exemestane. With respect to vaginal 
bleeding, mood alteration, impaired word finding, low energy, difficulty sleeping and 
hot flashes, the differences of between-groups were noted not significant. 
 
   Francini et al.153 examined the changes in body composition and lipid profiles in 
postmenopausal women who switched from tamoxifen to exemestane. EROTC 
QLQ-C30 was used to assess HRQoL. This randomized study reported that compared 
with baseline, exemestane group had improved global QoL scores, global health status 
and physical functioning, but there were no statistically significant between-group 
differences. In the exemestane group, fat mass had significantly decreased and the 
FFM/FM (Fat-Free Mass/Fat Mass) ratio had significantly increased, but not in the 
tamoxifen group; the differences were statistically significant. At the end of the 
one-year study period, triglycerides and high-density lipoprotein cholesterol 
significantly decreased, and low-density lipoprotein cholesterol significantly increased 
in the exemestane group. 
 
   There were three studies based on Tamoxifen Exemestane Adjuvant Multicenter 
(TEAM) Trial. One was menopausal sub-study, and the other two were cognitive 
sub-studies.  
   
   Jones et al.
154
 investigated menopausal symptoms of breast cancer patients 
randomized to adjuvant tamoxifen or exemestane by a self-report questionnaire. After 
one year, vaginal dryness, decreased libido, bone/muscle aches, and sleeping difficulty 
were reported more significantly frequently in exemestane group, while hot flashes and 
less vaginal discharge were reported more significantly in tamoxifen group. No 
significant differences in vaginal bleeding, mood change, impaired word finding or low 
energy were observed. 
 
   Schilder CM and colleagues examined the cognitive functioning related to either 
tamoxifen or exemestane, and compared it with that of non-cancer subjects.
155, 156  The 
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first cognitive testing examined patients following doxorubicin/cyclophosphamide 
(AC) chemotherapy. It revealed no statistically significant differences between 
tamoxifen or exemestane users. Results from this test also suggested that tamoxifen use 
is possibly associated with worse verbal functioning, while exemestane use is possibly 
associated with slower manual motor speed. Both groups performed significantly 
worse on verbal fluency and information processing speed than healthy controls.
151 
The 
second cognitive testing examined patients following tamoxifen. It revealed that 
tamoxifen use was related to statistically significant lower verbal memory functioning 
and executive functioning, whereas exemestane use was not related to statistically 
significant lower cognitive functioning.
152
 
 
   Thomas et al.
157
 investigated the improvement of hot flashes, mood and QoL of 
postmenopausal women switching to an AI after tamoxifen. The FACT-B + ES, Hot 
Flashes Diary (HFD), Mood Rating Scale (MRS), Arthralgia Grading System and 
Patient Preference Questionnaire were used. All women had significant hot flashes at 
trial entry. The hot flashes score, total mean combined FACT+ES score, endocrine 
subscale score, and Mood Rating Scale (MRS) score significantly improved. The 
overall arthralgia rate at three months was higher in patients receiving AI (AI 47% vs. 
tamoxifen 30%; p = 0.0001). At six weeks, 72% patients preferred to remain on an AI, 
while at or after three months, 58% preferred to remain on an AI. 
 
   Mamounas EP et al.
158
 conducted a QoL sub-study to compare self-reported 
symptoms on patients treated with exemestane with those treated with placebo. 
MENQOL was assessed through 24 months of follow-up. In this sub-study, compliance 
with questionnaires was from 80% to 97%. No significant treatment effects were noted 
in the vasomotor, psychosocial, physical, or sexual scales, even though patients 
receiving exemestane had higher symptom severity in numerical form on all of these 
four scales. 
 
   Boehm et al.
159
 evaluated the side effects caused by tamoxifen treatment and its 
influence on the quality of life. A 50-item self-administrated questionnaire was 
designed and used on the bases of the Functional Living Index Cancer (FLIC) and 
FACT-B. This survey reported that breast cancer patients experienced significant 
impaired QoL. Tamoxifen treatment was negatively associated with the physical, 
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emotional and social functioning, and most of psychosocial issues (e.g., loss of vitality, 
loss of energy, loss of femininity, mood swings, irritability, nervous feeling or 
difficulties in concentrating). But loss of sexual interest showed no significant 
correlation with overall. 
 
   Crew KD et al.
160
 investigated AI-related joint symptoms in postmenopausal 
women taking AIs for early-stage breast cancer. A 25-item self-administered 
questionnaire was performed to assess the presence of joint symptoms. 47% of the 
patients reported AI-related joint pain and 44% reported AI-related joint stiffness. 
Compared with patients who did not receive tamoxifen, patients who had tamoxifen 
therapy previously had lower probability to develop AI-related joint stiffness (Odds 
Ratio 0.40; p < 0.05). 
 
   Henry NL et al.
161
 investigated musculoskeletal symptoms of early stage breast 
cancer patients treated with AI therapy with at least six months follow-up. In order to 
assess changes in musculoskeletal symptoms, patients completed the Health 
Assessment Questionnaire (HAQ) and Visual Analog Scale (VAS) at baseline, 1, 3, 6, 
and 12 months, respectively. The median time from initiation of AI to onset of 
symptoms was 1.6 months. 45.4% of the patients met criteria for rheumatologic referral. 
Referred patients had statistically significantly higher HAQ and VAS scores at baseline 
and referral. At the time of referral, the median HAQ and VAS score for referred 
patients were 0.375 and 51 respectively. At the time of rheumatology evaluation, the 
primary symptoms were joint pain and stiff joints. Other reported symptoms included 
muscle pain, morning stiffness, tingling, numbness, and joint swelling. After median 
6.1 months, 13 patients discontinued AI therapy due to musculoskeletal toxicity. 
 
   Ruhstaller T et al.
134
 used a validated self-reporting measurement - the Checklist for 
Patients with Endocrine Therapy (C-PET) to assess the overall frequency of 
subjectively experienced symptoms by patients receiving endocrine therapy. Then they 
compared these symptoms with side effects reported in pivotal trials – the Arimidex, 
Tamoxifen, Alone or in Combination (ATAC) Trial, and the Breast International Group 
(BIG) 1-98 Study. Only the reporting of weight gain and hot flashes/sweats was 
significantly greater for those receiving adjuvant therapies compared to those with 
metastatic disease. The following symptoms were significantly more often recorded by 
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the women in the adjuvant setting completing the C-PET than by physicians‟ reports in 
pivotal trials: hot flashes/sweats, low energy, fluid retention and vaginal dryness. 
Similar differences were observed in the metastatic and adjuvant setting. 
 
   Ochayon L et al.
162
 described symptoms and QoL of breast cancer patients receiving 
adjuvant hormonal therapy through the FACT-B + ES and a socio-demographic and 
medical information questionnaire. It was found that fewer symptoms were correlated 
with higher QoL, but the mean QoL score for the participants was higher than that for a 
healthy population. Among all the symptoms, mood swings and irritability were 
strongly associated with a decrease in QoL. In addition, patients who exercised had 
higher QoL scores. 
 
   Mouridsen H et al.
163
 compared letrozole and tamoxifen in the first-line therapy of 
advanced breast cancer postmenopausal women according to Karnofsky Performance 
Status (KPS). For both treatment groups, the distributions of baseline KPS scores were 
similar. Compared with tamoxifen group, time to worsening of   20 points in KPS 
score was significantly longer in letrozole group (Hazard Ratio 0.62; p = 0.001), but 
KPS was relatively insensitive to change in these patients. In patients with mainly lung 
metastases, significantly fewer letrozole patients than tamoxifen patients experienced 
deteriorations in their KPS scores by at least 20 points (letrozole 14% vs. tamoxifen 
30%; p=0.0003), and letrozole had higher odds of improvement in KPS score by at least 
20 points (Hazard Ratio 2.67; p = 0.0631). These data demonstrated that letrozole was 
superior over tamoxifen. 
 
Summary 
 
As the survival rate of breast cancer patients is increasing, issues concerning patient 
tolerability and QoL become increasingly important. The side effect profiles of 
hormonal therapies can affect patient-rated HRQoL outcomes. However, there is a 
dearth of the QoL information from randomized trials of hormonal therapy. 
 
In this breast cancer hormonal therapy QoL review, two questionnaires were 
widely used: the Functional Assessment of Cancer Therapy-Breast (FACT-B) plus 
Endocrine Subscale (ES), and the Menopause Specific Quality of Life (MENQOL). 
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Both of them contain the specific items for assessing the hormonal therapy related 
side effects. 
 
The FACT-G is the first questionnaire of the Functional Assessment of Chronic 
Illness Therapy (FACIT) continuum to assess cancer therapy.
164
 It measures general 
aspects of QoL among cancer patients. It consists of 27 items for the assessment of 
four domains of QoL: Physical Well-Being (PWB) (seven items), Socio-Family 
Well-Being (SFWB) (seven items), Emotional Well-Being (EWB) (six items), and 
Functional Well-Being (FWB) (seven items). Patients are asked to score each item for 
the past week on a 4-point scale (0 = “not at all”, 1 = “a little bit”, 2 = “somewhat”, 3 
= “quite a bit”, 4 = “very much”). The scores of PWB, SFWB, and FWB range from 0 
to 28 points. The scores of EWB range from 0 to 24 points. The total FACT-G score 
is the sum of the above four subscale scores and ranges from 0 to 108. The FACT-G 
has been demonstrated to be valid and reliable.
164
 The FACT-B measures general 
QoL associated with cancer (27 questions referred to the FACT-G), as well as 
additional dimensions more specific to breast cancer patients (nine questions).
165
 The 
Endocrine Subscale (ES) comprises 18 items. It is designed to use with the FACT-B. 
Four other items related to endocrine (sleep, fatigue, nervousness and nausea) are 
included in the FACT-G already.
166
 The FACT-B plus ES is proved to be reliable and 
validated.
165, 166 
   
   The Menopause Specific Quality of Life (MENQOL) is a validated QoL tool that 
measures the level of discomfort associated with menopause related symptoms.
167
 It 
consists of 29 items covering vasomotor, physical, psychosocial and sexual domain. 
The score for each item is from 1 to 8, with lower scores presenting lower levels of 
discomfort or better quality of life. 
 
   In the above studies, patients receiving hormonal therapies experienced a decreased 
QoL. Although QoL studies generally indicated that AIs were tolerated well and had 
no greater impact on QoL than tamoxifen, these hormonal therapies affected slightly 
different domains. Compared with patients taking tamoxifen, fewer cases of 
thromboembolic and gynecological events (vaginal discharge and bleeding), as well as 
a lower incidence of endometrial cancer were observed in those taking AIs. Side effects 
that were more frequent with adjuvant AI therapy in comparison to tamoxifen included 
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arthralgia and myalgia, joint discomfort, bone loss, decreased libido, vaginal dryness 
and dyspareunia, and cardiovascular system and blood lipids problems. However, the 
side effects could not be attributed to hormonal therapies alone. Many symptoms 
experienced by women in these studies were age or menopause related. In addition, 
some studies included patients that had received chemotherapy before, which could 
also produce unexpected side effects. 
 
In summary, despite that different trial design and instruments were used to assess 
QoL, the results of the QoL studies included in the above review were very similar. 
They showed that although the side effect profiles of tamoxifen and AIs varied 
significantly, there were no clinically important differences in overall QoL. 
 
3.3.2 Studies on Patient Satisfaction with Medication 
 
   Treatment satisfaction is a growing research area in particular in chronic illnesses 
field. It is recognized as an important outcome measure in many chronic diseases (e.g., 
coronary heart disease, arthritis, migraine, diabetes, asthma and rheumatoid 
arthritis).
133
 However, this endpoint has barely been considered with regard to cancer 
treatment. There is a paucity of research assessing cancer medication satisfaction. This 
section will firstly present the studies on patient satisfaction with breast cancer-related 
medications. Then the studies on factors affecting patient satisfaction with medication 
will be documented. 
 
Patient Satisfaction with Breast Cancer-related Medications 
 
   The studies focusing on satisfaction with breast cancer-related medication are 
limited. Only three studies were identified.  
 
   Carlsson et al.
168
 examined the differences of the quality of life/ life satisfaction 
between Swedish women with breast cancer treated with 
complementary/anthroposophical care and matched patients treated with conventional 
treatment. The quality of life was measured by the European Organisation for 
Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC 
 119 
 
QLQ-C30) and the Life Satisfaction Questionnaire (LSQ). LSQ consists of 34 items 
covering six different dimensions: physical symptoms, sickness impact, quality of 
everyday activities, socioeconomic situation, quality of family relation and quality of 
close friend relationship. These items are answered and scored from 1 (very much) to 
7 (not at all), with higher score indicating greater life satisfaction. Then the scores of 
these items are summarized and transformed to range from 0 to 100, where 100 
indicates maximum quality of life on each subscale.
168
 This study revealed that the 
women who had chosen anthroposophical care increased their perceived quality of 
life or life satisfaction. There were significant improvements in emotional functioning 
and in overall quality of life in the EORTC QLQ-C30. In the LSQ improvement was 
seen in physical symptoms, sickness impact, quality of everyday activities and 
socioeconomic situation. There were no significant changes in any of the 
scales/factors in women who had chosen conventional medical treatment. 
 
   A study examined the impact of potential determinants for early-stage breast 
cancer patients‟ preferences for adjuvant chemotherapy by the treatment preference 
instrument.
169
 Patients in the chemotherapy group were matched with patients in the 
no-chemotherapy group. In the chemotherapy group, patients were scheduled for 
adjuvant chemotherapy before (T1), during (T2), and 1 month after chemotherapy 
(T3). Then the elicited preferences were compared to responses from patients in the 
no-chemotherapy group. At all measurement points, the patients in the 
no-chemotherapy group needed more benefit from adjuvant chemotherapy before they 
would be willing to accept this treatment than those in the chemotherapy group. The 
differences were significant (p < 0.01). Of the demographic variables, a statistically 
significant relationship between age and preferences was found only at T2 in the 
no-chemotherapy group. This study also point out that compared with the positive 
experience of the treatment, reconciliation with the treatment decision was a more 
important determinant of patients‟ preferences. 
 
   Another study explored the possible relationship between patient satisfaction with 
antiemetic treatment and quality of life (QoL).
170
 Antiemetic drugs are one of the 
most common used drugs for relieving the side effects produced by chemotherapy in 
cancer treatment. The study sample consisted of 136 chemotherapy patients with 
breast cancer. QoL was evaluated using the Rotterdam Symptom Checklist (RSCL). 
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At day five after chemotherapy, 55 of the 136 patients were very satisfied, 65 were 
satisfied, and 16 were unsatisfied with antiemetic treatment. Patient statement of 
satisfaction was related to psychological distress (p = 0.002), physical symptom 
distress (p = 0.002), activity level (p = 0.002), the control of nausea (p < 0.01) and 
vomiting (p < 0.0001). 
 
Factors affecting Patient Satisfaction with Medication 
 
   Patient satisfaction with medication is not only affected by the treatment, but also by 
patient characteristics and social factors, such as patients‟ age, medication and health 
characteristics, and physician or pharmacists‟ advice. With the absence of breast cancer 
studies on this topic, the studies chosen below could still demonstrate the same 
principles.  
 
   Cohen G
171
 made an attempt to relate satisfaction to age and self-reported health 
status in Scotland. The items on patient satisfaction were taken from a general 
population health survey. It was reported that dissatisfaction decreased markedly with 
age, and also showed a moderately significant association with psychosocial health 
status and pain.  
 
   Geitona et al.
172
 conducted a cross-sectional national survey to examine medication 
use and satisfaction of Greek households. Satisfaction questionnaire consisted of two 
parts: a set of items drawn from the WHO health survey, and a set of items based on 
eight aspects of medication use: physician‟s consultation, physician‟s response to 
adverse events, pharmacists‟ consultation and advice, the resolution of symptoms, 
route of drug administration, drug tolerability, drug cost, and perceived contribution of 
the treatment to the improvement of health. A five-point scale (responses of “fully 
satisfied”, “satisfied”, “moderately satisfied”, “poorly satisfied” and “not at all 
satisfied”) was used to measure the rating of satisfaction. In general, except the costs, 
respondents reported a high level of satisfaction with every aspect of medication use 
examined. High degree of satisfaction with medication use was associated with elderly 
people, self-reported health status, city area of residence and the health insurance 
scheme with greater funds. 
 
 121 
 
   A study was conducted to examine the impact of mood on patients‟ quality of life 
and satisfaction with health service care.
173
 Thirty-seven patients from a mood 
disorders clinic were asked to rate their current mood, quality of life, and satisfaction 
with health service care. The Psychiatric Affective Balance Rating Uniscale (PABRU) 
was designed specifically to assess the mood state of a person with affective disorders. 
The Spitzer Uniscale and the subscales of the Quality of Life Inventory (QOLI) were 
used to assess quality of life. The Patient/Staff Service Appraisal Questionnaire 
(P/S-SAQ) asked patients to record their satisfaction with their care. In this study, 
patients‟ rating of their current mood was highly correlated with their global quality of 
life rating, as well as QOLI ratings in specific domains. Only one service delivery 
satisfaction score was significantly associated with current mood ratings, namely the 
individualized care. 
 
   A cross-sectional survey was carried out to examine patients‟ experiences of 
treatment with antipsychotic medications and satisfaction with it.
174
 This study used a 
self-administered questionnaire. Satisfaction was rated on a five-point scale (very 
satisfied, satisfied, not sure, dissatisfied, and very dissatisfied). 68% patients reported 
that they were satisfied or very satisfied with their medication and 71% stated that they 
found the medication helpful. These patients also pointed out that they were satisfied 
with the communication between them and their mental health professionals. In 
addition, being of non-white ethnic origin, experiencing side effects, dissatisfaction 
with communication with clinicians and lack of involvement in treatment decision were 
found to be associated with dissatisfaction with treatment (all p < 0.05). 
 
   Chen K et al.
175
 assessed factors associated with patient satisfaction with 
antihypertensive therapy. The measure for medication satisfaction included the 
following items: overall satisfaction with the current medication, probability of 
continuing treatment, and probability of recommending the treatment to the other 
people with the similar condition. The outcomes were compared between patients who 
had self-reported controlled blood pressure and patients with uncontrolled blood 
pressure. This study reported that patients with controlled blood control had 
significantly better overall satisfaction with their medication (p < 0.001) and higher 
probability to continue the medication (p < 0.001). In addition, patients without 
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experiencing adverse events had significantly better overall satisfaction with their 
medication than patients experienced adverse events (p < 0.001). 
 
   Hoffman et al.
176
 investigated the correlations of demographic, socioeconomic, 
and clinical characteristics with localized prostate carcinoma treatment satisfaction. A 
24-month survey consisting of general and disease-specific measures of HRQoL, 
report of urinary, bowel and sexual function, the perception of any problems with 
these functions, and some other items regarding subsequent cancer treatments and 
treatment satisfaction was used. It was noted that 59.2% of patients undergoing 
treatment were satisfied with their treatment decisions, of which 76.8% stated that 
they definitely would make the same treatment decision again. Some factors, such as 
receiving an active treatment (50.5%), perception of being cancer free (66.4%), 
having urinary (64.2%) and bowel (60.5%) control, having normal erectile function 
(65.9%), having a good overall health (71.3%) and social support (68.1%), were 
significantly and positively associated with satisfaction (all p < 0.05). Additionally, 
compared with non-Hispanic men, after undergoing radical prostatectomy or 
androgen deprivation, Hispanic men were less satisfied. 
 
   Sanda et al.
177
 examined the factors associated with quality of life in prostate 
cancer patients and the effects on satisfaction with the overall outcome of treatment. 
The Expanded Prostate Cancer Index Composite (EPIC-26) and Service Satisfaction 
Scale for Cancer Care (SCA) were used. This study showed that changes in quality of 
life (sexual function, vitality, and urinary function) were significantly correlated with 
the degree of outcome satisfaction among patients and their families. In comparison to 
patients of other racial backgrounds, blacks were significantly less satisfied with their 
overall treatment outcome (p = 0.04). 
 
   Data from the 2005 National Health and Wellness Survey were collected to 
evaluate the effects of individual and condition characteristics on satisfaction with 
overactive bladder (OAB) medications.
178
 In this survey, there are questions about 
medication satisfaction, which was rated on a five-point scale from 1 (not at all satisfied) 
to 5 (extremely satisfied). In this study, satisfaction with treatment was higher among 
those for whom OAB interfered as little as possible with their normal daily activities. 
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Those who were satisfied also tended to have more frequent medication use and longer 
duration of use.  
 
   Bultman and Svarstad
179
 used an interview questionnaire to examine the association 
between patient satisfaction with antidepressant medication therapy and pharmacist 
monitoring. It revealed that pharmacist monitoring was predictive of satisfaction and 
adherence for individuals taking an antidepressant for the first time. 32% patients found 
pharmacists helpful in solving problems related to the antidepressant. 
 
   There are some studies examining the contributing factors of satisfaction with 
diabetic medications. These studies reported that patients with lower education levels 
and lower income are less satisfied with treatment.
180 
Patients having any side effects 
were associated with lower satisfaction with treatment.
181, 182
 Additionally, satisfaction 
was positively associated with concurrent medications.
182
 Lower self-rated mental and 
physical health status were correlated with lower treatment satisfaction.
181,
 
183
 
 
Summary 
 
   Breast cancer is the most frequently diagnosed type of cancer among women, and 
most of them are treated by hormonal medications which are accompanied with 
different profiles of side effects. However, the QoL studies included in the above 
reviews showed that although the side effect profiles of tamoxifen and AIs varied 
significantly, there were no clinically important differences in overall QoL. 
Consequently, patient satisfaction, including different aspects of the treatment 
experience, will be particularly helpful to compare different hormonal medication 
treatments. Unfortunately, to date there is no study assessing patient satisfaction with 
breast cancer hormonal medications, especially its contributing factors. Therefore, it is 
important to know how tamoxifen and AIs impact breast cancer patients‟ satisfaction, 
and serve as the baseline for the policy makers on how to possibly improve breast 
cancer outcomes over time. A number of predictors for satisfaction with medications 
have been identified from previous studies, such as side effects, concurrent 
medication use, long-term and consistent use of medication, and self-reported health 
status.  
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3.4 Methodology 
 
   This study compares the side effects reported by breast cancer patients with 
different hormonal medications, and then examines both individual and condition 
characteristics that affect patient satisfaction with these medications. Nowadays, 
various media are available for collecting patient-reported outcomes (PROs), and the 
Internet is increasingly recognized as an important source of information. In addition 
to the wide availability and easy access to the Internet, patients‟ turning to the Web is 
mainly due to the dissatisfaction with the information provided by health care 
providers. When patients experience significant side effects, their needs for therapy 
modifications and supportive care often change.
184
 Although patients consider their 
health care providers to be the most trusted source of health information, they are 
often dissatisfied with the information provided to them. Two studies reported that 87% 
of cancer patients stated that they wanted as much information about their illness as 
possible,
185,186
 of which approximately 54% feel that their health care providers did 
not provide them with adequate information.
186
 Studies focusing on breast cancer 
patients revealed that many patients desired to get more detailed information, 
especially they want to collaborate with their physician in major treatment decision.
187
 
Providing information as much as possible to cancer patients could help these patients 
reduce anxiety, improve drug compliance, gain better control, promote participation 
and self-care, generate feelings of safety, and create sensible expectations.
188
  
 
   There is a noteworthy finding that the quality of cancer information from the 
Internet is not so bad after all in comparison to other topic areas. A study examined 
patient and caregiver‟s interest in Internet-based cancer services. It indicated that 80% 
cancer patients and their caregivers were interested in treatment-related information 
on the Internet, and 65% expressed an interest in online support groups.
189
 Currently, 
breast cancer is one of the most common health related search topics from the 
Internet,
190
 and the quality of information about it on the web is more complete and 
accurate than about other topic areas.
190, 191
 Studies assessing the accuracy of cancer 
websites have found that the inaccuracy rate is 5.1% for breast cancer,
191
 9% for 
English or 4% for Spanish breast cancer documents.
192
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   This section will firstly introduce the data source. Secondly, the study sample and 
variables will be presented. Thirdly, it will describe the statistical analytic methods 
used in this study. 
 
3.4.1 Data Source 
 
   The patient self-reported data in this study was collected from an Internet website 
www.askapatient.com. This website is designed to provide information about patients‟ 
experience with prescribed drugs approved by the FDA, such as brand names, 
prescription purpose, usage instruction, special precautions, side effects, and more. On 
the website, patients can rate their medications and share comments with other 
patients about a range of medicines that they are taking or have taken.  
 
   Figure 6 uses Arimidex which is the brand name of anastrozole as an example to 
illustrate how breast cancer patients rate this hormonal medication. Firstly, patients 
are asked to rate this drug on a scale from 1 (most dissatisfied) to 5 (most satisfied). 
Then they are asked to fill in the reason for taking Arimidex. Some basic demographic 
information in separate fields, including age, gender, dose and the length of time they 
have been taking the drug, are also needed. There are two fields available for patients 
to enter discursive comments: one is “Side effects” and the other one is “Comments”. 
In both fields, respondents typically write between 25 and 100 words. Although 
patients are not asked to name other drugs they might be taking concurrently or 
previously, some patients provide such details in “Comments”. 
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Figure 6: Website Interface 
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   Overall, this database includes patients‟ demographics, drug and feedback 
information, which, more specifically, is the following key data elements: 
 
 Eligibility information 
o Gender 
o Age 
o Reasons for taking drug 
 Prescription drug claims 
o Days of drug supplied 
o Dosage amount 
 Feedback information 
o Drug rating, the level of satisfaction is from 1 (dissatisfied) to 5 (very 
satisfied) 
o Self-reported side effects 
o Patient‟s comments, including patient usage history, experience and side 
effects 
 
Reasons for Using Data from Askapatient Website 
 
   The first reason to use data from Askapatient website is that this website is so far 
the best resource for patient opinion about drug performance, which was established 
ten years ago and all the prescription drugs are currently approved by the FDA. It is a 
database collecting patient experience of medicine and ratings of medicine 
effectiveness, and also including respondents‟ opinion polls on healthcare topics and a 
section of health care research assistance.
138
 Therefore, it could be said that 
Askapatient website is a high quality site. 
 
   Secondly, patients are asked to rate the drugs they are taking on this website. The 
drug-ratings reflect the information of patient satisfaction, which has been shown to 
associate with quality of life, and patients are more probably to feel happy with their 
participation in the whole process of decision making if they feel satisfied with the 
adequacy of information provided.
188
 Additionally, satisfaction information may be 
served as a benchmark for health professionals to identify potential areas for service 
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improvement and optimize health expenditure through patient-guided planning and 
evaluation.
35
 
 
   The third reason is that Askapatient website enables to assess side effects without 
being influenced by caregivers, as it is completed by the patient without the help of 
nurses or consulting the doctor. Unlike the validated HRQoL questionnaire, on this 
website patients could list any side effect they experienced, from serious, 
life-threatening to minor, easy-to-manage ones.  
 
   The last reason is that all the data on Askapatient website is publicly available. 
These communications are analogous to public records, because the data are 
anonymous, and posting a comment on a drug does not require registration. Due to the 
anonymous nature and privacy policy of this website, conducting a passive analysis of 
the comments without seeking informed consent from their authors is ethically 
acceptable.
193
 Furthermore, in terms of format, this online medium is more flexible 
than a face-to-face or telephone survey. Patients from different care settings and 
countries could share their experiences with drugs. 
 
3.4.2 Definitions of Study Sample and Variables 
 
   This section will present the study sample and a short explanation about the patient 
and condition characteristics which could influence satisfaction. 
 
3.4.2.1 Study Sample 
 
   The analysis of this study was confined to drugs that had at least 30 patient entries, 
as of April 28
th
, 2010. Patients‟ self-reported socio-demographic, drug and feedback 
data were collected. Due to the missing information about the dosage amount before 
February, 2010, this kind of information is not taken into account. To be eligible for 
inclusion, patients were required to 
 
 have an diagnosis for breast cancer, 
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 be female patients, because the percentage of male breast cancer patients in 
this database is less than 2%, which was too small for valid comparisons, 
 be at least 40 years old, because 98% breast cancer patients were aged 40 and 
older in this database, and menopause normally happens after 40 years old,
194
 
 have at least one pharmacy dispensing for any of the following drugs: 
o Anastrozole (Arimidex®)  
o Letrozole (Femara®) 
o Exemestane (Aromasin®) 
o Tamoxifen (Nolvadex®) 
 take the drug for at least three months, because most symptoms occur soon 
after patients start hormonal treatment,
195
 
 self-report all the information, and 
 fill in both fields labeled “Comment” and “Side-effect”. 
 
   All the entries were scrutinized. A provisional list of possible adverse events was 
used as a guide to examine the side effects from “Comment” and “Side-effect”. This 
list was derived from the known side effect profiles of tamoxifen and AIs and from 
the literature. Additional effects and experiences were also identified during 
inspection of the comments. In addition, all the duplicated entries and entries 
submitted by relatives were excluded.  
 
   Figure 7 summarizes the inclusion criteria and final sample. Overall, 1,121 
patients fulfilled the above criteria as of April 28
th
, 2010. All the patients were female 
with age greater than 40, self-reported with the diagnosis of breast cancer, and they 
took the hormonal medication for at least three months. For the purpose of comparing 
AIs with tamoxifen in breast cancer patients, four monotherapy cohorts were created 
from the 1,121 patients who fulfilled the above criteria: namely, tamoxifen, 
anastrozole, exemestane, and letrozole monotherapy cohort. These were created based 
on their drug dispensing and with an observation period of at least three months. 
Because the objective was to compare each AI to tamoxifen, the reference group was 
defined as the tamoxifen group, and the treatment groups were defined as each of the 
three monotherapy groups. In anastrozole cohort, there were 602 patients. In letrozole 
cohort there were 446 patients. 24 patients were in exmestane cohort and 49 patients 
were in tamoxifen cohort.  
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Figure 7: Sample Selection  
 
 
 
3.4.2.2 Definition of Covariates 
 
   Patient and condition characteristics that could influence satisfaction were 
included in the multivariate analyses. Below is a list of these covariates with a short 
explanation. 
 
Anastrozole Letrozole Exemestane Tamoxifen
N=602 N=446 N=24 N=49
Notes:
1. Counts as of 04/28/2010.
Ask a patient.com Database
1
At least taking the drug  ≥ 3 months
N=1,262
N=1,184
Select non-duplicated and self-reported
N=1,551
N=1,611
N=1,121
Select patients ≥ 40 age
N=1,180
Patients with a diagnosis of breast cancer
Select both fields labeled "Comment" and "Side-effect" texted
Select only female patients
N=1,147
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Age 
 
   Dummies were used to account for different age categories: 40 - 64 years, and 
above 65 years. Age can also be used as a continuous variable. 
 
Treatment Duration 
 
   The duration of hormonal medication treatment was unified in months. 
 
Concurrent Drug Use 
 
   For relieving the side effect, such as hot flashes, pain, depression, nausea, vaginal 
dryness etc., some other drugs were also taken at the same time. A dummy was used 
to identify each of these medications that had concurrent drug use or has mono-drug 
use. Value 1 indicated concurrent drug use, while value 0 indicated mono-drug use. 
 
Prior Drug Use 
    
   In order to identify whether each of these medications switched from another drug 
or not, a dummy was used. Value 1 indicated switching from another drug, while 
value 0 indicated not switching. 
 
Currently taking Medication Status 
 
   A dummy was used to identify if the patients were currently still taking 
medication or not. Value 1 indicated currently still taking medication, while value 0 
indicated medication withdrawal. 
 
3.4.3 Statistical Analytic Methods 
 
   Statistical analyses are performed using SAS software version 9.2 (SAS Institute, 
Cary, NC). All tests for statistical significance were two-sided, and the 5% level was 
used as cutoff for statistical significance. 
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Descriptive Analysis 
 
   Patient characteristics, such as demographics and medical history, were described 
for each cohort. Side effects experienced by patients after taking tamoxifen and AIs 
were also reported separately. 
   Descriptive statistics and correlations between these variables were computed 
based on the frequencies and percentages for categorical variables, mean and standard 
deviation for continuous variables. Categorical variables were compared using 
Pearson χ2 test or Fisher‟s exact test to know if the characteristics of an AI cohort 
were significantly different from those of tamoxifen group. Continuous variables were 
compared using Wilcoxon rank sum test for non-parametric variables, and two-sided 
Student‟s t-test for normally distributed variables.  
Multivariate Analysis 
 
a) Comparison of Side Effects 
 
   Most symptoms occur soon after patients start hormonal treatment,
195
 thus the 
recording of these symptoms at the initial three-month follow-up visit was used as the 
measure of symptom occurrence. Tamoxifen group was used as the reference group to 
facilitate comparisons with other therapeutic options. Unadjusted and adjusted 
Incidence Rates Ratio (IRR) and Odds Ratio (OR) were estimated between study 
cohorts. 
 
   IRR referred to the side effects incurred during the three-month study period by 
tamoxifen patients versus AIs patients. OR evaluated the likelihood of tamoxifen 
patients having at least one occurrence of side effects during the three-month study 
period compared to that of AIs patients.  
 
   Statistically significant differences between the cohorts were tested using 
generalized linear model (GLM) regression models with a log link and a Poisson 
distribution for IRR and logistic regression models for OR. Results were presented as 
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IRR and OR. 95% confidence intervals (CIs) were calculated. Multivariate regression 
models were controlled for age, duration of medication, concurrent drug use, and 
prior drug use. 
 
b) Comparison of Satisfaction  
 
   To capture the factors affecting patient satisfaction with medications, two 
multivariate analyses were conducted. One is the comparison between satisfaction and 
non-satisfaction. The other one is the comparison of satisfaction levels. 
 
Comparison between Satisfaction and Non-Satisfaction 
 
   The probability of being satisfied for patients treated with tamoxifen was 
compared with that of patients treated with AIs. A logistic regression approach was 
used with satisfaction as the dependent variable. Independent variables included age, 
duration of medication, concurrent drug use, prior drug use, currently taking hormonal 
medication status, and most common side effects. Here, the dependent variable 
satisfaction was dichotomous, and it was coded as: 
 
 1 (drug rating   3) 
 0 (drug rating   3) 
    
   Value 1 indicated satisfaction, while value 0 indicated non-satisfaction. Proc 
genmod with link=logit, dist=binominal options was performed in the binary logistic 
regression. OR evaluated the probability of AIs patients experiencing satisfaction 
compared to that of tamoxifen patients. The adjusted OR was reported with their 
respective p-values (using tamoxifen as the reference group). Differences across 
cohort levels were tested for statistical significance. 
 
Comparison of Satisfaction Levels 
 
   The likelihood of rating a higher drug-rating in the group of patients treated with 
tamoxifen was compared with that of patients treated with AIs. An ordinal logistic 
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regression was used. Here, the dependent variable – drug-rating of satisfaction – was 
polytomous, and it was coded in descending order: 5 = Very Satisfied, 4 = Satisfied, 3 
= Somewhat Satisfied, 2 = Not Satisfied, 1 = Dissatisfied. Proc logistic was used with 
the link=clogit option. Here, clogit stands for cumulative logit. 
 
   OR evaluated the likelihood of AIs patients rating a higher score compared with 
that of tamoxifen patients. The covariates used in multivariate analyses were age, 
duration of hormonal medication, concurrent drug use, prior drug use, currently taking 
hormonal medication status, and most common side effects. The adjusted OR was 
reported with their respective p-values (using tamoxifen as the reference group). 
Differences across cohort levels were tested for statistical significance. 
 
3.5 Results 
 
   The first section describes and compares the patient characteristics. The second 
section provides the comparison of side effects reported by patients taking tamoxifen 
and AIs. Age, duration of hormonal medication, concurrent drug use, and prior drug 
use are controlled for multivariate analyses. The third section includes the impact of 
each AI and tamoxifen cohorts on the satisfaction rating separately. Then the results of 
multivariate analyses are presented.  
 
3.5.1 Patient Characteristics 
 
   Table 19 describes overall patient characteristics. At the time of the study, most 
patients were in the 50-59 age range. Compared with AIs cohorts, more tamoxifen 
patients were in the 40-49 age range, while less tamoxifen patients were aged older 
than 60 years. In every AIs cohort, the mean age of patients was significantly older 
than that in tamoxifen cohort (p < 0.05). For the AIs cohorts, all of the mean age was 
more than 55 years old. For the tamoxifen cohort, the mean age was 52.7 years (SD = 
8.4). With regard to the treatment duration, those taking anastrozole had been taking 
their drug 3 months longer than those taking tamoxifen. Compared with tamoxifen 
group, the duration of letrozole and exemestane treatments was shorter (19.3 months, 
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15.3 months, 19.7 months for letrozole, exemestane and tamoxifen respectively). 
However, these differences were not statistically significant. 
 
Table 19: Characteristics of Breast Cancer Patients with Hormonal Medications 
 
 
   Approximately 24% of all patients explicitly reported that they had switched from 
another drug. The difference between tamoxifen and anastrozole was not evident 
(tamoxifen 18.4% vs. anastrozole 17.8%). In anastrozole group, about 15.3% patients 
took tamoxifen previously, and only 1.7% patients took other AIs previously. These 
differences were statistically significant (p < 0.01). Although more patients taking 
letrozole had prior drug use than patients taking tamoxifen, no significant difference 
was recorded (p = 0.0504). In letrozole group, approximately 26% patients had 
switched from tamoxifen (p < 0.0001), and 8.7% patients had switched from the other 
AIs. Exemestane group had the highest percentage of patients who had prior drug use 
(54.2%), and compared with tamoxifen, this difference was statistically significant (p 
= 0.0028). Almost half number of patients (45.8%) used tamoxifen prior to 
exemestane, and 33.3% patients used to take the other AIs prior to exemestane. For 
tamoxifen cohort, 10.2% users used AIs previously.  
 
   For relieving the side effect, such as hot flashes, pain, depression, nausea, vaginal 
Tamoxifen 
1
N=49
N (%) N (%) N (%) N (%)
Age Distribution
40-49 Years 19 (38.8%) 92 (15.3%) 0.0002 ** 88 (19.7%) 0.0052 ** 3 (12.5%) 0.0294
50-59 Years 19 (38.8%) 303 (50.3%) 0.1379  238 (53.4%) 0.0699  15 (62.5%) 0.0806
60+ Years 11 (22.4%) 207 (34.4%) 0.1146  120 (26.9%) 0.6097  6 (25.0%) 0.8086
Age (years; Mean ± SD) 52.7±8.4 57.0±7.4 <.0001 ** 55.7±7.2 0.002 ** 56.0±6.9 0.031 *
19.7±29.1 22.6±18.6 0.0741  19.3±17.5 0.5776  15.3±7.6 0.4659  
Treatment History
Prior Drug Use 9 (18.4%) 107 (17.8%) 0.8482  146 (32.7%) 0.0504  13 (54.2%) 0.0028 **
AI 5 (10.2%) 10 (1.7%) 0.0033 ** 39 (8.7%) 0.7900  8 (33.3%) 0.0230 *
Tamoxifen - 92 (15.3%) 0.0009 ** 116 (26.0%) <.0001 ** 11 (45.8%) <.0001 **
Concurrent Drug Use 2 (4.1%) 21 (3.5%) 0.6890  8 (1.8%) 0.2595  3 (12.5%) 0.3229  
Current Still Taking Medication 27 (55.1%) 250 (41.5%) 0.0720  142 (31.8%) 0.0022 ** 9 (37.5%) 0.2140  
Notes:
[1] Tamoxifen is the reference group.
SD: Standard Deviation
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
N=24
ExemestaneLetrozole
N=446
Anastrozole
N=602
P-Value 
2
P-Value 
2
P-Value 
2
[2] P-values are based on Fisher‟s exact tests for categorical variables, Wilcoxon rank sum test for continuous variables.
Characteristics
Duration of Treatment in Months 
(Mean ± SD)
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dryness etc., some other drugs were also taken at the same. Compared with other three 
cohorts, more patients had concurrent drug use with exemestane to relieve side effects, 
which accounted for 12.5%. Letrozole group has the lowest percentage of patients 
who took concurrent drug, which was 1.8%. However, significant differences were 
barely recorded. 
 
   Moreover, compared with patients taking AIs, more patients taking tamoxifen 
insisted on taking it, which was more than half percentage. There was a significantly 
lower rate of insisting on taking letrozole than tamoxifen (letrozole 31.8% vs. 
tamoxifen 55.1%, p = 0.0022). 
 
   Table 20 presents the reasons for stopping current hormonal medication. Among 
the patients who stopped the current medication, more than 80% explicitly reported 
that they withdrew because of the side effects. Besides side effects, there were some 
other reasons that patients chose to withdraw the medication. One out of the seven 
exemestane patients and two out of the 18 tamoxifen patients reported that the reason 
was the ineffectiveness of the medication. Some patients complained that the 
medication was too expensive, they could not afford it. Some patients stopped the 
medication due to the finish of treatment. Less than 2% patients did not explain why 
they stopped taking anastrozole. 
 
Table 20: Reasons for Stopping Medication Treatment 
 
 
Stop due to side 
effects
Stop due to the 
ineffectiveness 
of the drug
Stop due to 
other reasons
Not 
reported
N (%) N (%) N (%) N (%)
Aromatase Inhibitors
Anastrozole (Arimidex®) 105 (93.8%) - 5 (4.5%) 2 (1.8%)
Letrozole (Femara®) 71 (94.7%) - 4 (5.3%) -
Exemestane (Aromasin®) 6 (85.7%) 1 (14.3%) - -
SERM
1 
Tamoxifen (Nolvadex®) 15 (83.3%) 2 (11.1%) 1 (5.6%) -
Notes:
1. Selective Estrogen Receptor Modulators
Drug Class
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3.5.2 Comparison of Side Effects 
 
   Different hormonal medications are associated with different side effects profiles 
which may be specific to individual patient. In this study, musculoskeletal disorders 
included pain (arthralgia, myalgia, bone pain), stiff joint, swollen joint, trigger fingers, 
muscle weakness, and cramps. Hot flashes and sweats were considered vasomotor 
symptoms. Gynecologic side effects consisted of loss of libido, vaginal dryness, 
dyspareunia, vaginal discharge/bleeding, and other serious side effects, such as 
ovarian cysts and uterine fibroid. Headache, dizziness, Carpal Tunnel Syndrome (CTS) 
and neuropathy were parts of nervous system problems. CTS is a condition with pain 
and muscle weakness or numbness in the fingers, hand and wrist, even the arm, 
because the median nerve is pressed or squeezed at the wrist.
196  
Neuropathy is a 
disorder in the function of a nerve or particular group of nerves.
197
 The most common 
form is peripheral neuropathy, which refers to the damage to the peripheral nerves that 
connect the spinal cord to muscles, skin and internal organs.
198
 It mainly affects the 
feet and legs, and it is among the most common neurologic complication of cancer.
199
 
In this study, neuropathy was composed of hand/foot pain, stiffness, swelling, 
difficulty of walking and standing, and off balance. Mental awareness included loss of 
memory, loss of concentration, confusion, forgetfulness, and cognitive difficulty. Skin 
problems and alopecia were considered dermatologic side effects. 
 
   Figure 8 illustrates the top five most common side effects reported across all four 
cohorts. They were arthralgia or myalgia, nervous system problems, vasomotor 
symptoms, low energy/lethargy and weight fluctuations. It was evident that arthralgia 
or myalgia was most commonly recorded for AIs, while tamoxifen was associated 
with the most frequent complaints of vasomotor symptoms. Exemestane had more 
complains about nervous system problems and less complains about weight 
fluctuations than anastrozole, letrozole or tamoxifen.  
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Figure 8: Top 5 Most Common Side Effects Reporting Rates 
 
 
 
3.5.2.1 Descriptive Analysis 
 
   Table 21 describes the proportions of patients experiencing different side effects, 
and presents the results of Fisher‟s exact test of the difference in the distributions of 
effects among the four cohorts. It shows that AIs patients experienced significantly 
more musculoskeletal symptoms, nervous system problems and sleep disorders than 
tamoxifen patients. In contrast, tamoxifen patients experienced significantly more 
vasomotor symptoms than AI patients. There were no differences of osteopenia, 
mental awareness, mood disorders, dermatologic side effects, weight change, low 
energy/lethargy, gastrointestinal symptoms and cardiovascular disease. A small 
number of people (< 5%) taking each sort of drug reported high cholesterol, eye 
problems, urinary tract problems, liver/lung/bladder problems, dry mouth, edema etc., 
which were too small for valid comparisons.  
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
Anastrozole Letrozole Exemestane Tamoxifen
: Arthralgia/Myalgia
: Nervous System Problems
: Vasomotor Symptoms
: Low energy/Lethargy             
: Weight Fluctuations
 139 
 
 
 
Table 21: Frequencies of Side Effects Reported by Breast Cancer Patients 
with Hormonal Medications 
 
 
Tamoxifen 
1
N=49
N (%) N (%) N (%) N (%)
Musculoskeletal Symptoms 21 (42.9%) 515 (85.5%) <.0001 ** 378 (84.8%) <.0001 ** 17 (70.8%) 0.0282 *
Pain 17 (34.7%) 493 (81.9%) <.0001 ** 362 (81.2%) <.0001 ** 16 (66.7%) 0.0130 *
Arthralgia/Myalgia 17 (34.7%) 473 (78.6%) <.0001 ** 348 (78.0%) <.0001 ** 15 (62.5%) 0.0434 *
Bone pain 3 (6.1%) 75 (12.5%) 0.2533  57 (12.8%) 0.2477  3 (12.5%) 0.3876  
Joint-Stiffness 1 (2.0%) 80 (13.3%) 0.0215 * 43 (9.6%) 0.1076  2 (8.3%) 0.2500  
Joint-Swelling 0 (0.0%) 21 (3.5%) 0.3932  22 (4.9%) 0.1514  0 (0.0%) -
Trigger Fingers 0 (0.0%) 47 (7.8%) 0.0405 * 28 (6.3%) 0.0971  3 (12.5%) 0.0325 *
Muscle Weakness 1 (2.0%) 9 (1.5%) 0.5453  9 (2.0%) 1.0000  0 (0.0%) 1.0000  
Cramps 7 (14.3%) 12 (2.0%) 0.0002 ** 10 (2.2%) 0.0006 ** 0 (0.0%) 0.0877  
Osteopenia 0 (0.0%) 43 (7.1%) 0.0655  25 (5.6%) 0.1583  1 (4.2%) 0.3288  
Nervous System Problems 12 (24.5%) 241 (40.0%) 0.0332 * 194 (43.5%) 0.0139 * 15 (62.5%) 0.0022 **
Headache 2 (4.1%) 42 (7.0%) 0.7646  33 (7.4%) 0.5609  2 (8.3%) 0.5937  
Dizziness 3 (6.1%) 16 (2.7%) 0.1657  17 (3.8%) 0.4356  0 (0.0%) 0.5462  
Carpal Tunnel Syndrome 1 (2.0%) 63 (10.5%) 0.0756  43 (9.6%) 0.1076  8 (33.3%) 0.0004 **
Neuropathy 10 (20.4%) 177 (29.4%) 0.2496  149 (33.4%) 0.0760  13 (54.2%) 0.0065 **
Gynecologic Side Effects 10 (20.4%) 145 (24.1%) 0.7272  134 (30.0%) 0.1864  2 (8.3%) 0.3146  
Loss of Libido 0 (0.0%) 100 (16.6%) 0.0003 ** 76 (17.0%) 0.0003 ** 2 (8.3%) 0.1050  
Vaginal Dryness 4 (8.2%) 67 (11.1%) 0.6398  81 (18.2%) 0.1079  0 (0.0%) 0.2955  
Dyspareunia 0 (0.0%) 8 (1.3%) 1.0000  9 (2.0%) 0.6091  0 (0.0%) -
Vaginal Discharge/Bleeding 5 (10.2%) 9 (1.5%) 0.0024 ** 3 (0.7%) 0.0003 ** 0 (0.0%) 0.1644  
 Other 
3
4 (8.2%) 3 (0.5%) 0.0008 ** 2 (0.4%) 0.0011 ** 0 (0.0%) 0.2955  
Vasomotor Symptoms 29 (59.2%) 220 (36.5%) 0.0022 ** 137 (30.7%) 0.0001 ** 4 (16.7%) 0.0009 **
Hot Flashes 26 (53.1%) 206 (34.2%) 0.0123 * 118 (26.5%) 0.0002 ** 3 (12.5%) 0.0009 **
Sweats 7 (14.3%) 42 (7.0%) 0.0836  42 (9.4%) 0.3095  2 (8.3%) 0.7085  
Mental Awareness 10 (20.4%) 118 (19.6%) 0.8530  91 (20.4%) 1.0000  7 (29.2%) 0.5563  
Loss of Memory 5 (10.2%) 81 (13.5%) 0.6626  59 (13.2%) 0.6588  6 (25.0%) 0.1606  
Loss of Concentration 4 (8.2%) 50 (8.3%) 1.0000  32 (7.2%) 0.7715  2 (8.3%) 1.0000  
Confusion 4 (8.2%) 35 (5.8%) 0.5249  26 (5.8%) 0.5238  2 (8.3%) 1.0000  
Forgetfullness 3 (6.1%) 32 (5.3%) 0.7409  35 (7.8%) 1.0000  2 (8.3%) 1.0000  
Cogitive Difficulty 2 (4.1%) 3 (0.5%) 0.0480 * 5 (1.1%) 0.1462  0 (0.0%) 1.0000  
Sleep Disorders 2 (4.1%) 123 (20.4%) 0.0038 ** 97 (21.7%) 0.0021 ** 7 (29.2%) 0.0046 **
Mood Disorders 7 (14.3%) 148 (24.6%) 0.1178  105 (23.5%) 0.1546  4 (16.7%) 1.0000
Anxiety 0 (0.0%) 23 (3.8%) 0.4063  19 (4.3%) 0.2405  1 (4.2%) 0.3288  
Mood Swing 2 (4.1%) 61 (10.1%) 0.2135  32 (7.2%) 0.5611  0 (0.0%) 1.0000  
Depression 5 (10.2%) 101 (16.8%) 0.3138  73 (16.4%) 0.3081  3 (12.5%) 1.0000  
Notes:
[3] Other included serious gynecologic side effects, such as ovarian cysts, uterine fibroid etc.
[1] Tamoxifen is the reference group.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
[2] P-values are calculated using Fisher‟s exact tests.
Side Effects
Exemestane
N=602 N=446 N=24
Anastrozole Letrozole
P - Value
2
P - Value
2
P - Value
2
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Table 21 (continued): 
 
 
 
 
 
Tamoxifen 
1
N=49
N (%) N (%) N (%) N (%)
Dermatologic Side Effects 6 (12.2%) 133 (22.1%) 0.1452  107 (24.0%) 0.0727  2 (8.3%) 1.0000  
Skin 3 (6.1%) 56 (9.3%) 0.6087  37 (8.3%) 0.7853  2 (8.3%) 1.0000  
Alopecia 3 (6.1%) 87 (14.5%) 0.1312  84 (18.8%) 0.0280 * 0 (0.0%) 0.5462  
Growth of Facial Hair 0 (0.0%) 8 (1.3%) 1.0000  0 (0.0%) - 0 (0.0%) -
Weight/Appetite Fluctuations 12 (24.5%) 187 (31.1%) 0.4205  149 (33.4%) 0.2608  3 (12.5%) 0.3568  
Increase of Weight 12 (24.5%) 181 (30.1%) 0.5156  147 (33.0%) 0.2616  2 (8.3%) 0.1236  
Loss of Weight 0 (0.0%) 1 (0.2%) 1.0000  2 (0.4%) 1.0000  0 (0.0%) -
Increase of Appetite 0 (0.0%) 1 (0.2%) 1.0000  0 (0.0%) - 0 (0.0%) -
Loss of Appetite 1 (2.0%) 6 (1.0%) 0.4233  2 (0.4%) 0.2690  1 (4.2%) 1.0000  
Low Energy/Lethargy 13 (26.5%) 217 (36.0%) 0.2145  132 (29.6%) 0.7423  10 (41.7%) 0.2832
Fatigue 9 (18.4%) 176 (29.2%) 0.1372  106 (23.8%) 0.4779  7 (29.2%) 0.3693  
Weakness 1 (2.0%) 11 (1.8%) 0.6122  5 (1.1%) 0.4668  1 (4.2%) 1.0000  
Loss of Energy 4 (8.2%) 50 (8.3%) 1.0000  30 (6.7%) 0.7637  3 (12.5%) 0.6770  
Gastrointestinal Symptoms 3 (6.1%) 48 (8.0%) 1.0000  40 (9.0%) 0.7880  3 (12.5%) 0.3876  
Nausea 1 (2.0%) 22 (3.7%) 1.0000  17 (3.8%) 1.0000  1 (4.2%) 1.0000  
Constipation 1 (2.0%) 11 (1.8%) 0.6122  11 (2.5%) 1.0000  1 (4.2%) 1.0000  
Diarrhea 0 (0.0%) 7 (1.2%) 1.0000  3 (0.7%) 1.0000  0 (0.0%) -
Other 
4
2 (4.1%) 13 (2.2%) 0.3135  13 (2.9%) 0.6521  1 (4.2%) 1.0000  
Cardiovascular Diseases 
5
2 (4.1%) 37 (6.1%) 0.7596  27 (6.1%) 0.7568  1 (4.2%) 1.0000  
High Cholesterol 0 (0.0%) 24 (4.0%) 0.2458  25 (5.6%) 0.1583  1 (4.2%) 0.3288  
Dyspnea 4 (8.2%) 6 (1.0%) 0.0043 ** 5 (1.1%) 0.0074 ** 1 (4.2%) 1.0000  
Eye Problems 
6
2 (4.1%) 16 (2.7%) 0.6385  32 (7.2%) 0.5611  0 (0.0%) 1.0000  
Urinary Tract Problems 2 (4.1%) 8 (1.3%) 0.1697  12 (2.7%) 0.6393  1 (4.2%) 1.0000  
Other Side Effects 5 (10.2%) 60 (10.0%) 1.0000 14 (3.1%) 0.0309 * 0 (0.0%) 0.1644
Edema 2 (4.1%) 12 (2.0%) 0.2845  4 (0.9%) 0.1113  0 (0.0%) 1.0000  
Flu-like Symptoms 0 (0.0%) 26 (4.3%) 0.2491  5 (1.1%) 1.0000  - -
Tinnitus 0 (0.0%) 5 (0.8%) 1.0000  - - - -
Dry Mouth 0 (0.0%) 10 (1.7%) 1.0000  - - - -
Teeth Problems 0 (0.0%) 4 (0.7%) 1.0000  1 (0.2%) 1.0000  - -
Liver Problems 2 (4.1%) 9 (1.5%) 0.1978  3 (0.7%) 0.0791  0 (0.0%) 1.0000  
Lung Problems 1 (2.0%) 4 (0.7%) 0.3246  0 (0.0%) 0.0990  0 (0.0%) 1.0000  
Bladder Problems 0 (0.0%) 3 (0.5%) 1.0000  1 (0.2%) 1.0000  - -
Notes:
[4] Other gastrointentinal symptoms inlcuded taste change, acid reflux, stomach/bowel problems, bloating and esophagus.
[5] Cardiovascular diseases included hypertention, heart palpitation and low blood pressure.
[6] Eye problems included dry eyes, tearing and blurred vision.
Side Effects
P - Value
2
P - Value
2
P - Value
2
Anastrozole Letrozole Exemestane
N=602 N=446 N=24
[2] P-values are calculated using Fisher‟s exact tests.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
[1] Tamoxifen is the reference group.
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  In the anastrozole group, patients experienced significantly more musculoskeletal 
symptoms compared with those in the tamoxifen group (anastrozole 85.5% vs. 
tamoxifen 42.9%; p < 0.0001). Arthralgia/myalgia was reported more significantly 
frequently in anastrozole group (78.6% vs. 34.7%; p < 0.0001). The incidence of joint 
stiffness and trigger fingers with anastrozole was statistically significantly higher than 
with tamoxifen (p < 0.05), while the incidence of cramps with anastrozole was 
significantly lower (2% vs. 14.3%; p = 0.0002). 241 cases (40.0%) of nervous system 
problems were reported in the anastrozole group, compared with 12 cases (24.5%) in 
the tamoxifen group, and this was statistically significant (p = 0.0332). With regard to 
gynecologic side effects, patients receiving anastrozole had significantly more loss of 
libido occurrence than those receiving tamoxifen (16.6% vs. 0.0%; p = 0.0003). Most 
of these events were in patients who reported vaginal dryness and dyspareunia. 
Vaginal discharge/bleeding and other serious gynecologic side effects occurred 
significantly more often in tamoxifen group (p < 0.005). Vasomotor symptoms 
occurred significantly less often in anastrozole patients than in tamoxifen patients 
(36.5% vs. 59.2%; p = 0.0022), including significantly less hot flashes (34.2% vs. 
53.1%; p = 0.0123). In addition, compared with the tamoxifen patients, anastrozole 
patients experienced significantly more sleep disorders (20.4% vs. 4.1%; p = 0.0038), 
less impairment in cognitive function (0.5% vs. 4.1%; p = 0.048) and less dyspnea 
(1.0% vs. 8.2%; p = 0.0043). 
 
   Letrozole group was associated with significantly increased incidence of    
musculoskeletal symptoms (letrozole 84.8% vs. tamoxifen 42.9%; p < 0.0001). In 
letrozole group, arthralgia/myalgia was reported more significantly frequently (78.0% 
vs. 34.7%; p < 0.0001), while cramps was reported less frequently (2.2% vs. 14.3%; p 
= 0.0006). Tamoxifen was significantly better tolerated than letrozole with respect to 
nervous system problems (tamoxifen 24.5% vs. letrozole 43.5%; p = 0.0139). In 
addition, decreased libido was reported more frequently with letrozole than with 
tamoxifen (letrozole 17.0% vs. tamoxifen 0.0%; p = 0.0003), while vaginal 
discharge/bleeding (0.7% vs. 10.2%) and other serious gynecologic side effects (0.4% 
vs. 8.2%) were reported less frequently in letrozole group (p < 0.01). In terms of 
vasomotor symptoms, they occurred significantly less often in patients receiving 
letrozole than those receiving tamoxifen (30.7% vs. 59.2%; p = 0.0001). Furthermore, 
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letrozole users experienced significantly more sleep disorders (21.7% vs. 4.1%; p = 
0.0021), and alopecia (18.8% vs. 6.1%; p = 0.028), and significantly less dyspnea (1.1% 
vs. 8.2%; p = 0.0074). 
 
   Exemestane also resulted in significantly more musculoskeletal symptoms than 
tamoxifen (exemestane 70.8% vs. tamoxifen 42.9%; p = 0.0282). In exemestane 
group, arthralgia/myalgia and trigger fingers were reported more significantly 
frequently (62.5% vs. 34.7% for arthralgia/myalgia; 12.5% vs. 0.0% for trigger 
fingers; p < 0.05). The frequency of nervous system problems was reported 
significantly higher in exemestane group (62.5% vs. 24.5%; p = 0.0022), including 
more significant carpal tunnel syndrome (33.3% vs. 2.0%; p = 0.0004) and 
neuropathy (54.2% vs. 20.4%; p = 0.0065). Furthermore, exemestane was 
significantly better tolerated than tamoxifen with regard to vasomotor symptoms (16.7% 
vs. 59.2%; p = 0.0009), including significantly less hot flashes (12.5% vs. 53.1%; p = 
0.0009). While tamoxifen was significantly better tolerated than exemestane regarding 
sleep disorders (tamoxifen 29.2% vs. exemestane 4.1%; p = 0.0046). 
 
3.5.2.2 Multivariate Analysis 
 
The incidence and likelihood of developing side effects for postmenopausal breast 
cancer patients treated with tamoxifen and each AI during the first three months were 
compared by using univariate and multivariate regression models. Tamoxifen patients 
were the reference group. Age, duration of hormonal medication, concurrent drug use, 
and prior drug use were controlled for the analysis. The results of comparison 
between tamoxifen and anastrozole/letrozole/exemestane will be presented separately. 
An IRR > 1 indicated that AIs patients had higher incidence of incurring one side 
effect than tamoxifen patients, while an OR > 1 indicated that AIs patients had a 
higher probability of experiencing one side effect compared to tamoxifen patients. 
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a) Anastrozole vs. Tamoxifen 
 
   Table 22 shows that after controlling for the different confounding factors, 
patients receiving anastrozole were associated with a significant increase in the 
musculoskeletal symptoms incidence rate than those receiving tamoxifen (adjusted 
IRR 2.14 [1.37 - 3.36], p = 0.0009; adjusted OR 12.12 [6.19 - 23.74], p < 0.0001). 
Patients in anastrozole group reported significantly more pain symptoms than those in 
tamoxifen group (adjusted IRR 2.25 [1.55 - 4.21], p = 0.0002; adjusted OR 11.68 
[5.99 - 22.80], p < 0.0001). Compared with tamoxifen patients, anastrozole patients 
had higher probability of developing arthralgia or myalgia (adjusted OR 9.80 [5.04 - 
19.06]; p < 0.0001), stiff joint (adjusted OR 8.20 [1.11 - 60.71]; p = 0.0393), while 
they had lower probability of developing cramps group (adjusted OR 0.10 [0.04 - 
0.28]; p < 0.0001). The incidence of nervous system problems was also significantly 
higher in anastrozole group (adjusted OR 2.20 [1.11 - 4.36]; p = 0.0243). Regarding 
gynecologic side effects, patients receiving anastrozole had a greater risk of vaginal 
dryness (adjusted OR 1.64 [0.56 - 4.80]; p = 0.3647), whereas they had a significantly 
lower risk of vaginal discharge/bleeding (adjusted OR 0.16 [0.05 - 0.53]; p = 0.0025) 
and other serious gynecologic side effects (adjusted OR 0.07 [0.01 - 0.35]; p = 
0.0011). In addition, tamoxifen patients were more likely to develop vasomotor 
symptoms, especially hot flashes (adjusted OR 0.55 [0.30 - 1.00]; p = 0.049). 
Furthermore, patients receiving anastrozole were also associated with significantly 
increased occurrence of sleep disorders with an OR of 5.98 (p = 0.0145), and 
significantly decreased incidence rate of cognitive difficulty with an OR of 0.15 (p = 
0.0468), and dyspnea with an OR of 0.13 (p = 0.0033). 
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Table 22: Comparison of Side Effects Reported by Breast Cancer Patients 
Anastrozole vs. Tamoxifen 
Tamoxifen
N=49
IRR (95% CI) IRR (95% CI) OR (95% CI) OR (95% CI)
Musculoskeletal Symptoms 2.00 (1.29 - 3.09) 0.0019 ** 2.14 (1.37 - 3.36) 0.0009 ** 7.89 (4.29 - 14.52) <.0001 ** 12.12 (6.19 - 23.74) <.0001 **
Pain 2.36 (1.46 - 3.83) 0.0005 ** 2.55 (1.55 - 4.21) 0.0002 ** 8.51 (4.56 - 15.89) <.0001 ** 11.68 (5.99 - 22.80) <.0001 **
Arthralgia/Myalgia 2.26 (1.40 - 3.67) 0.0009 ** 2.47 (1.50 - 4.08) 0.0004 ** 6.90 (3.71 - 12.83) <.0001 ** 9.80 (5.04 - 19.06) <.0001 **
Bone Pain 2.03 (0.64 - 6.45) 0.2276  2.04 (0.64 - 6.49) 0.2291  2.18 (0.66 - 7.19) 0.1997  2.19 (0.66 - 7.28) 0.2000  
Joint-Stiffness 6.51 (0.91 - 46.79) 0.0626  7.09 (0.98 - 51.16) 0.0521  7.36 (1.00 - 54.04) 0.0498 * 8.20 (1.11 - 60.71) 0.0393 *
Cramps 0.14 (0.05 - 0.35) <.0001 ** 0.12 (0.05 - 0.32) <.0001 ** 0.12 (0.05 - 0.33) <.0001 ** 0.10 (0.04 - 0.28) <.0001 **
Nervous System Problems 1.63 (0.92 - 2.92) 0.0966  1.68 (0.94 - 3.01) 0.0815  2.06 (1.05 - 4.03) 0.0350 * 2.20 (1.11 - 4.36) 0.0243 *
Headache 1.71 (0.41 - 7.06) 0.4589  1.74 (0.42 - 7.23) 0.4491  1.76 (0.41 - 7.51) 0.4435  1.80 (0.42 - 7.76) 0.4322  
Carpal Tunnel Syndrome 5.13 (0.71 - 36.97) 0.1048  5.23 (0.72 - 37.82) 0.1013  5.61 (0.76 - 41.35) 0.0906  5.81 (0.78 - 43.10) 0.0853  
Neuropathy 1.44 (0.76 - 2.72) 0.2613  1.55 (0.56 - 4.31) 0.3964  1.62 (0.79 - 3.33) 0.1846  1.66 (0.80 - 3.44) 0.1739  
Gynecologic Side Effects
Vaginal Dryness 1.36 (0.50 - 3.74) 0.5470  1.55 (0.56 - 4.31) 0.3964  1.41 (0.49 - 4.04) 0.5237  1.64 (0.56 - 4.80) 0.3647  
Vaginal Discharge/Bleeding 0.15 (0.05 - 0.44) 0.0006 ** 0.18 (0.06 - 0.56) 0.0030 ** 0.13 (0.04 - 0.42) 0.0005 ** 0.16 (0.05 - 0.53) 0.0025 **
Other Serious Side Effects 0.06 (0.01 - 0.27) 0.0003 ** 0.08 (0.02 - 0.37) 0.0014 ** 0.06 (0.01 - 0.26) 0.0002 ** 0.07 (0.01 - 0.35) 0.0011 **
Vasomotor Symptoms 0.62 (0.42 - 0.91) 0.0147 * 0.68 (0.46 - 1.02) 0.0593  0.40 (0.22 - 0.72) 0.0023 ** 0.46 (0.25 - 0.85) 0.0132 *
Hot Flashes 0.64 (0.43 - 0.97) 0.0351 * 0.72 (0.47 - 1.10) 0.1286  0.46 (0.26 - 0.83) 0.0094 ** 0.55 (0.30 - 1.00) 0.0490 *
Sweats 0.49 (0.22 - 1.09) 0.0792  0.56 (0.24 - 1.26) 0.1584  0.45 (0.19 - 1.06) 0.0686  0.51 (0.21 - 1.24) 0.1385  
Sleep Disorders 5.01 (1.24 - 20.24) 0.0239 * 4.94 (1.22 - 20.04) 0.0254 * 6.03 (1.45 - 25.19) 0.0137 * 5.98 (1.42 - 25.10) 0.0145 *
Cogitive Difficulty 0.12 (0.02 - 0.73) 0.0212 * 0.16 (0.03 - 0.99) 0.0486 * 0.12 (0.02 - 0.72) 0.0208 * 0.15 (0.02 - 0.97) 0.0468 *
Dyspnea 0.12 (0.03 - 0.43) 0.0011 ** 0.14 (0.04 - 0.53) 0.0037 ** 0.11 (0.03 - 0.42) 0.0010 ** 0.13 (0.03 - 0.51) 0.0033 **
Notes:
CI: Confidence Intervals
N=602 N=602
Univariate Multivariate 
1
Univariate Multivariate 
1Side Effects
Anastrozole Anastrozole
P - Value P - Value P - Value
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P - Value
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
[1] Adjusted differences were estimated from multivariate regression models controlling for age, duration of hormonal medication, concurrent drug use, and prior drug use.
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b) Letrozole vs. Tamoxifen 
 
   After adjustment for age, duration of hormonal medication, concurrent drug use 
and prior drug use, Table 23 presents that compared with patients in tamoxifen group, 
patients in letrozole group were associated with a significantly higher musculoskeletal 
symptoms incidence rate (adjusted IRR 2.05 [1.31 - 3.23], p = 0.0018; adjusted OR 
8.60 [4.46 - 16.59], p < 0.0001), especially arthralgia or myalgia (adjusted IRR 2.33 
[1.41 - 3.86], p = 0.001; adjusted OR 7.37 [3.81 - 14.25], p < 0.0001). However, 
patients in tamoxifen group more easily experienced cramps (adjusted IRR 0.17 [0.06 
- 0.46]; p = 0.0005; adjusted OR 0.15 [0.05 - 0.42]; p = 0.0003). Similar to 
anastrozole, letrozole was also associated with a significantly increased incidence rate 
of nervous system problems at the three-month follow-up visit (adjusted OR 2.27 
[1.13 - 4.56]; p = 0.0208). Additionally, letrozole patients had a higher risk of 
developing vaginal dryness with an OR of 2.74 (p = 0.0796), and significantly lower 
risk of developing vaginal discharge/bleeding (adjusted OR 0.06 [0.01 - 0.27]; p = 
0.0002) and other serious gynecologic side effects (adjusted OR 0.05 [0.01 - 0.29]; p 
= 0.0008). With respect to vasomotor symptoms, letrozole users less easily 
experienced them than tamoxifen users with an IRR of 0.53 (p = 0.0026). The risk of 
hot flashes was higher in tamoxifen group (adjusted OR 0.32 [0.18 - 0.60]; p = 
0.0004), so did the sweats (adjusted OR 0.68 [0.28 - 1.66]; p = 0.3974). Furthermore, 
letrozole group had higher probability of developing sleep disorders (adjusted OR 
6.52 [1.54 - 27.59]; p = 0.0109) and alopecia (adjusted OR 3.20 [0.96 - 10.71]; p = 
0.0588). Oppositely, letrozole users had lower probability of developing dyspnea 
(adjusted OR 0.11 [0.03 - 0.49]; p = 0.0034). 
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Table 23: Comparison of Side Effects Reported by Breast Cancer Patients 
Letrozole vs. Tamoxifen 
Tamoxifen
N=49
IRR (95% CI) IRR (95% CI) OR (95% CI) OR (95% CI)
Musculoskeletal Symptoms 1.98 (1.27 - 3.07) 0.0024 ** 2.05 (1.31 - 3.23) 0.0018 ** 7.41 (3.98 - 13.80) <.0001 ** 8.60 (4.46 - 16.59) <.0001 **
Pain 2.34 (1.44 - 3.81) 0.0006 ** 2.44 (1.47 - 4.04) 0.0005 ** 8.11 (4.30 - 15.30) <.0001 ** 8.90 (4.59 - 17.23) <.0001 **
Arthralgia/Myalgia 2.25 (1.38 - 3.66) 0.0011 ** 2.33 (1.41 - 3.86) 0.0010 ** 6.68 (3.56 - 12.54) <.0001 ** 7.37 (3.81 - 14.25) <.0001 **
Bone pain 2.09 (0.65 - 6.67) 0.2141  2.15 (0.65 - 7.09) 0.2072  2.25 (0.68 - 7.46) 0.1863  2.30 (0.66 - 8.07) 0.1935  
Joint-Stiffness 4.72 (0.65 - 34.31) 0.1248  5.33 (0.73 - 39.00) 0.0995  5.12 (0.69 - 38.04) 0.1103  5.95 (0.79 - 44.91) 0.0836  
Cramps 0.16 (0.06 - 0.41) 0.0002 ** 0.17 (0.06 - 0.46) 0.0005 ** 0.14 (0.05 - 0.38) 0.0001 ** 0.15 (0.05 - 0.42) 0.0003 **
Nervous System Problems 1.78 (0.99 - 3.18) 0.0535  1.70 (0.94 - 3.05) 0.0783  2.37 (1.21 - 4.67) 0.0124 * 2.27 (1.13 - 4.56) 0.0208 *
Headache 1.81 (0.43 - 7.55) 0.4140  1.67 (0.39 - 7.15) 0.4871  1.88 (0.44 - 8.08) 0.3973  1.74 (0.39 - 7.78) 0.4686  
Carpal Tunnel Syndrome 4.72 (0.65 - 34.31) 0.1248  5.14 (0.70 - 37.51) 0.1068  5.12 (0.69 - 38.04) 0.1103  5.75 (0.76 - 43.24) 0.0894  
Neuropathy 1.64 (0.86 - 3.11) 0.1314  1.58 (0.83 - 3.02) 0.1628  1.96 (0.95 - 4.03) 0.0685  1.91 (0.91 - 3.99) 0.0870  
Gynecologic Side Effects
Vaginal Dryness 2.22 (0.82 - 6.07) 0.1185  2.47 (0.87 - 7.01) 0.0887  2.50 (0.87 - 7.14) 0.0878  2.74 (0.89 - 8.43) 0.0796  
Vaginal Discharge/Bleeding 0.07 (0.02 - 0.28) 0.0002 ** 0.07 (0.02 - 0.29) 0.0003 ** 0.06 (0.01 - 0.26) 0.0002 ** 0.06 (0.01 - 0.27) 0.0002 **
Other Serious Side Effects 0.05 (0.01 - 0.30) 0.0008 ** 0.06 (0.01 - 0.31) 0.0009 ** 0.05 (0.01 - 0.28) 0.0007 ** 0.05 (0.01 - 0.29) 0.0008 **
    
Vasomotor Symptoms 0.52 (0.35 - 0.77) 0.0013 ** 0.53 (0.35 - 0.80) 0.0026 ** 0.31 (0.17 - 0.56) 0.0001 ** 0.31 (0.17 - 0.58) 0.0002 **
Hot Flashes 0.50 (0.33 - 0.76) 0.0013 ** 0.51 (0.33 - 0.79) 0.0025 ** 0.32 (0.17 - 0.58) 0.0002 ** 0.32 (0.18 - 0.60) 0.0004 **
Sweats 0.66 (0.30 - 1.47) 0.3074  0.72 (0.32 - 1.63) 0.4267  0.62 (0.26 - 1.48) 0.2826  0.68 (0.28 - 1.66) 0.3974  
Sleep Disorders 5.33 (1.31 - 21.61) 0.0192 * 5.27 (1.29 - 21.49) 0.0204 * 6.53 (1.56 - 27.37) 0.0103 * 6.52 (1.54 - 27.59) 0.0109 *
Dyspnea 0.14 (0.04 - 0.51) 0.0031 ** 0.13 (0.03 - 0.51) 0.0037 ** 0.13 (0.03 - 0.49) 0.0028 ** 0.11 (0.03 - 0.49) 0.0034 **
Alopecia 3.08 (0.97 - 9.73) 0.0558  2.74 (0.87 - 8.71) 0.0864  3.56 (1.08 - 11.72) 0.0369 * 3.20 (0.96 - 10.71) 0.0588  
Notes:
CI: Confidence Intervals
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
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P - Value P - Value P - Value P - Value
[1] Adjusted differences were estimated from multivariate regression models controlling for age, duration of hormonal medication, concurrent drug use, and prior drug use.
Side Effects
Letrozole Letrozole
N=446 N=446
Univariate 
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c) Exemestane vs. Tamoxifen   
 
   In Table 24, exemestane patients reported significantly more musculoskeletal 
symptoms at the three-month follow-up visit than tamoxifen patients (adjusted OR 
3.54 [1.09 - 11.52]; p = 0.0355) after adjustment for all other characteristics. Patients 
in exemestane group more easily developed pain, especially arthralgia or myalgia 
(adjusted OR 3.54 [1.10 - 11.45]; p = 0.0344). The result of bone pain did not change 
after adjusting for established risk factors, even though the risk of developing was 
higher in exemestane group. Compared with tamoxifen patients, exemestane patients 
had a significant increase in nervous system problems incidence rate (adjusted OR 
4.22 [1.29 - 13.83]; p = 0.0173). Patients receiving exemestane were associated with a 
significant higher risk of carpal tunnel syndrome with an OR of 15.76 (p = 0.0163), 
and neuropathy with an OR of 3.77 (p = 0.0309). The probability of developing 
headache was higher in exemestane as well with an OR of 1.13, but it was not 
statistically significant (p = 0.9284). Similar to anastrozole and letrozole, exemestane 
was also associated with a significantly decreased incidence rate of vasomotor 
symptoms compared with tamoxifen (adjusted IRR 0.32 [0.10 - 0.98]; p = 0.0459; 
adjusted OR 0.17 [0.04 - 0.62]; p = 0.0079). Tamoxifen resulted in a significant higher 
incidence rate of hot flashes (adjusted OR 0.17 [0.04 - 070]; p = 0.0145). However, 
there was non-significant difference of night sweats between the two groups, even 
though the risk was higher in tamoxifen patients. Additionally, it was observed that 
sleep disorders was more easily to develop in exemestane patients with an IRR of 
7.61 (p = 0.0294) and an OR of 12.92 (p = 0.0156) than that in tamoxifen patients. 
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Table 24: Comparison of Side Effects Reported by Breast Cancer Patients 
Exemestane vs. Tamoxifen 
Tamoxifen
N=49
IRR (95% CI) IRR (95% CI) OR (95% CI) OR (95% CI)
Musculoskeletal Symptoms 1.65 (0.87 - 3.13) 0.1235  1.72 (0.83 - 3.56) 0.1436  3.24 (1.14 - 9.22) 0.0277 * 3.54 (1.09 - 11.52) 0.0355 *
Pain 1.92 (0.97 - 3.80) 0.0608  2.08 (0.96 - 4.53) 0.0642  3.76 (1.34 - 10.57) 0.0119 * 4.66 (1.39 - 15.59) 0.0124 *
Arthralgia/Myalgia 1.80 (0.90 - 3.61) 0.0966  1.89 (0.85 - 4.18) 0.1176  3.14 (1.14 - 8.65) 0.0272 * 3.54 (1.10 - 11.45) 0.0344 *
Bone pain 2.04 (0.41 - 10.12) 0.3820  2.63 (0.44 - 15.57) 0.2874  2.19 (0.41 - 11.77) 0.3607  2.94 (0.44 - 19.73) 0.2665  
Nervous System Problems 2.55 (1.19 - 5.45) 0.0156 * 2.16 (0.91 - 5.13) 0.0818  5.14 (1.79 - 14.72) 0.0023 ** 4.22 (1.29 - 13.83) 0.0173 *
Headache 2.04 (0.29 - 14.49) 0.4754  1.18 (0.12 - 11.20) 0.8871  2.14 (0.28 - 16.17) 0.4624  1.13 (0.08 - 15.42) 0.9284  
Carpal Tunnel Syndrome 16.33 (2.04 - 130.59) 0.0085 ** 11.14 (1.24 - 100.04) 0.0314 * 24.00 (2.78 - 206.96) 0.0038 ** 15.76 (1.66 - 149.54) 0.0163 *
Neuropathy 2.65 (1.16 - 6.05) 0.0203 * 2.21 (0.86 - 5.66) 0.0997  4.61 (1.59 - 13.33) 0.0048 ** 3.77 (1.13 - 12.60) 0.0309 *
Vasomotor Symptoms 0.28 (0.10 - 0.80) 0.0175 * 0.32 (0.10 - 0.98) 0.0459 * 0.14 (0.04 - 0.47) 0.0014 ** 0.17 (0.04 - 0.62) 0.0079 **
Hot Flashes 0.24 (0.07 - 0.78) 0.0177 * 0.29 (0.08 - 1.02) 0.0542  0.13 (0.03 - 0.48) 0.0024 ** 0.17 (0.04 - 0.70) 0.0145 *
Sweats 0.58 (0.12 - 2.81) 0.5014  1.00 (0.15 - 6.49) 0.9976  0.55 (0.10 - 2.85) 0.4726  1.01 (0.13 - 7.76) 0.9950  
Sleep Disorders 7.15 (1.48 - 34.40) 0.0142 * 7.61 (1.22 - 47.28) 0.0294 * 9.68 (1.83 - 51.22) 0.0076 ** 12.92 (1.62 - 102.79) 0.0156 *
Notes:
CI: Confidence Intervals
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Multivariate 
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[1] Adjusted differences were estimated from multivariate regression models controlling for age, duration of hormonal medication, concurrent drug use, and prior drug use.
Side Effects
Exemestane Exemestane
N=24 N=24
Univariate Multivariate 
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Univariate 
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3.5.3 Comparison of Satisfaction 
 
   The satisfaction information was determined by the rating of medication, which 
used a five-point scale (1 “dissatisfied”, 2 “not satisfied”, 3 “somewhat satisfied”, 4 
“satisfied”, and 5 “very satisfied”). The specific ratings for each of the four cohorts 
were listed in Figure 9. 
 
Figure 9: Overall Patient Satisfaction with Hormonal Medications 
 
 
 
   Figure 9 shows that anastrozole had the highest mean rating (2.9 out of 5, close to 
satisfaction) followed by letrozole and tamoxifen (2.7 out of 5, close to satisfaction), 
while exemestane had the lowest mean drug rating (2.3 out of 5, not satisfied). 
Anastrozole and tamoxifen had relatively high percentage of rating “very satisfied” 
(10.1% for anastrozole, 8.2% for tamoxifen). Tamoxifen also had the highest 
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
Anastrozole Letrozole Exemestane Tamoxifen
Mean: 2.7
SD: 1.4
Mean: 2.3
SD: 1.1
Mean: 2.7
SD: 1.2
Mean: 2.9
SD: 1.2
1-Dissatisfied - I would not recommend taking this medicine
2-Not satisfied - this medicine did not work to my satisfaction
3-Somewhat Satisfied - this medicine helped somewhat 
4-Satisfied - this medicine helped
5-Very Satisfied - this medicine cured me or helped me a great deal
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percentage of patients who rated the drug as dissatisfaction. For all four cohorts, most 
of the patients rated their satisfaction score 3 (somewhat satisfaction).  
 
   As presented in Table 25, side effect was a major reason affecting patient 
satisfaction. 99% patients explicitly reported that they experienced at least one side 
effect. Patients who reported side effects rated their drugs significantly lower than 
patients who reported not experiencing any side effect (p < 0.05). Compared with 
tamoxifen patients, more patients receiving AIs reported at least one side effect (93.9% 
for tamoxifen vs. 99.2% for anastrozole, 99.3% for letrozole, and 100% for 
exemestane, respectively). Few patients with AIs therapy reported no side effects; the 
percentage was less than 1%. It was noted that the rating of exemestane was the 
lowest, and all exemestane patients experienced side effects. Although tamoxifen had 
the lowest percentage of patients who reported more than one side effect, it had the 
highest percentage of patients who explicitly reported no side effect (6.1%).  
 
Table 25: Mean Satisfaction for Patients Reporting ≥ 1 Side Effects 
Compared to Patients Reporting No Side Effect 
 
 
   For all hormonal medications, musculoskeletal symptoms, nervous system 
problems, vasomotor symptoms, sleep disorders and gynecologic side effects 
significantly negatively impacted patients‟ rating compared with patients who 
reported no side effects. See Table 26.  
 
N(%)
Mean 
Rating
SD N(%)
Mean 
Rating
SD
Anastrozole 602 597 (99.2%) 2.9 1.2 5 (0.8%) 5.0 0.0 <.0001 **
Letrozole 446 443 (99.3%) 2.7 1.2 3 (0.7%) 4.7 0.6 0.0250 *
Exemestane 24 24 (100%) 2.3 1.1 - - - -
Tamoxifen 49 46 (93.9%) 2.6 1.4 3 (6.1%) 4.3 0.6 0.0124 *
Total 1,121 1,110 (99.0%) 2.8 1.2 11 (1.0%) 4.7 0.5 <.0001 **
Notes:
** p < 0.01 and * p < 0.05 for the test of the null hypothesis of equality of means ratings between patients with and 
without side effects.
SD: Standard Deviation
Drug Class
Patients Reporting ≥1 
Side Effects
Patients Explicitly 
Reporting No Side Effect
Number 
of 
Patients
P-Value
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Table 26: Mean Satisfaction for Patients Reporting Most Common Side 
Effects Compared to Patients Reporting No Side Effect 
 
 
   The mean satisfaction drug-rating for anastrozole patients reporting no side effect 
was 5.0, which was much higher than that for them reporting musculoskeletal 
symptoms (2.8), nervous system problems (2.6), vasomotor symptoms (2.9), sleep 
disorders (2.6), or gynecologic side effects (2.7). The same trend was found for 
letrozole and tamoxifen patients, the difference of drug-rating is almost two scores. 
For exemestane patients, all patients reported at least one side effect. The mean 
drug-rating for patients reporting one of the above side effects was between 2.0 and 
2.4. It meant that they were not satisfied with exemestane. 
 
3.5.3.1 Comparison between Satisfaction and Non-Satisfaction 
 
   Table 27 presents the outcome of comparing the likelihood of being satisfied for 
patients treated with tamoxifen with patients treated with each AI. Drug rating   3 
indicated satisfaction.  
 
  After controlling for the different confounding factors (i.e., age, duration of 
medication, medication history, currently taking medication status and some side 
effects), anastrozole patients had higher probability of feeling satisfied than tamoxifen 
patients (adjusted OR 2.37 [1.10 - 5.09]; p = 0.0267). In univariate analysis, letrozole 
patients had lower probability of feeling satisfied than tamoxifen patients. Despite that 
Mean 
Rating
SD
Mean 
Rating
SD
Mean 
Rating
SD
Mean 
Rating
SD
Mean 
Rating
SD
Mean 
Rating
SD
Anastrozole 2.8 1.2 ** 2.6 1.1 ** 2.9 1.1 ** 2.6 1.1 ** 2.7 1.1 ** 5.0 0.0
Letrozole 2.6 1.1 * 2.5 1.1 * 2.6 1.1 * 2.5 1.1 * 2.8 1.2 * 4.7 0.6
Exemestane 2.2 1.0 2.4 1.3 2.0 0.8 2.0 1.2 2.0 1.4 - -
Tamoxifen 2.5 1.4 ** 2.0 1.1 ** 2.5 1.4 ** 3.5 2.1  2.2 1.3 ** 4.3 0.6
Notes:
Sleep 
Disorders
Gynecologic 
Side Effects
Patients Explicitly 
Reporting No 
Side Effect
SD: Standard Deviation
** p < 0.01 and * p < 0.05 for the test of the null hypothesis of equality of means ratings between patients with and without side effects.
Drug Class
Musculoskeletal 
Symptoms
Nervous System 
Problems
Vasomotor 
Symptoms
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the regression-adjusted probability of letrozole patients feeling satisfied was 1.47 
times higher than that of tamoxifen patients; the difference was not statistically 
significant (p = 0.3278). Moreover, the adjusted OR 0.51 suggested that the 
probability of satisfaction was 0.51 times less likely to occur in exemestane patients 
compared with tamoxifen patients. However, this difference was not significant (p = 
0.3918). 
 
Table 27: Comparison between Satisfaction and Non-Satisfaction
1
  
Binary Logistic Regression  
 
 
   Table 28.1 - 28.3 summarize outcomes of the factors affecting satisfaction rating 
of patients treated with tamoxifen in comparison to patients treated with each AI. 
Tamoxifen group was the reference group. 
 
   As shown in Table 28.1, the probability to be satisfied was associated with longer 
duration of medication (OR = 1.03; p < 0.0001), currently no medication withdrawal 
(OR = 4.20; p < 0.0001), younger age (OR = 0.96; p = 0.0023), less musculoskeletal 
symptoms (OR = 0.39; p = 0.0008), less nervous system problems (OR = 0.68; p = 
0.0354), and less sleep disorders (OR = 0.58; p = 0.0174). Although concurrent drug 
use, vasomotor symptoms caused the probability of being satisfied to increase, the 
differences were not recorded. 
 
 
 
OR (95% CI) OR (95% CI) OR (95% CI)
Univariate Analysis 1.07 (0.59-1.93) 0.8240  0.83 (0.46-1.52) 0.5503  0.49 (0.18-1.33) 0.1616  
Multivariate Analysis 2.37 (1.10-5.09) 0.0267 * 1.47 (0.68-3.15) 0.3278  0.51 (0.11-2.40) 0.3918  
Notes:
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Exemestane 
2
N=602 N=446 N=24
[2] The multivariate logistic regression for anastrozole and exemestane were adjusted for age, duration of hormonal medication, concurrent drug use, prior 
drug use, currently taking medication status, musculoskeletal symptoms, nervous system problems, vasomotor symptoms, gynecology side effects, and 
sleep disorders.
[3] The multivariate logistic regression for letrozole was adjusted for age, duration of  hormonal medication, concurrent drug use, prior drug use, currently 
taking medication status, musculoskeletal symptoms, nervous system problems, vasomotor symptoms, gynecology side effects, sleep disorders and 
dermatology side effects.
P - Value
Tamoxifen 
N=49
P - Value P - Value
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Anastrozole 
2
Letrozole 
3
[1] Drug rating ≥ 3 were considered satisfaction.
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Table 28.1: Factors affecting on Satisfaction Rating - Anastrozole vs. Tamoxifen 
Satisfaction vs. Non-Satisfaction 
 
 
Table 28.2: Factors affecting on Satisfaction Rating - Letrozole vs. Tamoxifen 
Satisfaction vs. Non-Satisfaction 
 
 
   Table 28.2 shows that longer duration of medication and currently consistent use 
of medication caused the rating of satisfaction to increase (OR = 1.03 for duration, 
OR = 5.40 for currently consistent use of medication; p < 0.0001). Musculoskeletal 
Parameter Estimate SE OR
Age -0.0387 0.0127 0.96 -0.0635 -0.0138 0.0023 **
Duration 0.0267 0.0055 1.03 0.0160 0.0374 <.0001 **
Prior Drug Use -0.2300 0.2329 0.79 -0.6865 0.2265 0.3234  
Concurrent Drug Use 0.3899 0.5060 1.48 -0.6019 1.3816 0.4410  
Currently Consistent Use of Medication 1.4358 0.1919 4.20 1.0596 1.8120 <.0001 **
Musculoskeletal Symptoms -0.9290 0.2785 0.39 -1.4748 -0.3832 0.0008 **
Nervous System Problems -0.3877 0.1843 0.68 -0.7489 -0.0264 0.0354 *
Vasomotor Symptoms 0.2143 0.1900 1.24 -0.1580 0.5867 0.2592  
Gynecologic Side Effects -0.2752 0.2142 0.76 -0.6950 0.1446 0.1988  
Sleep Disorders -0.5400 0.2271 0.58 -0.9851 -0.0949 0.0174 *
Notes:
SE: Standard Error; CI: Confidence Intervals.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
P-Value
Analysis of Parameter Estimate 
95% CI
Parameter Estimate SE OR
Age -0.0127 0.0147 0.99 -0.0415 0.0162 0.3893  
Duration 0.0269 0.0066 1.03 0.0140 0.0399 <.0001 **
Prior Drug Use 0.1988 0.2230 1.22 -0.2383 0.6358 0.3727  
Concurrent Drug Use 0.2790 0.7681 1.32 -1.2265 1.7845 0.7164  
Currently Consistent Use of Medication 1.6861 0.2358 5.40 1.2239 2.1483 <.0001 **
Musculoskeletal Symptoms -0.5716 0.2796 0.56 -1.1197 -0.0235 0.0410 *
Nervous System Problems -0.5397 0.2117 0.58 -0.9546 -0.1249 0.0108 *
Vasomotor Symptoms -0.4081 0.2231 0.66 -0.8454 0.0293 0.0674  
Gynecologic Side Effects -0.0230 0.2367 0.98 -0.4869 0.4409 0.9224  
Sleep Disorders -0.3519 0.2630 0.70 -0.8674 0.1636 0.1810  
Dermatology Side Effects -0.0092 0.2584 0.99 -0.5157 0.4973 0.9716  
Notes:
SE: Standard Error; CI: Confidence Intervals.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Analysis of Parameter Estimate 
95% CI P-Value
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symptoms and nervous system problems caused probability of being satisfied to 
decrease (OR = 0.56 for musculoskeletal symptoms, OR = 0.58 for nervous system 
problems; p < 0.05). 
 
Table 28.3: Factors affecting on Satisfaction Rating - Exemestane vs. Tamoxifen 
Satisfaction vs. Non-Satisfaction 
 
 
  In Table 28.3, only currently no medication withdrawal is the significant 
determinant for satisfaction. The probability of satisfaction was 5.15 times more likely 
to occur if patients currently were still taking medication (p = 0.0091). 
 
3.5.3.2 Comparison of Satisfaction Levels 
 
   Table 29 shows the outcome of the likelihood of a higher drug-rating in the group 
of patients treated with tamoxifen compared with patients treated with AIs. 
 
   After adjusting for the contributing factors, the likelihood of rating a higher score 
with anastrozole patients was 3.62 times than with tamoxifen patients (p < 0.0001). 
Compared with tamoxifen patients, the probability of higher drug-rating significantly 
increased in letrozole patients with odds of 2.17 (p = 0.0206). The tendency to a 
higher drug-rating was decreased by a multiple of 0.50 in exemestane group. However, 
the difference was not statistically significant. 
Parameter Estimate SE OR
Age -0.0519 0.0404 0.95 -0.1311 0.0273 0.1993  
Duration -0.0050 0.0115 1.00 -0.0276 0.0177 0.6667  
Prior Drug Use 0.3393 0.7023 1.40 -1.0372 1.7159 0.6290  
Concurrent Drug Use 24.8373 - - - - 0.9999
Currently Consistent Use of Medication 1.6390 0.6281 5.15 0.4080 2.8700 0.0091 **
Musculoskeletal Symptoms -0.3197 0.5921 0.73 -1.4803 0.8409 0.5892  
Nervous System Problems -0.4660 0.6414 0.63 -1.7231 0.7911 0.4675  
Vasomotor Symptoms -0.4418 0.6532 0.64 -1.7220 0.8384 0.4988  
Gynecologic Side Effects -0.3141 0.7626 0.73 -1.8088 1.1806 0.6804  
Sleep Disorders -0.1160 0.9213 0.89 -1.9217 1.6898 0.8998  
Notes:
SE: Standard Error; CI: Confidence Intervals.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Analysis of Parameter Estimate 
95% CI P-Value
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Table 29: Comparison of Satisfaction Levels 
1
 
Ordered Logistic Regression 
 
 
   Table 30.1 - 30.3 summarize the outcomes of the factors affecting the comparison 
of satisfaction levels between patients treated with tamoxifen and patients treated with 
each AI. Tamoxifen group was the reference group. 
 
Table 30.1: Factors affecting on Satisfaction Rating - Anastrozole vs. Tamoxifen 
Satisfaction Levels 
 
 
   As shown in Table 30.1, age, medication condition, side effects were determinants 
of rating a higher satisfaction score. The likelihood to a higher rating increased by 2% 
OR (95% CI) OR (95% CI) OR (95% CI)
Univariate Analysis 1.35 (0.77-2.36) 0.2906  1.06 (0.60-1.87) 0.8470  0.62 (0.26-1.45) 0.2682  
Multivariate Analysis 
2,3
3.62 (1.90-6.91) <.0001 ** 2.17 (1.13-4.20) 0.0206 * 0.50 (0.14-1.78) 0.2825  
Notes:
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Tamoxifen 
N=49
P - Value P - Value P - Value
[2] The multivariate logistic regression for anastrozole and exemestane were adjusted for age, duration of hormonal medication, concurrent drug use, prior 
drug use, currently taking medication status, musculoskeletal symptoms, nervous system problems, vasomotor symptoms, gynecology side effects, and 
sleep disorders.
[1] Satisfaction level was a 5-point scale (from 1 “dissatisfied” to 5 "very satisfied").
[3] The multivariate logistic regression for letrozole was adjusted for age, duration of  hormonal medication, concurrent drug use, prior drug use, currently 
taking medication status, musculoskeletal symptoms, nervous system problems, vasomotor symptoms, gynecology side effects, sleep disorders and 
dermatology side effects.
N=24
Letrozole 
3
N=446
Anastrozole 
2
N=602
R
ef
er
en
ce
 G
ro
u
p
Exemestane 
2
Parameter Estimate SE OR
Age -0.0340 0.0101 0.97 -0.0538 -0.0142 0.0008 **
Duration 0.0223 0.0040 1.02 0.0146 0.0301 <.0001 **
Prior Drug Use 0.0014 0.1864 1.00 -0.3639 0.3668 0.9938  
Concurrent Drug Use 0.2739 0.3736 1.32 -0.4583 1.0062 0.4634  
Currently Consistent Use of Medication 1.1849 0.1508 3.27 0.8894 1.4804 <.0001 **
Musculoskeletal Symptoms -1.1253 0.2132 0.32 -1.5431 -0.7075 <.0001 **
Nervous System Problems -0.6091 0.1483 0.54 -0.8997 -0.3185 <.0001 **
Vasomotor Symptoms 0.1424 0.1503 1.15 -0.1521 0.4370 0.3433  
Gynecologic Side Effects -0.4467 0.1683 0.64 -0.7765 -0.1168 0.0080 **
Sleep Disorders -0.5019 0.1826 0.61 -0.8597 -0.1441 0.0060 **
Notes:
SE: Standard Error; CI: Confidence Intervals.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
95% CI
Analysis of Parameter Estimate 
P-Value
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due to longer duration of medication (p < 0.0001) and 227% due to currently 
consistent use of medication (p < 0.0001), while it decreased by 3% due to elder age 
(p = 0.0008), 68% due to musculoskeletal symptoms (p < 0.0001), 46% due to 
nervous system problems (p < 0.0001), 36% due to gynecologic side effects (p = 
0.0008) and 39% due to sleep disorders (p = 0.006), respectively. However, even 
though prior drug use, concurrent drug use and vasomotor symptoms caused the odds 
of rating a higher score to increase, significant differences were barely recorded. 
 
Table 30.2: Factors affecting on Satisfaction Rating - Letrozole vs. Tamoxifen 
Satisfaction Levels 
 
 
   Table 30.2 presents that patients were more likely to rate a higher score if they had 
longer duration of medication (OR = 1.02; p < 0.0001) and currently no medication 
withdrawal (OR = 3.66; p < 0.0001). Whereas they are less likely to rate a higher 
score if they experienced musculoskeletal symptoms (OR = 0.48; p = 0.0015), and 
nervous system problems (OR = 0.60; p = 0.0029). Although gynecologic side effects, 
sleep disorders and dermatology side effects caused the odds of rating a higher score 
decreased, the differences were not statistically significant. 
 
   Table 30.3 shows that concurrent drug use and currently no medication 
withdrawal were the significant predictors for a higher satisfaction score. Specifically, 
Parameter Estimate SE OR
Age -0.0156 0.0121 0.98 -0.0392 0.0081 0.1963  
Duration 0.0222 0.0051 1.02 0.0123 0.0322 <.0001 **
Prior Drug Use 0.1491 0.1813 1.16 -0.2062 0.5043 0.4108  
Concurrent Drug Use 0.3101 0.5795 1.36 -0.8258 1.4459 0.5926  
Currently Consistent Use of Medication 1.2985 0.1827 3.66 0.9404 1.6566 <.0001 **
Musculoskeletal Symptoms -0.7335 0.2313 0.48 -1.1869 -0.2802 0.0015 **
Nervous System Problems -0.5172 0.1737 0.60 -0.8577 -0.1768 0.0029 **
Vasomotor Symptoms -0.2848 0.1786 0.75 -0.6349 0.0652 0.1107  
Gynecologic Side Effects -0.1049 0.1889 0.90 -0.4751 0.2653 0.5785  
Sleep Disorders -0.4080 0.2086 0.66 -0.8169 0.0008 0.0505  
Dermatology Side Effects -0.0945 0.2061 0.91 -0.4984 0.3094 0.6465  
Notes:
SE: Standard Error; CI: Confidence Intervals.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Analysis of Parameter Estimate 
95% CI P-Value
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the likelihood to rate a higher score significantly increased by concurrent drug use 
with odds 6.39 (p = 0.0487), and currently no medication withdrawal with odds 5.26 
(p = 0.0024). 
 
Table 30.3: Factors affecting on Satisfaction Rating - Exemestane vs. Tamoxifen 
Satisfaction Levels 
 
 
3.6 Discussion  
 
   This study used patient self-reported data collected through www.askapatient.com 
to examine the side effects reported by postmenopausal breast cancer patients 
receiving hormonal medications (tamoxifen, anastrozole, letrozole and exemestane), 
and examine the impact on patient satisfaction. This section presents the major 
findings, the limitations, health policy implications and suggestions for future studies. 
 
3.6.1 Major Findings 
    
   Firstly, this study assessed and compared the side effects associated with 
hormonal medications reported by breast cancer patients. As known from several 
publications, physician-guided symptom assessment is not sufficient to give a full 
picture of the real side effects produced by hormonal treatments, hence it normally 
Parameter Estimate SE OR
Age -0.0467 0.0326 0.95 -0.1105 0.0172 0.1519  
Duration -0.0021 0.0090 1.00 -0.0198 0.0156 0.8194  
Prior Drug Use 0.9427 0.5951 2.57 -0.2237 2.1091 0.1132  
Concurrent Drug Use 1.8552 0.9412 6.39 0.0105 3.6999 0.0487 *
Currently Consistent Use of Medication 1.6598 0.5470 5.26 0.5878 2.7319 0.0024 **
Musculoskeletal Symptoms -0.2012 0.4790 0.82 -1.1401 0.7377 0.6745  
Nervous System Problems -0.9348 0.5383 0.39 -1.9898 0.1203 0.0825  
Vasomotor Symptoms -0.3746 0.5379 0.69 -1.4289 0.6797 0.4862  
Gynecologic Side Effects -0.9938 0.6440 0.37 -2.2560 0.2685 0.1228  
Sleep Disorders 0.5509 0.7430 1.73 -0.9053 2.0070 0.4584  
Notes:
SE: Standard Error; CI: Confidence Intervals.
** p-value significant at α = 0.01; * p-value significant at α = 0.05.
Analysis of Parameter Estimate 
95% CI P-Value
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underestimates the real treatment burden.
134, 144, 145
 Usually, physicians or researchers 
are more interested in severe side effects like bone fractures or thrombosis, than in 
uncomplicated, non-life-threatening and easy-to-manage symptoms such as insomnia, 
weight gain or low energy. Nevertheless, these less serious symptoms may also 
significantly affect the patients‟ quality of life and satisfaction. On the other side, 
patients do not always discuss their symptoms with the doctor, possibly because some 
symptoms may not constantly disturb them, some symptoms are attributed to 
menopause, or it is an embarrassment to speak about particular symptoms, for 
example decreased libido, or problems regarding intercourse. It is also possible that 
they suppose that the doctor may not be interested in these less serious symptoms. 
Other reasons include the patient perceive that the oncologist is not the correct person 
to address some symptoms, e.g. gynecologist deals with gynecologic problems, 
dermatologist deals with dermatologic problems. Hence, the validated HRQoL 
questionnaires for breast cancer may fail to show the full picture of patients‟ reported 
side effects.  
 
This study used data collected from Askapatient website, where patients could 
share any experiences on medications without being influenced by caregivers or 
physicians. A majority of the patients (99%) reporting their experience with the use of 
tamoxifen and AIs underwent significant side effects. Consistent with the findings of 
previous literature review, the current study also found that patients commonly 
reported pains, hot flashes, fatigue, while taking tamoxifen or an AI. Statistically 
significant differences were observed between the tamoxifen and AIs for side effects 
as well. Similar to the results reported in some studies, compared with the tamoxifen 
group, significantly more joint/muscle/bone pain,
200
 joint stiffness,
160
 nervous system 
problems,
196 
vaginal dryness and loss of libido
142, 143
 took place in anastrozole group, 
whereas significantly less vaginal discharge/bleeding,
143, 145
 hot flashes,
145
 cognitive 
difficulty
201, 202
 occurred. There were no differences of gastrointestinal symptoms
142, 
145
 or cardiovascular events
200
 between the two treatment groups. Patients in the 
letrozole group experienced significantly severer problems of musculoskeletal 
symptoms,
203
 hair thinning,
204
 or sleep difficulty,
148
 whereas significantly less 
vaginal discharge/bleeding and vasomotor symptoms.
203,
 
205
 Aligned with the 
previous researches, statistically significant differences were reported between 
patients taking exemestane and patients taking tamoxifen. Exemestane was associated 
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with significantly more bone/muscle aches,
 152, 154
 carpal tunnel syndrome,
206
 vaginal 
dryness,
152
 decreased libido,
152
 and insomnia,
147, 154
 but with significantly less nervous 
system problems,
207 , 208
 vaginal discharge,
144
 hot flashes
144
. In addition, barely 
difference of mental awareness,
 
mood disorders, or low energy/lethargy, between 
exemestane and tamoxifen were recorded, in spite of constant complaint.
 152, 154
   
 
   In addition to the side effects discussed above, the current study also showed that 
anastrozole has been associated with increased rates of tinnitus, dry mouth and growth 
of facial hair. Dry eyes and blurred vision incurred more often in letrozole patients. 
Some other minor side effects, such as nausea, flu-like symptoms, teeth problems and 
bladder problems were noted in anastrozole and letrozole patients. For tamoxifen, it 
appeared to cause more dyspnea, edema and urinary tract problems, less sleep 
disorders than AIs patients. Regarding dyspnea and sleep disorders, tamoxifen was 
associated with significantly higher frequency of dyspnea than anastrozole and 
letrozole, and significantly lower frequency of sleep disorders than anastrozole, 
letrozole and exemestane. 
 
   Secondly, this study examined patient satisfaction with hormonal medications. 
The numerical ratings of the medications‟ effect indicated that many users found the 
medications helpful overall, with a positive or middle rating. Among these four 
cohorts, patients were somewhat satisfied with anastrozole, letrozole and tamoxifen. 
And anastrozole got the highest level of satisfaction (2.9 out of 5), while exemestane 
had the lowest drug rating (2.3 out of 5), which meant that patients were least satisfied 
with it. Letrozole and tamoxifen had the same drug rating (2.7 out of 5). For all four 
cohorts, most of the patients rated their satisfaction score 3.0 (somewhat satisfaction), 
because they did not know their drug was effective or not. One key reason was the 
short time of taking the medication; the other key reason was probably the same side 
effects with prior medication. 
 
   Consistent with literatures, side effects significantly negatively impacted patient 
satisfaction,
170, 175, 176, 177, 181, 182
 especially musculoskeletal symptoms and nervous 
system problems in this study. Besides the side effects, those who were satisfied 
tended to be long-term and currently consistent users of medication.
179
 However, this 
study did not fully support the hypothesis 5 - patients with concurrent drug use are 
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more likely to rate a higher score on satisfaction. Concurrent drug use help relieve 
some side effects, such as hot flashes, pain, etc. It should be a positive effect 
associated with satisfaction, which was reported by Brod et al.
182
 In the current study, 
although concurrent drug use caused the probability of being satisfied to increase, the 
differences were not recorded. The key reason is that only a few respondents reported 
this information. Hence, future research is needed to examine this factor. 
 
   Compared with tamoxifen patients, anastrozole patients had a significantly higher 
probability of experiencing satisfaction, and they had a significantly stronger 
likelihood of rating a higher score as well. Besides the above factors mentioned, it 
was also found that older patients were more likely to rate dissatisfaction. This is 
contradictory to the findings of Cohen G.
171
 One explanation is that most anastrozole 
patients were in age range 50-59. The median age for women to have their natural 
menopause onset is 51 years old.
194
 The menopausal patients are more likely to rate 
dissatisfaction in terms of menopausal symptoms and other side effects. In addition, 
sleep disorders also significantly negatively impacted patient satisfaction. 
 
   Letrozole patients only had a significantly stronger likelihood of rating a higher 
score. Long-term and currently no medication withdrawal had positive effect, while 
musculoskeletal symptoms or nervous system problems had negative effect. 
 
   In this study, exemestane patients had a lower probability of experiencing 
satisfaction than tamoxifen patients, despite adjusting for the contributing factors. One 
explanation was the small sample size of exemestane patients resulting in the 
inconclusive validity of the comparison. The other explanation was the prior drug use. 
Among the exemestane patients who switched from another drug, almost half number 
of patients (45.8%) used tamoxifen prior to exemestane, and 33.3% patients took the 
other AIs prior to exemestane. Patients may feel difficult to tell which drug caused the 
current side effects. In addition, relatively short duration of treatment could also affect 
the comparison results. Hence, further research is needed. 
 
   Finally, the data revealed that although many users found hormonal medications 
helpful overall with a positive or middle rating, they did not feel that they participated 
in treatment decisions. Furthermore, they reported that they had not been warned about 
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side effects, and they were not aware of some of their side effects rated to the 
medication until they read these comments. Hence, many patients felt very happy to 
find this website. Two examples from the comments of the data are shown below:  
 
   “I wish I had found this website 4 1/2 years ago. I started having severe joint pain 
about 6-8 months after starting Arimidex and was complaining to oncologist who said 
it had nothing to do with the drug. I believed him. He said I had arthritis and when it 
got a lot worse I went to arthritis specialist who confirmed it. I have been on for 5 
years and doctor said OK to quit taking it after next month but after reading this today 
I am quitting right now and praying my body will recover from these side effects. I 
searched the internet today to see if current opinion was to quit Arimidex after 5 years 
or if there was any benefit from additional years on the drug when I found this 
website. You all are saying the same things I have been saying for 4 1/2 years but I 
thought it was just me.”  
 
   “My oncologist doesn‟t seem to think any of this is from Femera when it is clearly 
written on the warning pamphlet that came with it……My oncologist had his nurse 
tell me over the phone that my being so ill was just in my mind. If that was the case 
why did my blood tests show I needed the boost shots?” 
 
   It is important that patients who wish to participate in treatment decisions are well 
informed about the treatment options and are given sufficient support to evaluate the 
potential consequences of the decision, including discussion with former patients who 
have similar experiences with the treatments. As noted by Eysenbach, if patients feel 
satisfied with the adequacy of information provided, the probability for them to feel 
happy with their participation in the entire process of making decision is higher,
188
 the 
probability for them to comply with medical treatment to gain a better outcome is 
higher as well. 
 
3.6.2 Study Strengths and Limitations  
 
   Nowadays, various media are available for collecting patient-reported outcomes 
(PROs), and the Internet is increasingly recognized as an important source of 
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information. Due to the wide availability and easy access of the Internet, as well as 
dissatisfaction with the information provided by health care providers, patients are 
becoming more inclined to turn to it for health information and support. Although 
there is a noteworthy finding that the quality of cancer information from the Internet 
is not so bad after all in comparison to other topic areas, research based on web data 
still has some limitations. The discussions in this section will present what strengths 
and limitations of this study using Askapatient website data. 
 
Study Strengths 
 
   The first strength of this study was certainly that Askapatient website provides 
high quality information. It is the best resource for patient opinion about drug 
performance, which was established ten years ago and all the prescription drugs are 
currently approved by the FDA. 
 
   Secondly, Askapatient website is able to assess side effects without the patient 
being influenced by caregivers, as it was completed independently by the patients 
without the help of nurses or consulting the doctor. Usually, the toxicities and 
tolerability of treatments in clinical trial are collected by doctors, nurses and/or the 
study coordinators. Since this kind of information could differ from those reported by 
patients, the validated HRQoL questionnaires for breast cancer may fail to show the 
full picture of patients‟ real side effects. This study provides additional empirical 
evidence on the side effects reported by breast cancer patients after taking hormonal 
medications. For example, anastrozole was associated with increased rates of tinnitus, 
dry mouth and growth of facial hair. Tamoxifen appeared to cause more dyspnea, 
edema, and urinary tract problems, but less sleep disorders than AIs patients.  
 
   Thirdly, as far as I know, this is the first study to compare breast cancer patients‟ 
satisfaction about tamoxifen and AIs. Patient satisfaction is the type of outcome that is 
studied less frequently than other patient-reported outcomes (PROs), particularly 
health-related quality of life (HRQoL). Nevertheless, such PROs are very important in 
the studies of cancer because they reflect patients‟ treatment-related behaviours, and 
consequently, it will impact the quality of life in cancer patients. Although the side 
effect profiles of tamoxifen and AIs varied significantly, there were no important 
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differences in overall QoL. Hence, the information of patient satisfaction with 
hormonal medications is very useful for policy makers to manage such medications 
and optimize health expenditure. 
 
Limitations 
 
   Askapatient database is a free discussion space without any medical authority. 
Any people could share their personal experiences with medications here. Meanwhile, 
there is no validation of how many entries one single patient may have contributed to 
the website. Although the reliance on self-reporting may not detract much from the 
study findings, other limitations should be noted. 
 
   Firstly, respondents in this study do not represent a random sample. This website 
presents patients‟ reporting only from those who were able to find this site on the 
Internet and wanted to share their experiences with prescribed drugs. At the same time, 
the respondents may be motivated to access this website due to unusually negative 
experiences with these drugs. Additionally, people who use the Internet are more 
likely to be better educated, younger and above middle class than the general 
population, although the users of Askapatient are older than average Internet users in 
the current study. Therefore, respondents in this study could not represent the general 
users of hormonal therapy medications. Moreover, the results are limited by relying 
upon the respondents‟ self-reports, which may potentially bias the results. 
 
   Secondly, this study may not assess the prevalence of hormonal 
medication-related side effects. Respondents may not report their complete 
experiences encountered during the period of treatment. Some respondents appeared 
to list all the side effects they experienced, the other mentioned only one or two 
without indicating if they still experienced other side effects. Furthermore, serious 
life-threatening side effects, such as cerebrovascular events, thromboembolic events 
and endometrial cancer, were rarely reported probably due to the physical incapability 
of self-reporting of the patients over the Internet or the relatively short duration of 
medication treatment. Therefore, not all of the hormonal medication-related side 
effects addressed in this study could be found in the previous literature review.  
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   Thirdly, in this study, all the hormonal medications must be taken for at least three 
months, which may not be sufficient to detect attrition that could occur over longer 
period of time. Moreover, the small sample size will influence its statistical 
representation of patients‟ satisfaction estimates. 
 
3.6.3 Health Policy Implication 
 
   Based on the findings from this study, some suggestions for the implication of 
health policy are provided here. Firstly, this study provides additional empirical 
evidence on the side effects reported by breast cancer patients after taking hormonal 
medications. In addition to the serious symptoms commonly reported, uncomplicated, 
non-life-threatening and easy-to-manage symptoms could be a basis for appropriate 
management decisions or regulatory reporting of breast cancer hormonal medications 
as well. Based on the side effects reported by the patients in this study, healthcare 
researchers and clinicians need to be aware that tamoxifen was associated 
significantly with higher frequency of dyspnea than anastrozole or letrozole, while 
AIs were associated with significantly higher frequency of sleep disorders than 
tamoxifen. In addition, anastrozole has been connected with increased rates of tinnitus, 
dry mouth and growth of facial hair. Dry eyes and blurred vision incurred with 
letrozole patients. The clinical implications inferred from the findings could provide an 
indication of best hormonal medication management. In addition, it could be a 
reference point for future research and benchmark into clinical practice. 
 
Secondly, satisfaction among hormonal medication users is associated with 
long-term and currently consistent treatment. For this reason, clinicians could further 
educate patients about the medications, and reinforce the importance for long-term 
compliance which is the key to successful management of breast cancer. 
 
Finally, this study showed that some other drugs were taken with hormonal 
medications at the same time to relieve side effects. One of the most frequently used 
drugs is bisphosphonates (e.g., Boniva, Fosamax) for treating osteoporosis. 
Nevertheless, in October 2010, the FDA warned patients and health care providers 
about the possible risk of atypical thigh bone fracture among patients who take 
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bisphosphonates.
209
 Therefore AIs resulting in bone fracture may need to be 
reconsidered in the future. 
 
3.6.4 Suggestions for Future Studies 
 
   Despite the study limitations, the present findings have policy implications 
meriting further examination. Additional research is needed in larger population, 
particularly with longer follow-up period, to fully explore the relationship among 
medication use, self-reported side effects and patient satisfaction. In this study, the 
duration of hormonal medications is relatively short, which may not have been 
sufficient to detect some serious side effects that could occur over longer period. As 
known from the literature, bone mineral density and cardiovascular disease occurred 
more frequently with AIs, while cerebrovascular events, thromboembolic events and 
endometrial cancer occurred more frequently with tamoxifen. These serious 
life-threatening side effects could also be a significant factor of affecting patient 
satisfaction. Thus, such side effects remain important issues of concern and need to be 
monitored and followed up in the further research. Likewise, the findings of current 
study did not fully support hypothesis 5 - patients with concurrent drug use are more 
likely to rate a higher score on satisfaction. Concurrent drug use could be a 
contributing factor of medication satisfaction, and previous literature review also 
reported that.
178
 However, in this study concurrent drug use caused the probability of 
being satisfied to increase, the differences were not recorded. Moreover, the 
significant factors identified in current study which impact medication satisfaction are 
not the only factors that have an effect, and further research is needed to identify 
additional factors, such as age, education and income level.  
 
   In addition, the five-Likert scale drug rating in Askapatient website has not been 
proved to be psychometrically validated. A more detailed analysis with reliable and 
validated treatment satisfaction questionnaire for medications is needed.  
 
   And the current study compared patient satisfaction rating on tamoxifen with that 
on each AI. Although anastrozole and letrozole patients showed a significantly higher 
probability of experiencing satisfaction than tamoxifen patients, further confirmation 
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of the findings is needed. With regard to the comparison between tamoxifen and 
exemestane, future research is required. Furthermore, from descriptive statistics about 
three AIs, anastrozole had higher mean rating than letrozole and exemestane. And 
exemestane had the lowest mean drug rating. Direct head-to-head comparisons of AIs 
are also needed in the future. 
 
3.6.5 Conclusion 
 
   This study used self-reported data to examine patient satisfaction and subjective 
experiences of treatment with breast cancer hormonal medications - tamoxifen and 
AIs (anastrozole, letrozole, exemestane). The results supported the hypotheses 
showing that in comparison to patients receiving tamoxifen, patients receiving AIs 
experienced significantly more arthralgia/myalgia, bone events, carpal tunnel 
syndrome, vaginal dryness, sexual dysfunction and sleep disorders, whereas 
significantly less hot flashes, night sweats, vaginal discharge/bleeding and other 
serious gynecologic side effects, such as ovarian cysts. When examining the 
contributing factors that affect hormonal medication satisfaction, it was clear that the 
occurrence of side effects was a major issue for breast cancer patients and influenced 
patient satisfaction. This study showed that side effects, especially musculoskeletal 
symptoms and nervous system problems, significantly and negatively affected patient 
satisfaction with hormonal medications. Additionally, long-term and currently 
consistent uses of medications were also important determinants of medication 
satisfaction. Compared with tamoxifen patients, anastrozole patients had a 
significantly higher probability of experiencing satisfaction, and they also had a 
significantly stronger likelihood of rating a higher score; while letrozole patients only 
showed a significantly stronger likelihood of rating a higher score. Future research to 
confirm the current results should use a larger sample, and a prospective methodology. 
Overall, choice of a hormonal medication should involve not only the effectiveness of 
an agent but also the subjective effects of medications, such as side effect profile and 
patient satisfaction. This kind of information could improve communication between 
patients and care providers regarding possible side effects, and improve the quality of 
life of patients on hormonal medication therapy as well. 
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Chapter 4: Conclusion 
 
   Nowadays, cancer is one of the leading causes of death in the world. The year 
2008 World Cancer Report released by the International Agency for Research on 
Cancer (IARC) estimates that globally there were over 12 million new cases of cancer 
diagnosed in 2008, 7 million deaths from cancer.
2
 And the incidence of cancer 
continues to increase; by the year 2030 there will be 27 million incident cases of 
cancer and 17 million cancer deaths.
2
 Due to the improved treatments, cancer survival 
rates have greatly increased in the past few decades. In particular, cancer drug 
treatment is vitally important in the treatments of patients in all stages of disease. 
Although the currently available cancer drug treatments improve the survival rate and 
relieve some symptoms to a certain extent, meanwhile they also produce some 
unexpected toxic side effects. It is noted that side effects cause patients‟ health-related 
quality of life (HRQoL) and patient satisfaction with medication to decrease. Hence, 
patient-reported outcomes (PROs) (i.e., treatment-related toxicity, the impact of 
treatments on HRQoL, and patient satisfaction) as an important therapeutic endpoint 
are increasingly being given a high priority in the management of cancer patients. 
 
   In addition, the costs of cancer treatment have increased substantially in the past 
twenty years.
 
The overall increase in spending for cancer care is due to the increase in 
both the price and the rates of use, which can be linked to the introduction of new 
medical technology. Compared with spending in many other areas of heath care, 
spending on cancer-related medications has risen faster. The strong upward rise 
causes cancer patients exceptionally affected by high out-of-pocket expenditures, at 
the same time it gives health economists a great cause for concern. Therefore, 
economic outcomes, especially understanding the pattern of prescription medication 
expenditures, are more and more important in cancer outcome research.  
 
   However, the literature assessing cancer patients‟ self-reported outcomes and 
expenditures, particularly with regards to prescriptions is lacking and mostly 
out-dated. To meet the demand, this thesis attempted to attribute PROs and 
expenditures of cancer patients with prescription medications by two empirical cancer 
outcome researches. One was a macro-level study which examined the factors related 
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to cancer prescription medication use, HRQoL and prescription medication 
expenditures in the United States by using national survey data. The other was a 
meso-level study which examined patient satisfaction and subjective experiences of 
treatment with breast cancer hormonal medications by using patient self-reported 
data. 
 
Study One: Impact of Medication on Health-related Quality of Life and 
Expenditures for Cancer Patients in the United States 
 
   The first study used the latest public-used data drawn from the year 2008 Medical 
Expenditures Panel Survey (MEPS) for research. The MEPS is a nationally 
representative survey of the civilian non-institutionalized U.S. population conducted by 
the Agency for Healthcare Research and Quality (AHRQ). In the United States, cancer 
is the second leading cause of all deaths, which accounts for nearly one of every four 
deaths.
4 
In an attempt to manage cancer, cancer medication plays an important role in 
the treatment of patients with cancer in all stages of disease. As known from several 
studies, cancer medication users have impaired HRQoL. In addition, as the largest 
portion of direct medical expenditures, cancer medication costs greatly increase 
annually. Nevertheless, there is a dearth of literature which has examined this topic by 
using nationally representative database such as the MEPS. The primary question for 
this study‟s inquiry was “What effects do cancer prescription medications have on the 
HRQoL and expenditures in patients with cancers?” 
 
   Firstly, this study used HRQoL measures to provide different perspectives on 
health status of cancer patients. The dependent variable - HRQoL, was assessed by 
using measures of SF-12 for general health status, Kessler Index (K-6) for general 
psychological distress, and Patient Health Questionnaire (PHQ-2) for depressive 
symptoms. To my knowledge, this is the first study to examine cancer patients‟ health 
status by using of these three different instruments. This study found that medication 
use for cancer treatment was associated with significant impairment of HRQoL in the 
U.S. adult cancer population. Specifically, cancer population reported worse physical 
or mental health, more serious psychological distress and depression than 
age-matched non-cancer population. These impairments were greater in physical than 
mental health. It also revealed that differences in the impairment associated with 
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cancer medication use existed across groups of different characteristics. Patients with 
less education or chronic diseases had worse HRQoL. In addition, elderly patients 
indicated poorer physical health, while Hispanics indicated poorer mental health. 
 
   Secondly, this study examined how certain demographic or socioeconomic 
characteristics are strongly associated with high financial burdens. After adjusting for 
different confounding factors, the adjusted annual mean total and out-of-pocket 
expenditures associated with cancer prescription medication were $2,572.1 and 
$597.1, respectively. The multivariate analysis revealed that patient characteristics 
such as age, region, insurance status, chronic conditions and HRQoL had significant 
impact on cancer prescription medication expenditures. Total and out-of-pocket 
expenditures were significantly increased with age. Amidst socioeconomic classes, 
patients living in the West incurred a lower prescription spending than those living in 
the other regions. Additionally, patients covered by Medicare insurance paid higher 
out-of-pocket money for prescription medicine in comparing with those in other 
insurance groups, and uninsured had the lowest average annual total expense. Patients 
enrolled under Medicaid or uninsured patients paid less for their medicines by 
out-of-pocket compared with their counterparts. This deviation gives the researchers 
and policy makers an alarm of paying attention to those vulnerable people regarding 
their access to health care. To the best of my knowledge, this study is also the first 
attempt to assess costs and health status associated with cancer patients taking 
prescription medications by using a nationally representative database. HRQoL 
assessment could provide information that is not available from diagnoses or other 
health record information resources. Meanwhile, it also reveals the patients‟ thoughts 
about the efficacy of treatment, which may influence their utilization of medical 
services. In models to predict medical expenditures, relatively few studies have used 
self-reported health status as a variable. The present study findings provided the 
empirical evidences that patients with lower physical SF-12 scores or higher 
depressive symptoms (PHQ-2) scores are more likely to spend higher out-of-pocket 
cancer medication expenditures. 
 
   Findings from this study give a comprehensive and up-to-date understanding of 
cancer and cancer prescription expenditures. By examining HRQoL and prescription 
medication expenditures incurred in cancer patients, especially specific groups of 
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people, policy makers can assist to determine the best strategy for interventions and 
perform efficient patient or medical costs management. However, a longitudinal study 
is needed to determine causal relationships to further test the associations between the 
medication-related factors and the HRQoL/prescription medication expenditures. 
Moreover, a more detailed analysis is needed to capture both direct and indirect costs 
to provide more precise overall predicted prescription medication expenditures for 
cancer. 
 
Study Two: Patient Satisfaction and Subjective Experiences of Treatment with 
Breast Cancer Hormonal Medications 
 
   The second study examined patient satisfaction and subjective experiences of 
treatment with breast cancer hormonal medications - tamoxifen and AIs (anastrozole, 
letrozole, and exemestane). It was conducted based on the patient self-reported data 
collected from an Internet website www.askapatient.com. This website is designed to 
provide information about patients‟ experience with prescription drugs currently 
approved by the FDA, along with many over-the-counter medicines. It provides high 
quality information, and it is the best resource for patient opinion about drug 
performance. This study focused on breast cancer, because breast cancer is the most 
frequently diagnosed type of cancer among women, and today it is the second leading 
cause of cancer death in women after lung cancer.
2
 Hormonal therapy, including 
tamoxifen and AIs (anastrozole, letrozole, and exemestane), is the best treatment 
choice for hormone-receptor-positive breast cancer patients, which make up 75-80% 
of breast cancer patients.
130, 131
 To date, the majority of outcome researches on cancer 
drug treatment focus on mortality and morbidity, because these outcomes are 
relatively easy to observe and data are readily available. As know from some 
publications examining patients‟ HRQoL, there are no clinically important differences 
in overall QoL, in spite of the significantly various side effect profiles of tamoxifen and 
AIs. Hence, the information of patient satisfaction is particularly useful to deeply 
understand the patients‟ perspective on their current treatment and differentiate among 
alternative treatments. Unfortunately, so far there have been no studies assessing 
patient satisfaction with breast cancer hormonal medications, especially its contributing 
factors. Therefore, this study is aimed to examine patient satisfaction and subjective 
experience of treatment with different hormonal medications. 
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   Firstly, this study documented the most common side effects reported by breast 
cancer patients after taking tamoxifen and AIs. It revealed that patients receiving AIs 
experienced significantly more arthralgia/myalgia, bone events, carpal tunnel 
syndrome, vaginal dryness, sexual dysfunction and sleep disorders, while patients 
receiving tamoxifen experienced significantly more hot flashes, night sweats, vaginal 
discharge/bleeding and some other serious gynecologic side effects, such as ovarian 
cysts.  
 
   Secondly, this study examined the factors affecting patient satisfaction with 
hormonal medications. Patient satisfaction is normally studied less frequently than 
other patient-reported outcomes (e.g., HRQoL). Nevertheless, such PROs are very 
important in the studies of cancer because they reflect patients‟ treatment-related 
behaviours, and consequently, it will impact the quality of life in cancer patients. This 
information can be served as the baseline for the policy makers on how to best 
improve cancer outcomes over time and optimize health expenditure. To my 
knowledge, this is the first study to examine breast cancer patients‟ satisfaction with 
different hormonal medications, and examine the contributing factors. This study 
pointed out that side effects, especially musculoskeletal symptoms and nervous 
system problems, significantly decreased patient satisfaction. Patients with longer 
duration of medication treatment, or persisting as current users of medications were 
more likely to rate a higher score on satisfaction. Compared with tamoxifen patients, 
anastrozole patients had a significantly higher probability of experiencing satisfaction, 
and they also had a significantly stronger likelihood of rating a higher score; while 
letrozole patients only showed a significantly stronger likelihood of rating a higher 
score. 
 
   Findings from this study can help health professionals to focus on more primary 
breast cancer care from the patient‟s perspective. A new benchmark for these values 
can be applied to the management of breast cancer hormonal medications - improve 
communication between patients and care providers regarding possible side effects, 
and improve patients‟ quality of life on hormonal medication therapy. However, it still 
suggests that further confirmation of the current findings is needed. For example, 
whether a research in a larger population sample, particularly with longer follow-up 
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period, or an analysis using the reliable and validated treatment satisfaction 
questionnaire for medications, report similar results. In addition, researchers should 
further explore factors impacting on patient satisfaction as well. 
 
Summary  
 
   In summary, this thesis employed PROs to conduct empirical research on 
treatment of cancer patients with prescription medications. It helped establish a 
framework for comprehensive and up-to-date understanding HRQoL and the real 
medical expenses spending on cancer-related medications among cancer patients. It 
was pointed out that cancer medication use was associated with significant 
impairment of HRQoL. Differences in the impairment also existed across groups of 
different characteristics. Additionally, total and out-of-pocket prescription medication 
expenditures were significantly affected by patient characteristics such as age, region, 
insurance status, chronic conditions and HRQoL. Meanwhile, this study also gave a 
better understanding of breast cancer patients‟ subjective experiences and satisfaction 
with hormonal medications. It revealed that musculoskeletal symptoms or nervous 
system problems had a significantly negative impact on patient satisfaction, while 
long-term medication treatment or currently consistent use of medications had a 
significantly positive impact on patient satisfaction. This thesis provides a new 
benchmark for these values which can be applied to the management of cancer 
medications, as well as a reference for future research and baseline into clinical 
practice. However, further confirmation of the findings from this thesis is needed, and 
researchers should further explore factors impacting on cancer patients‟ HRQoL, 
satisfaction and medication expenditures as well. 
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Appendices 
 
Appendix 1: ICD-9 Codes for Cancer in Current Study 
 
 
 
 
 
 
 
 
 
 
ICD-9 Codes Description Percent (%)
145 Malignant neoplasm of other and unspecified parts of mouth 0.35
149 Malignant neoplasm of other and ill-defined sites within the lip oral cavity and pharynx 0.45
153 Malignant neoplasm of colon 3.16
154 Malignant neoplasm of rectum rectosigmoid junction and anus 0.25
155 Malignant neoplasm of liver and intrahepatic bile ducts 0.75
157 Malignant neoplasm of pancreas 0.40
161 Malignant neoplasm of larynx 0.30
162 Malignant neoplasm of trachea bronchus and lung 3.21
170 Malignant neoplasm of bone and articular cartilage 0.80
171 Malignant neoplasm of connective and other soft tissue 0.30
172 Malignant melanoma of skin 3.31
173 Other malignant neoplasm of skin 17.24
174 Malignant neoplasm of female breast 8.62
179 Malignant neoplasm of uterus-part unspecified 2.06
180 Malignant neoplasm of cervix uteri 1.70
185 Malignant neoplasm of prostate 7.62
186 Malignant neoplasm of testis 0.50
188 Malignant neoplasm of bladder 1.40
189 Malignant neoplasm of kidney and other and unspecified urinary organs 1.30
193 Malignant neoplasm of thyroid gland 1.60
195 Malignant neoplasm of other and ill-defined sites 0.30
198 Secondary malignant neoplasm of other specified sites 1.15
199 Malignant neoplasm without specification of site 2.71
202 Other malignant neoplasms of lymphoid and histiocytic tissue 2.36
207 Other specified leukemia 0.35
208 Leukemia of unspecified cell type 1.50
211 Benign neoplasm of other parts of digestive system 2.81
214 Lipoma 0.90
215 Other benign neoplasm of connective and other soft tissue 2.91
216 Benign neoplasm of skin 9.17
217 Benign neoplasm of breast 0.40
218 Uterine leiomyoma 1.30
228 Hemangioma and lymphangioma any site 0.25
229 Benign neoplasm of other and unspecified sites 2.46
232 Carcinoma in situ of skin 2.81
237 Neoplasm of uncertain behavior of endocrine glands and nervous system 0.30
238 Neoplasm of uncertain behavior of other and unspecified sites and tissues 0.95
239 Neoplasms of unspecified nature 12.03
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Appendix 2: The U.S. states for Each Region  
 
 
       Agency for Healthcare Research and Quality, MEPS HC-121: 2008 Full Year Consolidated Data File.104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Region States
Northeast Connecticut, Maine, Massachusetts, New Hampshire, New Jersey,
New York, Pennsylvania, Rhode Island, and Vermont
Midwest Indiana, Illinois, Iowa, Kansas, Michigan, Minnesota, Missouri,
Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin
South Alabama, Arkansas, Delaware, District of Columbia, Florida,
Georgia, Kentucky, Louisiana, Maryland, Mississippi, North
Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia,
and West Virginia
West Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana,
Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming
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Appendix 3: Self-Administered Questionnaire (SAQ) 2008 
 
 
 
 176 
 
 177 
 
 178 
 
 179 
 
 180 
 
 181 
 
 
Cited from MEPS website 42  
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Abbreviation 
ACS: American Cancer Society 
AHRQ: Agency for Healthcare Research and Quality 
AI: Aromatase Inhibitor 
ALIQUOT: Anastrozole vs. Letrozole, an Investigation of Quality Of Life and 
Tolerability 
ATAC: Arimidex, Tamoxifen Alone or in Combination 
BCQ: Breast Chemotherapy Questionnaire 
BIG: Breast International Group 
CASC: Comprehensive Assessment of Satisfaction with Care 
CDC: Centers for Disease Control and Prevention 
CES-D: Centre for Epidemiological Studies-Depression Scale 
CHAMPVA: Civilian Health and Medical Program of the Department of Veterans 
Affairs 
CMS: Centers for Medicare & Medicaid Services 
C-PET: Checklist for Patients with Endocrine Therapy 
CTSQ: Cancer Therapy Satisfaction Questionnaire 
EORTC QLQ C-30: European Organization for the Research and Treatment of Cancer 
Quality of Life Questionnaire Core 30 
EPIC: Expanded Prostate Cancer Index Composite 
EWB: Emotional Well-Being 
FACIT: Functional Assessment of Chronic Illness Therapy 
FACT-B: Functional Assessment of Cancer Therapy-Breast Cancer 
FACT-ES: Functional Assessment of Cancer Therapy-Endocrine Subscale 
FACT-G: Functional Assessment of Cancer Therapy-General 
FDA: Food and Drug Administration 
FLIC: Functional Living Index Cancer 
FWB: Functional Well-Being 
GDP: Gross Domestic Product 
HAQ: Health Assessment Questionnaire 
HC: Household Component 
HCUP: Healthcare Cost and Utilization Project 
HHS: Health and Human Services 
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HMOS: Health Maintenance Organizations 
NCI: National Cancer Institute 
NHP: Nottingham Health Profile 
NIH: National Institutes of Health 
HRQoL: Health-related Quality of Life 
HUI: Health Utilities Index 
IARC: International Agency for Research on Cancer 
ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical 
Modification 
IES: Intergroup Exemestane Study  
IRR: Incidence Rate Ratio 
KPS: Karnofsky Performance Status 
K-6: Kessler Index 
LSQ: Life Satisfaction Questionnaire 
MCID: Minimal Clinically Important Difference 
MCS: Mental Component Summary 
MENQOL: Menopause-specific Quality of Life Questionnaire 
MEPS: Medical Expenditure Panel Survey 
MOS: Medical Outcomes Study 
MRS: Mood Rating Scale 
MSA: Metropolitan Statistical Area 
NAMCS: National Ambulatory Medical Care Survey 
NCI: National Cancer Institute 
NDC: National Drug Code 
NHIS: National Health Interview Survey 
NIH: National Institutes of Health 
NSABP: National Surgical Adjuvant Breast and Bowel Project 
NSAS BC: National Surgical Adjuvant in Study of Breast Cancer 
OECD: Organization for Economic Cooperation and Development 
OLS: Ordinary Least Squares 
OR: Odds Ratio 
PCI: Prostate Cancer Index 
PCS: Physical Component Summary 
PHQ-2: Patient Health Questionnaire 
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POMS: Profile of Mood States 
PROs: Patient Reported Outcomes 
PSUS: Primary Sampling Units 
PWB: Physical Well-Being 
QALY: Quality-Adjusted Life Year 
QoL: Quality of Life 
QOLI: Quality of Life Inventory 
Q-TWiST: Quality-adjusted Time Without Symptoms or Toxicity 
QWB: Quality of Well-Being  
RSCL: Rotterdam Symptom Checklist 
SAQ: Self-Administered Questionnaire 
SATMED-Q: Treatment Satisfaction with Medications Questionnaire 
SES: Socioeconomic Status 
SF-36: Medical Outcomes Study 36-item Short Form Health Survey 
SF-12v2: Medical Outcomes Study 12-item Short Form Health Survey, Version 2 
SG: Standard Gamble 
SWB: Social Well-Being 
TEAM: Tamoxifen Exemestane Adjuvant Multinational 
TRICARE: Military Health Services 
TSQM: Treatment Satisfaction Questionnaire for Medication 
TOI: Trial Outcome Index 
TRA: Theory of Reasoned Action 
TTO: Time Trade-Off 
VA: Veterans Administration 
VAMS: Visual Analogical Mental Scales 
VAS: Visual Analogue Scales 
WHO: World Health Organization 
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